


**CUMULATIVE
SUPPLEMENT 4**
April 2024



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

Department of Health and Human Services

Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2024

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**Cumulative Supplement 4
April 2024**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	x
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Products Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**CUMULATIVE SUPPLEMENT 4
April 2024**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
AKORN OPERATING CO LLC (AKORN)	EPIC PHARMA LLC (EPIC PHARMA LLC)
CADILA HEALTHCARE LTD (CADILA)	ZYDUS LIFESCIENCES LTD (ZYDUS LIFESCIENCES)
GLAXOSMITHKLINE (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE (GLAXOSMITHKLINE CONS)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)

GLENMARK GENERICS INC USA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LIMITED (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD INDIA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
LUPIN LTD (LUPIN LTD)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	XIROMED LLC (XIROMED)
PAR PHARMACEUTICAL (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM INC)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR STERILE PRODUCTS LLC (PAR STERILE PRODUCTS)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
TARO PHARMACEUTICALS USA INC (TARO)	TARO PHARMACEUTICALS INC (TARO)
VERTICE PHARMA MANAGEMENT CORP (VERTICE)	ENCUBE ETHICALS PRIVATE LTD (ENCUBE)
ZYDUS WORLDWIDE DMCC (ZYDUS)	ZYDUS LIFESCIENCES GLOBAL FZE (ZYDUS LIFESCIENCES)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug

products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2023</u>	<u>MAR</u> <u>2024</u>	<u>JUN</u> <u>2024</u>	<u>SEP</u> <u>2024</u>	<u>DEC</u> <u>2024</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23099 2784 (12.1%)	23058 2802 (12.2%)			
MULTISOURCE	20315 (87.9%)	20256 (87.8%)			
THERAPEUTICALLY EQUIVALENT	20252 (87.7%)	20198 (87.6%)			
NOT THERAPEUTICALLY EQUIVALENT	63 (0.3%)	58 (0.3%)			
EXCEPTIONS ⁴	46 (0.2%)	46 (0.2%)			
NEW MOLECULAR ENTITIES APPROVED	32	18			
NUMBER OF APPLICANTS	1214	1219			

1.7 CUMULATIVE SUPPLEMENT LEGEND

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

		TABLET;ORAL		ABACAVIR SULFATE AND LAMIVUDINE					
AB	!	CIPLA	EQ 600MG BASE;300MG	A091144	001	Mar 28, 2017	Jan	CHRS	
		EPZICOM							
	+	@ VIIV HLTHCARE	EQ 600MG BASE;300MG	N021652	001	Aug 02, 2004	Jan	DISC	
		TABLET, FOR SUSPENSION;ORAL		ABACAVIR SULFATE AND LAMIVUDINE					
	+	@ MYLAN LABS LTD	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023	Jan	DISC	

ABIRATERONE ACETATE

		TABLET;ORAL		ABIRATERONE ACETATE					
>A>	AB	MSN	500MG	A210686	002	Apr 24, 2024	Apr	NEWA	

ACETAMINOPHEN; BUTALBITAL

		TABLET;ORAL		BUTALBITAL AND ACETAMINOPHEN					
AA		QUAGEN	300MG;50MG	A214305	001	Feb 01, 2024	Jan	NEWA	
AA			325MG;50MG	A214291	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

		CAPSULE;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
>A>	AA	KEY THERAP	300MG;50MG;40MG	A206615	001	Aug 04, 2017	Apr	CAHN	
	AA	QUAGEN	300MG;50MG;40MG	A214288	001	Feb 08, 2024	Jan	NEWA	
	AA		325MG;50MG;40MG	A216376	001	Mar 12, 2024	Mar	NEWA	
	AA	SENORES PHARMS	300MG;50MG;40MG	A214087	001	Aug 13, 2021	Feb	CAHN	
	AA		325MG;50MG;40MG	A214087	002	Aug 13, 2021	Feb	CAHN	
>D>	AA	XSPIRE PHARMA	300MG;50MG;40MG	A206615	001	Aug 04, 2017	Apr	CAHN	
		TABLET;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
AA		QUAGEN	325MG;50MG;40MG	A214287	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

		CAPSULE;ORAL		TREZIX					
>A>		KEY THERAP	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	Apr	CAHN	
>D>		XSPIRE PHARMA	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	Apr	CAHN	

ACETAMINOPHEN; CODEINE PHOSPHATE

		TABLET;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE					
>D>	AA	SPECGX LLC	300MG;60MG	A040419	003	May 31, 2001	Apr	CHRS	
>A>	AA	!	300MG;60MG	A040419	003	May 31, 2001	Apr	CHRS	
>D>		@ STRIDES PHARMA	300MG;15MG	A089990	001	Sep 30, 1988	Apr	CMFD	
>A>	AA		300MG;15MG	A089990	001	Sep 30, 1988	Apr	CMFD	
>D>		@	300MG;30MG	A089805	001	Sep 30, 1988	Apr	CMFD	
>A>	AA		300MG;30MG	A089805	001	Sep 30, 1988	Apr	CMFD	
>D>		@	300MG;60MG	A089828	001	Sep 30, 1988	Apr	CMFD	
>A>	AA		300MG;60MG	A089828	001	Sep 30, 1988	Apr	CMFD	
		@ SUN PHARM INDS LTD	300MG;30MG	A085868	001		Jan	DISC	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

		TABLET;ORAL		HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
		@ PRINSTON INC	325MG;5MG	A214928	001	Dec 30, 2021	Mar	DISC	
		@	325MG;7.5MG	A214928	002	Dec 30, 2021	Mar	DISC	
		@	325MG;10MG	A214928	003	Dec 30, 2021	Mar	DISC	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

		TABLET;ORAL		PERCOCET					
>A>	AA	!	ENDO OPERATIONS	325MG;2.5MG	A040330	001	Jun 25, 1999	Apr	CAHN
>A>	AA	!		325MG;5MG	A040330	002	Jun 25, 1999	Apr	CAHN
>A>	AA	!		325MG;7.5MG	A040330	003	Nov 23, 2001	Apr	CAHN
>A>	AA	!		325MG;10MG	A040330	004	Nov 23, 2001	Apr	CAHN
>D>	AA	!	VINTAGE PHARMS LLC	325MG;2.5MG	A040330	001	Jun 25, 1999	Apr	CAHN
>D>	AA	!		325MG;5MG	A040330	002	Jun 25, 1999	Apr	CAHN
>D>	AA	!		325MG;7.5MG	A040330	003	Nov 23, 2001	Apr	CAHN

	TABLET;ORAL							
	PERCO CET							
>D> AA	!	325MG;10MG		A040330	004	Nov 23, 2001	Apr	CAHN
	<u>ACETAZOLAMIDE</u>							
	TABLET;ORAL							
	ACETAZOLAMIDE							
	@ AJANTA PHARMA LTD	125MG		A211151	001	Sep 11, 2023	Feb	DISC
	@	250MG		A211151	002	Sep 11, 2023	Feb	DISC
	@ TORRENT	125MG		A213706	001	Jan 26, 2024	Jan	DISC
AB		125MG		A213706	001	Jan 26, 2024	Jan	NEWA
	@	250MG		A213706	002	Jan 26, 2024	Jan	DISC
AB		250MG		A213706	002	Jan 26, 2024	Jan	NEWA
	<u>ACETIC ACID, GLACIAL</u>							
	SOLUTION/DROPS;OTIC							
	ACETIC ACID							
>D> AT	SAPTALIS PHARMS	2%		A040607	001	Feb 24, 2005	Apr	CHRS
>A> AT	!	2%		A040607	001	Feb 24, 2005	Apr	CHRS
	VOSOL							
>D> AT	! HIKMA	2%		N012179	001		Apr	DISC
>A>	+ @	2%		N012179	001		Apr	CRLD
>A>	@	2%		N012179	001		Apr	DISC
	<u>ACETYLCYSTEINE</u>							
	SOLUTION;INHALATION, ORAL							
	ACETYLCYSTEINE							
	@ EXELA PHARMA	20%		A205643	001	Nov 01, 2023	Feb	DISC
	<u>ACETYLCYSTEINE LYSINE</u>							
	FOR SOLUTION;ORAL							
	LEGUBETI							
	+! GALEPHAR	EQ 500MG BASE/PACKET		N215040	001	Feb 13, 2024	Feb	NEWA
	+!	EQ 2.5GM BASE/PACKET		N215040	002	Feb 13, 2024	Feb	NEWA
	<u>ACYCLOVIR</u>							
	OINTMENT;TOPICAL							
	ACYCLOVIR							
	@ COSETTE	5%		A205591	001	Nov 13, 2017	Mar	DISC
	SUSPENSION;ORAL							
	ACYCLOVIR							
	@ HIKMA	200MG/5ML		A077026	001	Jun 07, 2005	Mar	DISC
	@ VISTAPHARM LLC	200MG/5ML		A213951	001	Jan 11, 2021	Mar	CAHN
	<u>ADENOSINE</u>							
	SOLUTION;INTRAVENOUS							
	ADENOSINE							
	@ HOSPIRA	60MG/20ML (3MG/ML)		A203883	001	Mar 24, 2014	Feb	DISC
	@	90MG/30ML (3MG/ML)		A203883	002	Mar 24, 2014	Feb	DISC
	<u>ALBUTEROL SULFATE</u>							
	SOLUTION;INHALATION							
	ALBUTEROL SULFATE							
>A> AN	LEXENPHARM	EQ 0.021% BASE		A215571	001	May 03, 2024	Apr	NEWA
>A> AN		EQ 0.042% BASE		A215571	002	May 03, 2024	Apr	NEWA
	SYRUP;ORAL							
	ALBUTEROL SULFATE							
	@ HIKMA	EQ 2MG BASE/5ML		A074749	001	Jan 30, 1998	Mar	DISC
	<u>ALBUTEROL SULFATE; BUDESONIDE</u>							
	AEROSOL, METERED;INHALATION							
	AIRSUPRA							
	+! ASTRAZENECA	EQ 0.09MG BASE/INH;0.08MG/INH		N214070	001	Jan 10, 2023	Jan	CPOT
	<u>ALISKIREN HEMIFUMARATE</u>							
	TABLET;ORAL							
	ALISKIREN HEMIFUMARATE							
>D> AB	ANCHEN PHARMS	EQ 150MG BASE		A206665	001	Mar 22, 2019	Apr	CAHN
>D> AB		EQ 300MG BASE		A206665	002	Mar 22, 2019	Apr	CAHN
>A> AB	ENDO OPERATIONS	EQ 150MG BASE		A206665	001	Mar 22, 2019	Apr	CAHN
>A> AB		EQ 300MG BASE		A206665	002	Mar 22, 2019	Apr	CAHN

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

>A>	AB	ENDO OPERATIONS	100MG	A075798	001	Jun 27, 2003	Apr	CAHN
>A>	AB		300MG	A075798	002	Jun 27, 2003	Apr	CAHN
>D>	AB	LUPIN LTD	100MG	A211807	001	Dec 14, 2023	Apr	DISC
>A>	@		100MG	A211807	001	Dec 14, 2023	Apr	DISC
>D>	AB		300MG	A211807	002	Dec 14, 2023	Apr	DISC
>A>	@		300MG	A211807	002	Dec 14, 2023	Apr	DISC
>D>	AB	VINTAGE PHARMS	100MG	A075798	001	Jun 27, 2003	Apr	CAHN
>D>	AB		300MG	A075798	002	Jun 27, 2003	Apr	CAHN

ALPELISIB

>A>		GRANULES; ORAL						
>A>		VIJOICE						
>A>	+	NOVARTIS	50MG/PACKET	N218466	001	Apr 24, 2024	Apr	NEWA

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB		CHARTWELL RX	0.25MG	A207507	001	Jul 09, 2018	Mar	CAHN
AB			0.5MG	A207507	002	Jul 09, 2018	Mar	CAHN
AB			1MG	A207507	003	Jul 09, 2018	Mar	CAHN
AB			2MG	A207507	004	Jul 09, 2018	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@	ANCHEN PHARMS	0.5MG	A078469	001	Sep 29, 2011	Mar	DISC
@		1MG	A078469	002	Sep 29, 2011	Mar	DISC
@		2MG	A078469	003	Sep 29, 2011	Mar	DISC
@		3MG	A078469	004	Sep 29, 2011	Mar	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

>A>	AB	ENDO OPERATIONS	0.25MG	A078088	001	Jan 09, 2009	Apr	CAHN
>A>	AB		0.5MG	A078088	002	Jan 09, 2009	Apr	CAHN
>A>	AB	!	1MG	A078088	003	Jan 09, 2009	Apr	CAHN
>A>	AB		2MG	A078088	004	Jan 09, 2009	Apr	CAHN
>D>	AB	PAR PHARM	0.25MG	A078088	001	Jan 09, 2009	Apr	CAHN
>D>	AB		0.5MG	A078088	002	Jan 09, 2009	Apr	CAHN
>D>	AB	!	1MG	A078088	003	Jan 09, 2009	Apr	CAHN
>D>	AB		2MG	A078088	004	Jan 09, 2009	Apr	CAHN

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

>D>	@	AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr	CAHN
>D>	AP	+	0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr	CAHN
>D>		+	0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr	CAHN
>D>	AP	+	0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr	CAHN
>D>		+	0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr	CAHN
>D>	AP	+	0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr	CAHN
>D>		+	0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr	CAHN
>A>	@	ENDO OPERATIONS	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr	CAHN
>A>	AP	+	0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr	CAHN
>A>		+	0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr	CAHN
>A>	AP	+	0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr	CAHN
>A>		+	0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr	CAHN
>A>	AP	+	0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr	CAHN
>A>		+	0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr	CAHN

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

@ GENUS 50MG/5ML

A076352 001 Sep 10, 2004 Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

OSMOLEX ER

>D>	+	ADAMAS OPERATIONS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Apr	DISC
>A>	+	@	EQ 129MG BASE	N209410	001	Feb 16, 2018	Apr	DISC
>D>	+		EQ 193MG BASE	N209410	002	Feb 16, 2018	Apr	DISC
>A>	+	@	EQ 193MG BASE	N209410	002	Feb 16, 2018	Apr	DISC

AMBRISENTAN

TABLET; ORAL

AMBRISENTAN

>D>	AB	PAR PHARM INC	5MG	A209509	001	Apr 10, 2019	Apr	DISC
>A>		@	5MG	A209509	001	Apr 10, 2019	Apr	DISC
>D>	AB		10MG	A209509	002	Apr 10, 2019	Apr	DISC
>A>		@	10MG	A209509	002	Apr 10, 2019	Apr	DISC

AMCINONIDE

LOTION; TOPICAL

AMCINONIDE

! GENUS

0.1%

A076329 001 Nov 06, 2002 Jan CAHN

OINTMENT; TOPICAL

AMCINONIDE

AB

! GENUS

0.1%

A076096 001 Nov 19, 2002 Jan CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP

QILU

EQ 250MG BASE/ML

A218146 001 Mar 19, 2024 Mar NEWA

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

>A>	AB	! ENDO OPERATIONS	5MG	A070346	001	Jan 22, 1986	Apr	CAHN
>D>	AB	! PAR PHARM	5MG	A070346	001	Jan 22, 1986	Apr	CAHN

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER

>A>		BAXTER HLTHCARE	8%;14GM/100ML	N020734	019	Apr 13, 2021	Apr	NEWA
-----	--	-----------------	---------------	---------	-----	--------------	-----	------

AMINOCAPROIC ACID

SOLUTION; ORAL

AMICAR

+ @ HIKMA

0.25GM/ML

N015230 002

Mar DISC

AMINOCAPROIC ACID

AA

! TULEX PHARMS INC

0.25GM/ML

A212494 001 Aug 11, 2020 Mar CHRS

@ VISTAPHARM LLC

0.25GM/ML

A212814 001 Feb 26, 2020 Mar CAHN

TABLET; ORAL

AMICAR

+ @ HIKMA

500MG

N015197 001

Mar DISC

+ @

1GM

N015197 002 Jun 24, 2004

Mar DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

@ AIPING PHARM INC

EQ 2.5MG BASE

A077759 001 Jul 09, 2007 Feb CAHN

@

EQ 5MG BASE

A077759 002 Jul 09, 2007 Feb CAHN

@

EQ 10MG BASE

A077759 003 Jul 09, 2007 Feb CAHN

@ SUN PHARM INDS LTD

EQ 2.5MG BASE

A077974 001 Jul 09, 2007 Jan DISC

@

EQ 5MG BASE

A077974 002 Jul 09, 2007 Jan DISC

@

EQ 10MG BASE

A077974 003 Jul 09, 2007 Jan DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

>A>		@ AMNEAL	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018	Apr	CAHN
>A>		@	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018	Apr	CAHN
>A>		@	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018	Apr	CAHN
>A>		@	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018	Apr	CAHN
>D>		@ CIPLA	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018	Apr	CAHN
>D>		@	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018	Apr	CAHN
>D>		@	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018	Apr	CAHN
>D>		@	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018	Apr	CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	SCIEGEN PHARMS INC	EQ 5MG BASE;20MG	A209010	001	Dec 03, 2018	Feb	CMFD
AB		EQ 5MG BASE;40MG	A209010	002	Dec 03, 2018	Feb	CMFD
AB		EQ 10MG BASE;20MG	A209010	003	Dec 03, 2018	Feb	CMFD
AB		EQ 10MG BASE;40MG	A209010	004	Dec 03, 2018	Feb	CMFD

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

	@ DAVA PHARMS INC	125MG/5ML	A062927	001	Nov 25, 1988	Mar	DISC
	@	250MG/5ML	A062927	002	Nov 25, 1988	Mar	DISC
	AMOXIL						
>D>	+ @ US ANTIBIOTICS	400MG/5ML	N050760	002	Apr 15, 1999	Apr	CMFD
>A>	AB +	400MG/5ML	N050760	002	Apr 15, 1999	Apr	CMFD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

AB1	+ TAKEDA PHARMS USA	2.5MG; 2.5MG; 2.5MG; 2.5MG	N021303	001	Oct 11, 2001	Jan	CTEC
	ADDERALL XR 15						
AB1	+ TAKEDA PHARMS USA	3.75MG; 3.75MG; 3.75MG; 3.75MG	N021303	006	May 22, 2002	Jan	CTEC
	ADDERALL XR 20						
AB1	+ TAKEDA PHARMS USA	5MG; 5MG; 5MG; 5MG	N021303	002	Oct 11, 2001	Jan	CTEC
	ADDERALL XR 25						
AB1	+ TAKEDA PHARMS USA	6.25MG; 6.25MG; 6.25MG; 6.25MG	N021303	004	May 22, 2002	Jan	CTEC
	ADDERALL XR 30						
AB1	+! TAKEDA PHARMS USA	7.5MG; 7.5MG; 7.5MG; 7.5MG	N021303	003	Oct 11, 2001	Jan	CTEC
	ADDERALL XR 5						
AB1	+ TAKEDA PHARMS USA	1.25MG; 1.25MG; 1.25MG; 1.25MG	N021303	005	May 22, 2002	Jan	CTEC

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB1	ACTAVIS ELIZABETH	1.25MG; 1.25MG; 1.25MG; 1.25MG	A077302	001	Jun 22, 2012	Jan	CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A077302	002	Jun 22, 2012	Jan	CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A077302	003	Jun 22, 2012	Jan	CTEC
AB1		5MG; 5MG; 5MG; 5MG	A077302	004	Jun 22, 2012	Jan	CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A077302	005	Jun 22, 2012	Jan	CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A077302	006	Jun 22, 2012	Jan	CTEC
AB1	ANI PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A205401	001	Jan 22, 2019	Jan	CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A205401	002	Jan 22, 2019	Jan	CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A205401	003	Jan 22, 2019	Jan	CTEC
AB1		5MG; 5MG; 5MG; 5MG	A205401	004	Jan 22, 2019	Jan	CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A205401	005	Jan 22, 2019	Jan	CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A205401	006	Jan 22, 2019	Jan	CTEC
AB1	ASCENT PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214959	001	Sep 29, 2021	Jan	CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214959	002	Sep 29, 2021	Jan	CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214959	003	Sep 29, 2021	Jan	CTEC
AB1		5MG; 5MG; 5MG; 5MG	A214959	004	Sep 29, 2021	Jan	CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214959	005	Sep 29, 2021	Jan	CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214959	006	Sep 29, 2021	Jan	CTEC
AB1	ELITE LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A212037	001	Dec 11, 2019	Jan	CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A212037	002	Dec 11, 2019	Jan	CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A212037	003	Dec 11, 2019	Jan	CTEC
AB1		5MG; 5MG; 5MG; 5MG	A212037	004	Dec 11, 2019	Jan	CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A212037	005	Dec 11, 2019	Jan	CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A212037	006	Dec 11, 2019	Jan	CTEC
AB1	GRANULES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A217027	001	Jan 23, 2023	Jan	CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A217027	002	Jan 23, 2023	Jan	CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A217027	003	Jan 23, 2023	Jan	CTEC
AB1		5MG; 5MG; 5MG; 5MG	A217027	004	Jan 23, 2023	Jan	CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A217027	005	Jan 23, 2023	Jan	CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A217027	006	Jan 23, 2023	Jan	CTEC
AB1	IMPAX LABS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A076852	001	Feb 16, 2016	Jan	CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A076852	002	Feb 16, 2016	Jan	CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A076852	003	Feb 16, 2016	Jan	CTEC
AB1		5MG; 5MG; 5MG; 5MG	A076852	004	Feb 16, 2016	Jan	CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A076852	005	Feb 16, 2016	Jan	CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A076852	006	Feb 16, 2016	Jan	CTEC
AB1	LANNETT CO INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214403	001	Nov 26, 2021	Jan	CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214403	002	Nov 26, 2021	Jan	CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214403	003	Nov 26, 2021	Jan	CTEC
AB1		5MG; 5MG; 5MG; 5MG	A214403	004	Nov 26, 2021	Jan	CTEC

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB1		6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Jan CTEC
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Jan CTEC
AB1	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651	001	May 17, 2019	Jan CTEC
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A210651	002	May 17, 2019	Jan CTEC
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A210651	003	May 17, 2019	Jan CTEC
AB1		5MG;5MG;5MG;5MG	A210651	004	May 17, 2019	Jan CTEC
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A210651	005	May 17, 2019	Jan CTEC
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A210651	006	May 17, 2019	Jan CTEC
AB1	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019	Jan CTEC
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019	Jan CTEC
AB2		3.125MG;3.125MG;3.125MG;3.125MG	A211546	001	Aug 31, 2023	Jan CTEC
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019	Jan CTEC
AB1		5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019	Jan CTEC
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A211546	002	Aug 31, 2023	Jan CTEC
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019	Jan CTEC
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019	Jan CTEC
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A211546	003	Aug 31, 2023	Jan CTEC
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A211546	004	Aug 31, 2023	Jan CTEC
AB2	SUN PHARM INDS INC	3.125MG;3.125MG;3.125MG;3.125MG	A215997	001	Sep 27, 2023	Jan CTEC
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A215997	002	Sep 27, 2023	Jan CTEC
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A215997	003	Sep 27, 2023	Jan CTEC
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A215997	004	Sep 27, 2023	Jan CTEC
AB1	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019	Jan CTEC
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	Jan CTEC
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	Jan CTEC
AB1		5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	Jan CTEC
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	Jan CTEC
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Jan CTEC
AB2	TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Jan CTEC
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Jan CTEC
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Jan CTEC
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Jan CTEC
	MYDAYIS					
AB2	+ TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017	Jan CTEC
AB2	+	6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017	Jan CTEC
AB2	+	9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017	Jan CTEC
AB2	+!	12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017	Jan CTEC

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	SENORES PHARMS	5MG	A212901	001	May 22, 2020	Feb CAHN
AA		10MG	A212901	002	May 22, 2020	Feb CAHN
	@ SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Mar DISC
	@	10MG	A214574	002	Jan 27, 2021	Mar DISC
	EVEKEO					
AA	AZURITY	5MG	A200166	001	Aug 09, 2012	Mar CAHN
AA	!	10MG	A200166	002	Aug 09, 2012	Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

>D> EVEKEO ODT

>D>	+ AZURITY	5MG	N209905	001	Jan 30, 2019	Apr DISC
>A>	+ @	5MG	N209905	001	Jan 30, 2019	Apr DISC
>D>	+	10MG	N209905	002	Jan 30, 2019	Apr DISC
>A>	+ @	10MG	N209905	002	Jan 30, 2019	Apr DISC
>D>	+	15MG	N209905	003	Jan 30, 2019	Apr DISC
>A>	+ @	15MG	N209905	003	Jan 30, 2019	Apr DISC
>D>	+!	20MG	N209905	004	Jan 30, 2019	Apr DISC
>A>	+ @	20MG	N209905	004	Jan 30, 2019	Apr DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

>D>	AP	ASTRAL	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090579	001	Jan 08, 2016	Apr DISC
>A>	@		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090579	001	Jan 08, 2016	Apr DISC
>D>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090579	002	Jan 08, 2016	Apr DISC
>A>	@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090579	002	Jan 08, 2016	Apr DISC
>D>	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090578	001	Jan 11, 2016	Apr DISC
>A>	@		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090578	001	Jan 11, 2016	Apr DISC

APIXABAN

TABLET; ORAL

APIXABAN

AB	APOTEX	2.5MG	A210091	001	Feb 16, 2024	Feb NEWA
AB		5MG	A210091	002	Feb 16, 2024	Feb NEWA

APREMILAST

TABLET; ORAL

APREMILAST

AB	MANKIND PHARMA	10MG	A211734	001	Feb 07, 2024	Jan NEWA
AB		20MG	A211734	002	Feb 07, 2024	Jan NEWA
AB		30MG	A211734	003	Feb 07, 2024	Jan NEWA

APROCITENTAN

TABLET; ORAL

TRYVIO

+!	IDORSIA	12.5MG	N217686	001	Mar 19, 2024	Mar NEWA
----	---------	--------	---------	-----	--------------	----------

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

ARFORMOTEROL TARTRATE

AN	PHARMAMAX	EQ 0.015MG BASE/2ML	A214901	001	Apr 02, 2024	Mar NEWA
----	-----------	---------------------	---------	-----	--------------	----------

ARIPIPIRAZOLE

TABLET; ORAL

ARIPIPIRAZOLE

AB	LUPIN	2MG	A205589	001	Mar 18, 2024	Mar NEWA
AB		5MG	A205589	002	Mar 18, 2024	Mar NEWA
AB		10MG	A205589	003	Mar 18, 2024	Mar NEWA
AB		15MG	A205589	004	Mar 18, 2024	Mar NEWA
AB		20MG	A205589	005	Mar 18, 2024	Mar NEWA
AB		30MG	A205589	006	Mar 18, 2024	Mar NEWA

ARIPIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ARISTADA INITIO KIT

+	ALKERMES INC	675MG/2.4ML (281.25MG/ML)	N209830	001	Jun 29, 2018	Jan CPOT
---	--------------	---------------------------	---------	-----	--------------	----------

ASCIMINIB HYDROCHLORIDE

TABLET; ORAL

SCEMBLIX

>A>	+	NOVARTIS	EQ 100MG BASE	N215358	003	Apr 18, 2024	Apr NEWA
-----	---	----------	---------------	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

LANORINAL

AA	!	SANDOZ	325MG; 50MG; 40MG	A086996	002	Oct 11, 1985	Jan CAHN
----	---	--------	-------------------	---------	-----	--------------	----------

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

>A>	AB	ENDO OPERATIONS	25MG; 200MG	A207944	001	Jan 18, 2017	Apr CAHN
>D>	AB	PAR PHARM INC	25MG; 200MG	A207944	001	Jan 18, 2017	Apr CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

AB	APOTEX	EQ 10MG BASE	A078983	001	May 30, 2017	Mar CPOT
AB		EQ 18MG BASE	A078983	002	May 30, 2017	Mar CPOT
AB		EQ 25MG BASE	A078983	003	May 30, 2017	Mar CPOT
AB		EQ 40MG BASE	A078983	004	May 30, 2017	Mar CPOT
AB		EQ 60MG BASE	A078983	005	May 30, 2017	Mar CPOT
AB		EQ 80MG BASE	A078983	006	May 30, 2017	Mar CPOT
AB		EQ 100MG BASE	A078983	007	May 30, 2017	Mar CPOT
AB	AUROBINDO PHARMA	EQ 10MG BASE	A079016	001	May 30, 2017	Mar CPOT
AB		EQ 18MG BASE	A079016	002	May 30, 2017	Mar CPOT
AB		EQ 25MG BASE	A079016	003	May 30, 2017	Mar CPOT
AB		EQ 40MG BASE	A079016	004	May 30, 2017	Mar CPOT
AB		EQ 60MG BASE	A079016	005	May 30, 2017	Mar CPOT
AB		EQ 80MG BASE	A079016	006	May 30, 2017	Mar CPOT
AB		EQ 100MG BASE	A079016	007	May 30, 2017	Mar CPOT

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	DR REDDYS	EQ 10MG BASE	A090609	001	Feb 23, 2018	Mar	CPOT
AB		EQ 18MG BASE	A090609	002	Feb 23, 2018	Mar	CPOT
AB		EQ 25MG BASE	A090609	003	Feb 23, 2018	Mar	CPOT
AB		EQ 40MG BASE	A090609	004	Feb 23, 2018	Mar	CPOT
AB		EQ 60MG BASE	A090609	005	Feb 23, 2018	Mar	CPOT
AB		EQ 80MG BASE	A090609	006	Feb 23, 2018	Mar	CPOT
AB		EQ 100MG BASE	A090609	007	Feb 23, 2018	Mar	CPOT
AB	GLENMARK PHARMS LTD	EQ 10MG BASE	A079019	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079019	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079019	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079019	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079019	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079019	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079019	007	May 30, 2017	Mar	CPOT
AB	HETERO LABS LTD V	EQ 10MG BASE	A202682	001	Mar 11, 2021	Mar	CPOT
AB		EQ 18MG BASE	A202682	002	Mar 11, 2021	Mar	CPOT
AB		EQ 25MG BASE	A202682	003	Mar 11, 2021	Mar	CPOT
AB		EQ 40MG BASE	A202682	004	Mar 11, 2021	Mar	CPOT
AB		EQ 60MG BASE	A202682	005	Mar 11, 2021	Mar	CPOT
AB		EQ 80MG BASE	A202682	006	Mar 11, 2021	Mar	CPOT
AB		EQ 100MG BASE	A202682	007	Mar 11, 2021	Mar	CPOT
	@ STRIDES PHARMA	EQ 10MG BASE	A079021	001	Feb 18, 2021	Mar	CPOT
	@	EQ 18MG BASE	A079021	002	Feb 18, 2021	Mar	CPOT
	@	EQ 25MG BASE	A079021	003	Feb 18, 2021	Mar	CPOT
	@	EQ 40MG BASE	A079021	004	Feb 18, 2021	Mar	CPOT
	@	EQ 60MG BASE	A079021	005	Feb 18, 2021	Mar	CPOT
	@	EQ 80MG BASE	A079021	006	Feb 18, 2021	Mar	CPOT
	@	EQ 100MG BASE	A079021	007	Feb 18, 2021	Mar	CPOT
AB	TEVA PHARMS USA	EQ 10MG BASE	A079022	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079022	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079022	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079022	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079022	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079022	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079022	007	May 30, 2017	Mar	CPOT
AB	ZYDUS PHARMS USA INC	EQ 10MG BASE	A079017	007	Apr 05, 2023	Mar	CPOT
AB		EQ 18MG BASE	A079017	001	Sep 16, 2010	Mar	CPOT
AB		18MG	A079017	001	Sep 16, 2010	Jan	CMS1
AB		EQ 25MG BASE	A079017	002	Sep 16, 2010	Mar	CPOT
AB		25MG	A079017	002	Sep 16, 2010	Jan	CMS1
AB		EQ 40MG BASE	A079017	003	Sep 16, 2010	Mar	CPOT
AB		40MG	A079017	003	Sep 16, 2010	Jan	CMS1
AB		EQ 60MG BASE	A079017	004	Sep 16, 2010	Mar	CPOT
AB		60MG	A079017	004	Sep 16, 2010	Jan	CMS1
AB		EQ 80MG BASE	A079017	005	Sep 16, 2010	Mar	CPOT
AB		80MG	A079017	005	Sep 16, 2010	Jan	CMS1
AB		EQ 100MG BASE	A079017	006	Sep 16, 2010	Mar	CPOT
AB		100MG	A079017	006	Sep 16, 2010	Jan	CMS1
	STRATTERA						
	@ LILLY	EQ 5MG BASE	N021411	001	Nov 26, 2002	Mar	CPOT
AB	+	EQ 10MG BASE	N021411	002	Nov 26, 2002	Mar	CPOT
AB	+	EQ 18MG BASE	N021411	003	Nov 26, 2002	Mar	CPOT
AB	+	EQ 25MG BASE	N021411	004	Nov 26, 2002	Mar	CPOT
AB	+	EQ 40MG BASE	N021411	005	Nov 26, 2002	Mar	CPOT
AB	+	EQ 60MG BASE	N021411	006	Nov 26, 2002	Mar	CPOT
AB	+	EQ 80MG BASE	N021411	007	Feb 14, 2005	Mar	CPOT
AB	+	EQ 100MG BASE	N021411	008	Feb 14, 2005	Mar	CPOT

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	ANBISON LAB	EQ 10MG BASE	A211886	001	Jan 25, 2024	Jan	NEWA	
AB		EQ 20MG BASE	A211886	002	Jan 25, 2024	Jan	NEWA	
AB		EQ 40MG BASE	A211886	003	Jan 25, 2024	Jan	NEWA	
AB		EQ 80MG BASE	A211886	004	Jan 25, 2024	Jan	NEWA	
AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A217118	001	Feb 13, 2024	Feb	NEWA	
AB		EQ 20MG BASE	A217118	002	Feb 13, 2024	Feb	NEWA	
AB		EQ 40MG BASE	A217118	003	Feb 13, 2024	Feb	NEWA	
AB		EQ 80MG BASE	A217118	004	Feb 13, 2024	Feb	NEWA	
>D>	AB	CADILA PHARMS LTD	EQ 10MG BASE	A212103	001	Oct 16, 2023	Apr	DISC
>A>	@	EQ 10MG BASE	A212103	001	Oct 16, 2023	Apr	DISC	
>D>	AB	EQ 20MG BASE	A212103	002	Oct 16, 2023	Apr	DISC	

TABLET;ORAL

ATORVASTATIN CALCIUM

>A>	@	EQ 20MG BASE	A212103	002	Oct 16, 2023	Apr	DISC	
>D>	AB	EQ 40MG BASE	A212103	003	Oct 16, 2023	Apr	DISC	
>A>	@	EQ 40MG BASE	A212103	003	Oct 16, 2023	Apr	DISC	
>D>	AB	EQ 80MG BASE	A212103	004	Oct 16, 2023	Apr	DISC	
>A>	@	EQ 80MG BASE	A212103	004	Oct 16, 2023	Apr	DISC	
	@	INVAGEN PHARMS	EQ 10MG BASE	A204846	001	Jan 09, 2017	Mar	DISC
	@		EQ 20MG BASE	A204846	002	Jan 09, 2017	Mar	DISC
	@		EQ 40MG BASE	A204846	003	Jan 09, 2017	Mar	DISC
	@		EQ 80MG BASE	A204846	004	Jan 09, 2017	Mar	DISC
AB	LAURUS	EQ 10MG BASE	A214513	001	Jan 22, 2024	Jan	NEWA	
AB		EQ 20MG BASE	A214513	002	Jan 22, 2024	Jan	NEWA	
AB		EQ 40MG BASE	A214513	003	Jan 22, 2024	Jan	NEWA	
AB		EQ 80MG BASE	A214513	004	Jan 22, 2024	Jan	NEWA	
AB	SHANDONG XINHUA	EQ 10MG BASE	A211886	001	Jan 25, 2024	Mar	CAHN	
AB		EQ 20MG BASE	A211886	002	Jan 25, 2024	Mar	CAHN	
AB		EQ 40MG BASE	A211886	003	Jan 25, 2024	Mar	CAHN	
AB		EQ 80MG BASE	A211886	004	Jan 25, 2024	Mar	CAHN	

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

>D>	AT	! AMNEAL	1%	A214752	001	Jul 14, 2022	Apr	CTEC
>A>	AT1	!	1%	A214752	001	Jul 14, 2022	Apr	CTEC
>D>	AT	APOTEX	1%	A215624	001	Nov 26, 2021	Apr	CTEC
>A>	AT1		1%	A215624	001	Nov 26, 2021	Apr	CTEC
>D>	AT	MANKIND PHARMA	1%	A218148	001	Jan 08, 2024	Apr	CTEC
>A>	AT1		1%	A218148	001	Jan 08, 2024	Apr	CTEC
>D>	AT	+ RISING	1%	N206289	001	Jul 18, 2014	Apr	CTEC
>A>	AT1	+	1%	N206289	001	Jul 18, 2014	Apr	CTEC
>A>	AT2	SOMERSET	1%	A217791	001	Apr 29, 2024	Apr	NFTG
		ISOPTO ATROPINE						
>D>	+	! ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Apr	CFTG
>A>	AT2	+	1%	N208151	001	Dec 01, 2016	Apr	CFTG

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D>	AA	@ ANI PHARMS	0.025MG;2.5MG	A086727	001		Mar	DISC
>A>		MYLAN	0.025MG;2.5MG	A085762	001		Apr	DISC
>A>		@	0.025MG;2.5MG	A085762	001		Apr	DISC

AVACINCAPTAD PEGOL SODIUM

SOLUTION;INTRAVITREAL

IZERVAY

+	!	ASTELLAS	EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)	N217225	001	Aug 04, 2023	Jan	CAHN
---	---	----------	---------------------------------------	---------	-----	--------------	-----	------

AZELAIC ACID

GEL;TOPICAL

AZELAIC ACID

>D>	AB	TARO	15%	A210549	001	Aug 23, 2019	Apr	CAHN
>A>	AB		15%	A210549	001	Aug 23, 2019	Apr	CAHN

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

@	HIKMA	0.137MG/SPRAY	A091444	001	Oct 24, 2014	Mar	DISC
---	-------	---------------	---------	-----	--------------	-----	------

AZITHROMYCIN

TABLET;ORAL

AZITHROMYCIN

@	YUNG SHIN PHARM	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb	DISC
---	-----------------	---------------	---------	-----	--------------	-----	------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

>D>	@	AKORN	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065088	001	Feb 06, 2004	Apr	CAHN
>A>	@	SAPTALIS PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065088	001	Feb 06, 2004	Apr	CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	SAPTALIS PHARMS	500 UNITS/GM;10,000 UNITS/GM	A064028	001	Jan 30, 1995	Mar	CAHN
----	-----------------	------------------------------	---------	-----	--------------	-----	------

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

@ ACIC PHARMS

0.5MG/ML

A216309 001 Aug 10, 2023 Jan DISC

@

2MG/ML

A216309 002 Aug 10, 2023 Jan DISC

TABLET;ORAL

BACLOFEN

>A>	AB	ENDO OPERATIONS	10MG	A077068	002	Aug 30, 2005	Apr	CAHN
-----	----	-----------------	------	---------	-----	--------------	-----	------

>A>	AB		20MG	A077068	001	Aug 30, 2005	Apr	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

@ IMPAX

5MG

A077971 003 Jul 07, 2021 Mar DISC

@

10MG

A077971 001 Oct 26, 2007 Mar DISC

@

20MG

A077971 002 Oct 26, 2007 Mar DISC

AB	RUBICON	15MG	A209102	004	Feb 05, 2024	Feb	CTEC
----	---------	------	---------	-----	--------------	-----	------

15MG

A209102 004 Feb 05, 2024 Jan NEWA

>D>	AB	VINTAGE PHARMS	10MG	A077068	002	Aug 30, 2005	Apr	CAHN
-----	----	----------------	------	---------	-----	--------------	-----	------

>D>	AB		20MG	A077068	001	Aug 30, 2005	Apr	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB	ZYDUS LIFESCIENCES	750MG	A217592	001	Jun 08, 2023	Mar	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

>A>	AA	ENDO OPERATIONS	0.5MG	A040715	001	Aug 27, 2007	Apr	CAHN
-----	----	-----------------	-------	---------	-----	--------------	-----	------

>A>	AA		1MG	A040715	002	Aug 27, 2007	Apr	CAHN
-----	----	--	-----	---------	-----	--------------	-----	------

>A>	AA		2MG	A040715	003	Aug 27, 2007	Apr	CAHN
-----	----	--	-----	---------	-----	--------------	-----	------

@ INVAGEN PHARMS

0.5MG

A090294 001 Mar 29, 2010 Mar DISC

@

1MG

A090294 002 Mar 29, 2010 Mar DISC

@

2MG

A090294 003 Mar 29, 2010 Mar DISC

>D>	AA	VINTAGE	0.5MG	A040715	001	Aug 27, 2007	Apr	CAHN
-----	----	---------	-------	---------	-----	--------------	-----	------

>D>	AA		1MG	A040715	002	Aug 27, 2007	Apr	CAHN
-----	----	--	-----	---------	-----	--------------	-----	------

>D>	AA		2MG	A040715	003	Aug 27, 2007	Apr	CAHN
-----	----	--	-----	---------	-----	--------------	-----	------

BERDAZIMER SODIUM

GEL;TOPICAL

ZELSUVMI

+	!	LNHC	EQ 10.3% BASE	N217424	001	Jan 05, 2024	Jan	NEWA
---	---	------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

@ HIKMA EQ 0.05% BASE

A208849 001 Oct 11, 2019 Mar DISC

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	AUROBINDO PHARMA LTD	EQ 0.05% BASE	A218289	001	Apr 10, 2024	Mar	NEWA
----	----------------------	---------------	---------	-----	--------------	-----	------

@ PADAGIS US EQ 0.05% BASE

A206118 001 Nov 09, 2017 Jan CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

>D>	AB	!	TARO	EQ 0.05% BASE;1%	A075673	001	May 29, 2001	Apr	CAHN
-----	----	---	------	------------------	---------	-----	--------------	-----	------

>A>	AB	!		EQ 0.05% BASE;1%	A075673	001	May 29, 2001	Apr	CAHN
-----	----	---	--	------------------	---------	-----	--------------	-----	------

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB	CHARTWELL RX	50MG	A091011	001	Jun 10, 2015	Jan	CAHN
----	--------------	------	---------	-----	--------------	-----	------

@ RISING 50MG

A079185 001 Jul 06, 2009 Feb CAHN

BIMATOPROSTSOLUTION/DROPS; TOPICAL
BIMATOPROST

@	HIKMA	0.03%	A203051	001	Oct 09, 2018	Mar	DISC
---	-------	-------	---------	-----	--------------	-----	------

BIRCH TRITERPENESGEL; TOPICAL
FILSUVEZ

+!	CHIESI	10%	N215064	001	Dec 18, 2023	Jan	CAHN
----	--------	-----	---------	-----	--------------	-----	------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	HARMAN FINOCHEM	5MG	A217617	001	Jan 18, 2024	Jan	NEWA
AB		10MG	A217617	002	Jan 18, 2024	Jan	NEWA

BLEOMYCIN SULFATEINJECTABLE; INJECTION
BLEOMYCIN SULFATE

@	TEVA PHARMS USA	EQ 15 UNITS BASE/VIAL	A065033	001	Jun 27, 2000	Jan	DISC
@		EQ 30 UNITS BASE/VIAL	A065033	002	Jun 27, 2000	Jan	DISC

BORTEZOMIBINJECTABLE; INTRAVENOUS, SUBCUTANEOUS
BORTEZOMIB

>A>	AP	HETERO LABS LTD VI	3.5MG/VIAL	A212204	001	May 03, 2024	Apr	NEWA
-----	----	--------------------	------------	---------	-----	--------------	-----	------

BOSENTAN

TABLET; ORAL

BOSENTAN

>A>	@	ENDO OPERATIONS	62.5MG	A205699	001	Apr 26, 2019	Apr	CAHN
>A>	@		125MG	A205699	002	Apr 26, 2019	Apr	CAHN
>D>	@	PAR PHARM INC	62.5MG	A205699	001	Apr 26, 2019	Apr	CAHN
>D>	@		125MG	A205699	002	Apr 26, 2019	Apr	CAHN

BREMELANOTIDE ACETATESOLUTION; SUBCUTANEOUS
VYLEESI (AUTOINJECTOR)

>A>	+!	COSETTE	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Apr	CAHN
>D>	+!	PALATIN TECHNOLOGIES	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Apr	CAHN

BRIMONIDINE TARTRATESOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE

AB	SANDOZ	0.1%	A203172	001	Mar 04, 2024	Feb	NEWA
----	--------	------	---------	-----	--------------	-----	------

BROMFENAC SODIUMSOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

AB	LUPIN LTD	EQ 0.075% ACID	A211239	001	Feb 02, 2024	Jan	NFTG	
AB	+!	SUN PHARM	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Jan	CFTG

BUDESONIDESUSPENSION; ORAL
EOHILIA

+!	TAKEDA PHARMS USA	2MG/10ML	N213976	001	Feb 09, 2024	Feb	NEWA
----	-------------------	----------	---------	-----	--------------	-----	------

BUPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE

AP	ASPIRO	0.25%	A217821	001	Mar 27, 2024	Mar	NEWA
AP		0.5%	A217821	002	Mar 27, 2024	Mar	NEWA
AP		0.75%	A217821	003	Mar 27, 2024	Mar	NEWA

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
VIVACAINE

! SEPTODONT 0.5%;0.0091MG/ML A077250 001 Sep 27, 2006 Jan CTNA

BUPRENORPHINE HYDROCHLORIDE

IMPLANT; IMPLANTATION
PROBUPHINE

>A> + @ REACK PHARMS EQ 80MG BASE/IMPLANT N204442 001 May 26, 2016 Apr CAHN
>D> + @ TITAN PHARMS EQ 80MG BASE/IMPLANT N204442 001 May 26, 2016 Apr CAHN

INJECTABLE; INJECTION
BUPRENORPHINE HYDROCHLORIDE

@ AM REGENT EQ 0.3MG BASE/ML A078331 001 Mar 27, 2007 Jan DISC

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

>D> @ AUROBINDO PHARMA USA 75MG A075491 001 Apr 17, 2000 Apr CMFD
>A> AB 75MG A075491 001 Apr 17, 2000 Apr CMFD
>D> @ 100MG A075491 002 Apr 17, 2000 Apr CMFD
>A> AB 100MG A075491 002 Apr 17, 2000 Apr CMFD
@ INVAGEN PHARMS 75MG A207389 001 Sep 18, 2017 Mar DISC
@ 100MG A207389 002 Sep 18, 2017 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

@ ANCHEN PHARMS 100MG A091459 001 Jun 09, 2011 Feb DISC
@ 150MG A091459 002 Jun 09, 2011 Feb DISC
@ 150MG A091520 001 Jun 09, 2011 Feb DISC
@ 200MG A091459 003 Jun 09, 2011 Feb DISC
@ INVAGEN PHARMS 100MG A206674 001 Feb 09, 2016 Mar DISC
@ 150MG A206556 001 Aug 26, 2016 Mar DISC
@ 150MG A206674 002 Feb 09, 2016 Mar DISC
@ 200MG A206674 003 Feb 09, 2016 Mar DISC
@ 300MG A206556 002 Aug 26, 2016 Mar DISC
@ RISING 150MG A090941 001 May 03, 2010 Feb CAHN
AB3 TWI PHARMS 150MG A210081 001 Nov 03, 2017 Mar CAHN
AB3 300MG A210081 002 Nov 03, 2017 Mar CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB AIPING PHARM INC 5MG A202087 001 Dec 16, 2015 Jan CAHN
AB 10MG A202087 002 Dec 16, 2015 Jan CAHN
AB 15MG A202087 003 Dec 16, 2015 Jan CAHN
AB 30MG A202087 004 Dec 16, 2015 Jan CAHN
@ AMNEAL PHARMS CO 5MG A208829 001 May 24, 2017 Mar DISC
@ 7.5MG A208829 002 May 24, 2017 Mar DISC
@ 10MG A208829 003 May 24, 2017 Mar DISC
@ 15MG A208829 004 May 24, 2017 Mar DISC
@ 30MG A208829 005 May 24, 2017 Mar DISC

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

@ NEXUS 6MG/ML A207794 001 Jan 14, 2019 Mar DISC

CABAZITAXEL

SOLUTION; INTRAVENOUS

CABAZITAXEL

+! ACTAVIS 60MG/6ML (10MG/ML) N207970 001 Mar 14, 2024 Mar NEWA

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

@ HIKMA 0.005% A077579 001 Nov 19, 2009 Mar DISC

CALCITONIN SALMONINJECTABLE; INJECTION
CALCITONIN-SALMON

>A>	AP	DR REDDYS	200 IU/ML	A215715	001	Apr 11, 2024	Apr	NEWA
-----	----	-----------	-----------	---------	-----	--------------	-----	------

CALCIUM ACETATECAPSULE; ORAL
CALCIUM ACETATE

>D>	AB	INVAGEN PHARMS	667MG	A203135	001	Feb 07, 2013	Apr	CHRS
>A>	AB	!	667MG	A203135	001	Feb 07, 2013	Apr	CHRS
>D>		PHOSLO GELCAPS						
>D>	AB	+! FRESENIUS MEDCL	667MG	N021160	003	Apr 02, 2001	Apr	DISC
>A>		+ @	667MG	N021160	003	Apr 02, 2001	Apr	DISC

CALCIUM GLUCONATESOLUTION; INTRAVENOUS
CALCIUM GLUCONATE

>A>	AP	NIVAGEN PHARMS INC	10GM/100ML (100MG/ML)	A213071	003	Apr 30, 2024	Apr	NEWA
-----	----	--------------------	-----------------------	---------	-----	--------------	-----	------

CAPECITABINETABLET; ORAL
CAPECITABINE

AB		HETERO LABS LTD V	150MG	A210203	001	Mar 05, 2024	Feb	NEWA
AB			500MG	A210203	002	Mar 05, 2024	Feb	NEWA

CAPTOPRILTABLET; ORAL
CAPTOPRIL

AB		INNOGENIX	12.5MG	A074677	004	May 30, 1997	Mar	CAHN
AB			25MG	A074677	002	May 30, 1997	Mar	CAHN
AB			50MG	A074677	001	May 30, 1997	Mar	CAHN
AB			100MG	A074677	003	May 30, 1997	Mar	CAHN
AB		STASON PHARMS	12.5MG	A074677	004	May 30, 1997	Feb	CAHN
AB			25MG	A074677	002	May 30, 1997	Feb	CAHN
AB			50MG	A074677	001	May 30, 1997	Feb	CAHN
AB			100MG	A074677	003	May 30, 1997	Feb	CAHN

CARBAMAZEPINETABLET; ORAL
CARBAMAZEPINE

AB		BIONPHARMA	200MG	A218221	001	Feb 16, 2024	Feb	NEWA
		TABLET, EXTENDED RELEASE; ORAL						
		CARBAMAZEPINE						
		@ ANNEAL PHARMS	100MG	A212704	001	Sep 22, 2023	Feb	DISC
		@	200MG	A212704	002	Sep 22, 2023	Feb	DISC
		@	400MG	A212704	003	Sep 22, 2023	Feb	DISC
AB		APOTEX	100MG	A213159	001	Mar 08, 2024	Mar	NEWA
AB			200MG	A213159	002	Mar 08, 2024	Mar	NEWA
AB			400MG	A213159	003	Mar 08, 2024	Mar	NEWA

CARBINOXAMINE MALEATETABLET; ORAL
CARBINOXAMINE MALEATE
@ INVAGEN PHARMS

		4MG	A090435	001	Apr 15, 2010	Mar	DISC
--	--	-----	---------	-----	--------------	-----	------

CARBOPROST TROMETHAMINEINJECTABLE; INJECTION
CARBOPROST TROMETHAMINE

AP		ANI PHARMS	EQ 0.25MG BASE/ML	A215901	001	Jan 25, 2024	Jan	NEWA
AP		MICRO LABS	EQ 0.25MG BASE/ML	A218013	001	Apr 03, 2024	Mar	NEWA

CARMUSTINEINJECTABLE; INJECTION
CARMUSTINE

		@ INGENUS PHARMS LLC	100MG/VIAL	A211011	001	Jun 21, 2022	Feb	DISC
--	--	----------------------	------------	---------	-----	--------------	-----	------

CARVEDILOL

TABLET; ORAL

CARVEDILOL

>D>	AB	MYLAN	3.125MG	A077316	001	Sep 05, 2007	Apr	DISC
>A>		@	3.125MG	A077316	001	Sep 05, 2007	Apr	DISC
		@ SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Jan	DISC
		@	6.25MG	A076989	002	Sep 05, 2007	Jan	DISC
		@	12.5MG	A076989	003	Sep 05, 2007	Jan	DISC
		@	25MG	A076989	004	Sep 05, 2007	Jan	DISC
		COREG						
>A>	AB	+ WAYLIS THERAP	3.125MG	N020297	004	May 29, 1997	Apr	CAHN
>A>	AB	+	6.25MG	N020297	003	Sep 14, 1995	Apr	CAHN
>A>	AB	+!	12.5MG	N020297	002	Sep 14, 1995	Apr	CAHN
>A>	AB	+	25MG	N020297	001	Sep 14, 1995	Apr	CAHN
>D>	AB	+ WOODWARD	3.125MG	N020297	004	May 29, 1997	Apr	CAHN
>D>	AB	+	6.25MG	N020297	003	Sep 14, 1995	Apr	CAHN
>D>	AB	+!	12.5MG	N020297	002	Sep 14, 1995	Apr	CAHN
>D>	AB	+	25MG	N020297	001	Sep 14, 1995	Apr	CAHN

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

>A>	AB	+ WAYLIS THERAP	10MG	N022012	001	Oct 20, 2006	Apr	CAHN
>A>	AB	+	20MG	N022012	002	Oct 20, 2006	Apr	CAHN
>A>	AB	+!	40MG	N022012	003	Oct 20, 2006	Apr	CAHN
>A>	AB	+	80MG	N022012	004	Oct 20, 2006	Apr	CAHN
>D>	AB	+ WOODWARD	10MG	N022012	001	Oct 20, 2006	Apr	CAHN
>D>	AB	+	20MG	N022012	002	Oct 20, 2006	Apr	CAHN
>D>	AB	+!	40MG	N022012	003	Oct 20, 2006	Apr	CAHN
>D>	AB	+	80MG	N022012	004	Oct 20, 2006	Apr	CAHN

CASPOFUNGIN ACETATE

POWDER; INTRAVENOUS

CASPOFUNGIN ACETATE

AP		AREVA PHARMS	50MG/VIAL	A211263	001	Oct 01, 2021	Mar	CAHN
AP			70MG/VIAL	A211263	002	Oct 01, 2021	Mar	CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

QILU

EQ 3GM BASE/VIAL

A203661 003 Jan 24, 2024 Jan NEWA

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

>D>	AP	ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Apr	DISC
>A>		@	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Apr	DISC
>D>	AP		EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Apr	DISC
>A>		@	EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Apr	DISC

POWDER; INTRAVENOUS

CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

>D>		SAMSON MEDCL	EQ 100GM BASE	A209408	001	Aug 21, 2018	Apr	CHRS
>A>		!	EQ 100GM BASE	A209408	001	Aug 21, 2018	Apr	CHRS

CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM

POWDER; INTRAVENOUS

EXBLIFEP

+! ALLECRA THERAPS EQ 2GM BASE/VIAL; 0.5GM/VIAL

N216165 001 Feb 22, 2024 Feb NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

+ @ STERIMAX EQ 500MG BASE/VIAL

N050547 001 Jan CAHN

+ @ EQ 1GM BASE/VIAL

N050547 002 Jan CAHN

+ @ EQ 2GM BASE/VIAL

N050547 003 Jan CAHN

+ @ EQ 10GM BASE/VIAL

N050547 004 Dec 29, 1983 Jan CAHN

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

@ STERIMAX EQ 20MG BASE/ML

N050596 002 May 20, 1985 Jan CAHN

@ EQ 40MG BASE/ML

N050596 004 May 20, 1985 Jan CAHN

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ STERIMAX EQ 20MG BASE/ML

N050596 001 May 20, 1985 Jan CAHN

INJECTABLE; INJECTION

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ EQ 40MG BASE/ML N050596 003 May 20, 1985 Jan CAHN

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

AP + PAI HOLDINGS PHARM EQ 1GM BASE/VIAL N050588 001 Dec 27, 1985 Feb CMFD

AP + EQ 2GM BASE/VIAL N050588 002 Dec 27, 1985 Feb CMFD

CEFOTETAN

AP ! FRESENIUS KABI USA EQ 1GM BASE/VIAL A065374 001 Aug 09, 2007 Feb CTEC

AP ! EQ 2GM BASE/VIAL A065374 002 Aug 09, 2007 Feb CTEC

CEFPROZIL

TABLET; ORAL

CEFPROZIL

AB ALKEM LABS LTD 250MG A090857 001 Apr 09, 2024 Mar NEWA

AB 500MG A090857 002 Apr 09, 2024 Mar NEWA

>A> CEFTOBIPROLE MEDOCARIL SODIUM

>A> POWDER; INTRAVENOUS

>A> ZEVTERA

>A> +! BASILEA PHARM ALLSCH 667MG/VIAL N218275 001 Apr 03, 2024 Apr NEWA

CEFTRIAZONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAZONE

>D> AP ASTRAL EQ 250MG BASE/VIAL A091049 001 Jun 11, 2018 Apr DISC

>A> @ EQ 250MG BASE/VIAL A091049 001 Jun 11, 2018 Apr DISC

>D> AP EQ 500MG BASE/VIAL A091049 002 Jun 11, 2018 Apr DISC

>A> @ EQ 500MG BASE/VIAL A091049 002 Jun 11, 2018 Apr DISC

>D> AP EQ 1GM BASE/VIAL A091049 003 Jun 11, 2018 Apr DISC

>A> @ EQ 1GM BASE/VIAL A091049 003 Jun 11, 2018 Apr DISC

>D> AP EQ 2GM BASE/VIAL A091049 004 Jun 11, 2018 Apr DISC

>A> @ EQ 2GM BASE/VIAL A091049 004 Jun 11, 2018 Apr DISC

AP DEVA HOLDING AS EQ 250MG BASE/VIAL A210197 001 Jan 12, 2024 Jan NEWA

AP EQ 500MG BASE/VIAL A210197 002 Jan 12, 2024 Jan NEWA

AP EQ 1GM BASE/VIAL A210197 003 Jan 12, 2024 Jan NEWA

AP EQ 2GM BASE/VIAL A210197 004 Jan 12, 2024 Jan NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL

CETIRIZINE HYDROCHLORIDE

AA @ ACTAVIS MID ATLANTIC 5MG/5ML A078617 001 Feb 02, 2010 Feb CDFR

AA @ AMNEAL PHARMS 5MG/5ML A090766 001 Oct 07, 2009 Feb CDFR

AA @ APOZEAL PHARMS 5MG/5ML A078870 001 Apr 27, 2009 Feb CDFR

AA @ AUROBINDO PHARMA LTD 5MG/5ML A090751 001 Dec 16, 2009 Feb CDFR

AA @ BAJAJ 5MG/5ML A090191 001 Nov 12, 2009 Feb CDFR

AA @ BIONPHARMA 5MG/5ML A078488 001 Oct 06, 2008 Feb CDFR

AA @ CHARTWELL MOLECULAR 5MG/5ML A078876 001 May 11, 2012 Feb CDFR

AA @ LANNETT CO INC 5MG/5ML A078496 001 Sep 25, 2009 Feb CDFR

AA ! PADAGIS US 5MG/5ML A078398 001 Jun 17, 2008 Feb CDFR

AA @ PHARM ASSOC 5MG/5ML A078412 001 Jun 18, 2008 Feb CDFR

AA @ RANBAXY LABS LTD 5MG/5ML A077472 001 Jun 18, 2008 Feb CDFR

AA @ TARO 5MG/5ML A076601 001 Jun 20, 2008 Feb CDFR

AA @ TEVA PHARMS 5MG/5ML A077279 001 May 27, 2008 Mar DISC

AA @ WOCKHARDT 5MG/5ML A077279 001 May 27, 2008 Feb CDFR

AA @ ZYRTEC 5MG/5ML A078757 001 Aug 28, 2009 Feb CDFR

AA @ J AND J CONSUMER INC 5MG/5ML N020346 001 Sep 27, 1996 Feb CDFR

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA @ PHARM ASSOC 5MG/5ML A078412 001 Jun 18, 2008 Jan CMFD

CETRORELIX ACETATE

POWDER; SUBCUTANEOUS

CETRORELIX ACETATE

>A> AP GLAND EQ 0.25MG BASE/VIAL A218150 001 Apr 25, 2024 Apr NEWA

>A> AP LIVZON GRP EQ 0.25MG BASE/VIAL A214540 001 Apr 24, 2024 Apr NEWA

>A> AP QILU EQ 0.25MG BASE/VIAL A217776 001 Apr 16, 2024 Apr NEWA

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

@ FRESenius KABI USA EQ 1GM BASE/VIAL

A062365 001 Aug 25, 1982 Feb DISC

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

@ RK PHARMA EQ 500MG BASE/VIAL

A202493 001 Jun 18, 2014 Mar DISC

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

>D> @ DR REDDYS 25MG/ML

A080365 001

Apr CMFD

>A> AP 25MG/ML

A080365 001

Apr CMFD

AP ZYDUS PHARMS 25MG/ML

A217275 001 Mar 13, 2024 Mar NEWA

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB ZAMEER PHARMS 10MG

A212630 001 Nov 29, 2021 Feb CAHN

AB 25MG

A212630 002 Nov 29, 2021 Feb CAHN

AB 50MG

A212630 003 Nov 29, 2021 Feb CAHN

AB 100MG

A212630 004 Nov 29, 2021 Feb CAHN

AB 200MG

A212630 005 Nov 29, 2021 Feb CAHN

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

>D> AB APTAPHARMA INC 375MG

A212053 001 Sep 14, 2020 Apr DISC

>A> @ 375MG

A212053 001 Sep 14, 2020 Apr DISC

>D> AB 750MG

A212053 002 Sep 14, 2020 Apr DISC

>A> @ 750MG

A212053 002 Sep 14, 2020 Apr DISC

>A> AB ENDO OPERATIONS 375MG

A212743 002 Apr 29, 2021 Apr CAHN

>A> AB 750MG

A212743 001 Nov 02, 2020 Apr CAHN

AA HAVIX 500MG

A210961 001 Jan 22, 2024 Jan NEWA

>D> AB PAR PHARM INC 375MG

A212743 002 Apr 29, 2021 Apr CAHN

>D> AB 750MG

A212743 001 Nov 02, 2020 Apr CAHN

AA SENORES PHARMS 250MG

A215158 001 Jul 29, 2021 Feb CAHN

AA 500MG

A210961 001 Jan 22, 2024 Feb CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

@ ANCHEN PHARMS EQ 45MG FENOFIBRIC ACID

A201573 002 Jul 18, 2013 Mar DISC

@ EQ 135MG FENOFIBRIC ACID

A201573 001 Jul 18, 2013 Mar DISC

AB MACLEODS PHARMS LTD EQ 45MG FENOFIBRIC ACID

A207796 001 Feb 08, 2024 Feb NEWA

AB EQ 135MG FENOFIBRIC ACID

A207796 002 Feb 08, 2024 Feb NEWA

AB TWI PHARMS EQ 45MG FENOFIBRIC ACID

A210469 001 Jul 05, 2019 Mar CAHN

AB EQ 135MG FENOFIBRIC ACID

A210469 002 Jul 05, 2019 Mar CAHN

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB TARO 0.77%

A076790 001 Apr 12, 2005 Jan CAHN

SOLUTION; TOPICAL

CICLOPIROX

@ HIKMA 8%

A078270 001 Sep 18, 2007 Mar DISC

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

@ RISING 50MG

A077323 002 Apr 20, 2006 Feb CAHN

@ 100MG

A077323 001 Apr 20, 2006 Feb CAHN

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ PAI HOLDINGS PHARM EQ 300MG BASE/5ML

A074664 001 Oct 28, 1997 Feb DISC

@ PHARM ASSOC EQ 300MG BASE/5ML

A074553 001 Jan 27, 1997 Feb DISC

CIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

@ SAPTALIS PHARMS EQ 0.3% BASE

A 076555 001 Dec 11, 2008 Mar CAHN

SOLUTION/DROPS;OTIC

CETRAXAL

>A> +! KEY THERAP EQ 0.2% BASE

N 021918 001 May 01, 2009 Apr CAHN

>D> +! WRASER PHARMS EQ 0.2% BASE

N 021918 001 May 01, 2009 Apr CAHN

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

>D> @ AIPING PHARM INC EQ 250MG BASE

A 076593 002 Jun 09, 2004 Apr CMFD

>A> AB EQ 250MG BASE

A 076593 002 Jun 09, 2004 Apr CMFD

>D> @ EQ 500MG BASE

A 076593 003 Jun 09, 2004 Apr CMFD

>A> AB EQ 500MG BASE

A 076593 003 Jun 09, 2004 Apr CMFD

>D> @ EQ 750MG BASE

A 076593 004 Jun 09, 2004 Apr CMFD

>A> AB EQ 750MG BASE

A 076593 004 Jun 09, 2004 Apr CMFD

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

@ ANCHEN PHARMS 212.6MG;EQ 287.5MG BASE

A 078166 002 Nov 27, 2007 Mar DISC

@ 425.2MG;EQ 574.9MG BASE

A 078166 001 Nov 27, 2007 Mar DISC

! DR REDDYS LABS LTD 425.2MG;EQ 574.9MG BASE

A 077701 001 Mar 26, 2007 Mar CTEC

AB ! 425.2MG;EQ 574.9MG BASE

A 077701 001 Mar 26, 2007 Mar CHRS

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPROFLOXACIN; DEXAMETHASONE

AB AMNEAL 0.3%;0.1%

A 216501 001 Mar 22, 2024 Mar NEWA

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

>D> AP CAPLIN EQ 2MG BASE/ML

A 217725 001 Jun 09, 2023 Apr DISC

>A> @ EQ 2MG BASE/ML

A 217725 001 Jun 09, 2023 Apr DISC

>D> AP EQ 10MG BASE/ML

A 217725 002 Jun 09, 2023 Apr DISC

>A> @ EQ 10MG BASE/ML

A 217725 002 Jun 09, 2023 Apr DISC

AP HAINAN POLY EQ 2MG BASE/ML

A 216538 001 Mar 08, 2024 Mar NEWA

>D> AP MEITHEAL EQ 2MG BASE/ML

A 211668 001 Apr 25, 2019 Apr CHRS

>A> AP ! EQ 2MG BASE/ML

A 211668 001 Apr 25, 2019 Apr CHRS

>D> AP EQ 2MG BASE/ML

A 211669 001 Apr 25, 2019 Apr CHRS

>A> AP ! EQ 2MG BASE/ML

A 211669 001 Apr 25, 2019 Apr CHRS

>D> AP EQ 10MG BASE/ML

A 211668 002 Apr 25, 2019 Apr CHRS

>A> AP ! EQ 10MG BASE/ML

A 211668 002 Apr 25, 2019 Apr CHRS

AP PIRAMAL CRITICAL EQ 2MG BASE/ML

A 215516 003 Dec 14, 2022 Mar CMS1

>D> NIMBEX

>D> AP +! ABBVIE EQ 2MG BASE/ML

N 020551 001 Dec 15, 1995 Apr DISC

>A> + @ EQ 2MG BASE/ML

N 020551 001 Dec 15, 1995 Apr DISC

>D> NIMBEX PRESERVATIVE FREE

>D> AP +! ABBVIE EQ 2MG BASE/ML

N 020551 003 Dec 15, 1995 Apr DISC

>A> + @ EQ 2MG BASE/ML

N 020551 003 Dec 15, 1995 Apr DISC

>D> AP +! EQ 10MG BASE/ML

N 020551 002 Dec 15, 1995 Apr DISC

>A> + @ EQ 10MG BASE/ML

N 020551 002 Dec 15, 1995 Apr DISC

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB APOTEX EQ 10MG BASE

A 077046 001 Nov 24, 2004 Jan CAHN

AB EQ 20MG BASE

A 077046 002 Nov 24, 2004 Jan CAHN

AB EQ 40MG BASE

A 077046 003 Nov 24, 2004 Jan CAHN

>D> AB COSETTE EQ 10MG BASE

A 077048 001 Nov 16, 2004 Apr DISC

>A> @ EQ 10MG BASE

A 077048 001 Nov 16, 2004 Apr DISC

>D> AB EQ 20MG BASE

A 077048 002 Nov 16, 2004 Apr DISC

>A> @ EQ 20MG BASE

A 077048 002 Nov 16, 2004 Apr DISC

>D> AB EQ 40MG BASE

A 077048 003 Nov 16, 2004 Apr DISC

>A> @ EQ 40MG BASE

A 077048 003 Nov 16, 2004 Apr DISC

@ TARO EQ 10MG BASE

A 077278 001 Mar 22, 2006 Jan CAHN

@ EQ 20MG BASE

A 077278 002 Mar 22, 2006 Jan CAHN

@ EQ 40MG BASE

A 077278 003 Mar 22, 2006 Jan CAHN

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

@ NEW HEIGHTS

EQ 0.5MG BASE/5ML

A074884 001 Dec 17, 1997 Jan CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

>D>	AB	COSETTE	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr	DISC
>A>		@	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr	DISC
>D>	AB		EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr	DISC
>A>		@	EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr	DISC

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

AB1		ALEMBIC	EQ 1% BASE	A212466	001	Apr 02, 2024	Mar	NEWA
		@ AMNEAL	EQ 1% BASE	A215219	001	Nov 03, 2022	Feb	DISC

GEL;VAGINAL

XACIATO

+! ORGANON LLC

EQ 2% BASE

N215650 001 Dec 07, 2021 Jan CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

>A>		@ ENDO OPERATIONS	EQ 1% BASE	A203343	001	May 29, 2015	Apr	CAHN
>D>		@ VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	Apr	CAHN

CLOBAZAM

TABLET;ORAL

CLOBAZAM

@ BRECKENRIDGE

20MG

A209308 002 Oct 22, 2018 Jan DISC

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB2		TARO	0.05%	A208563	001	Mar 14, 2024	Mar	NEWA
-----	--	------	-------	---------	-----	--------------	-----	------

CREAM;TOPICAL

CLOBETASOL PROPIONATE

>D>	AB1	COSETTE	0.05%	A074139	001	Aug 03, 1994	Apr	DISC
>A>		@	0.05%	A074139	001	Aug 03, 1994	Apr	DISC
		CORMAX						
		@ HIKMA	0.05%	A074220	001	May 16, 1997	Mar	DISC

GEL;TOPICAL

EMBELINE

@ HIKMA

0.05%

A076141 001 Apr 12, 2002 Mar DISC

OINTMENT;TOPICAL

EMBELINE

@ HIKMA

0.05%

A074221 001 Mar 31, 1995 Mar DISC

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE

@ HIKMA

0.05%

A209871 001 Oct 27, 2017 Mar DISC

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

>D>	AT	COSETTE	0.05%	A074331	001	Dec 15, 1995	Apr	DISC
>A>		@	0.05%	A074331	001	Dec 15, 1995	Apr	DISC
		EMBELINE						
		@ HIKMA	0.05%	A074222	001	Dec 06, 1995	Mar	DISC

SUSPENSION/DROPS;OPHTHALMIC

CLOBETASOL PROPIONATE

+! FORMOSA

0.05%

N218158 001 Mar 04, 2024 Mar NEWA

CLOCORTOLONE PIVALATE

CREAM;TOPICAL

CLODERM

>D>	AB	+! EPI HLTH	0.1%	N017765	001		Apr	CAHN
>A>	AB	+! LEGACY PHARMA	0.1%	N017765	001		Apr	CAHN

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	CHARTWELL RX	25MG	A 074364	001	Mar 29, 1996	Mar	CAHN
AB		50MG	A 074364	002	Mar 29, 1996	Mar	CAHN
AB		75MG	A 074364	003	Mar 29, 1996	Mar	CAHN
	@ RK PHARMA	25MG	A 213221	001	Jun 22, 2020	Mar	DISC
	@	50MG	A 213221	002	Jun 22, 2020	Mar	DISC
	@	75MG	A 213221	003	Jun 22, 2020	Mar	DISC

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

>A>	AB	ENDO OPERATIONS	0.125MG	A 077171	001	Aug 03, 2005	Apr	CAHN
>A>	AB		0.25MG	A 077171	002	Aug 03, 2005	Apr	CAHN
>A>	AB		0.5MG	A 077171	003	Aug 03, 2005	Apr	CAHN
>A>	AB	!	1MG	A 077171	004	Aug 03, 2005	Apr	CAHN
>A>	AB		2MG	A 077171	005	Aug 03, 2005	Apr	CAHN
>D>	AB	PAR PHARM	0.125MG	A 077171	001	Aug 03, 2005	Apr	CAHN
>D>	AB		0.25MG	A 077171	002	Aug 03, 2005	Apr	CAHN
>D>	AB		0.5MG	A 077171	003	Aug 03, 2005	Apr	CAHN
>D>	AB	!	1MG	A 077171	004	Aug 03, 2005	Apr	CAHN
>D>	AB		2MG	A 077171	005	Aug 03, 2005	Apr	CAHN

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

	@ ANCHEN PHARMS	0.1MG	A 202984	001	Sep 30, 2013	Mar	DISC
	@ BLUEPHARMA INDUSTRIA	0.1MG	A 211433	001	Oct 12, 2018	Jan	CAHN

CLOTTRIMAZOLE

TROCHE/LOZENGE;ORAL

CLOTTRIMAZOLE

AB	THINQ PHARM-CRO PVT	10MG	A 215641	001	Feb 29, 2024	Feb	NEWA
----	---------------------	------	----------	-----	--------------	-----	------

COBICISTAT

TABLET;ORAL

COBICISTAT

AB	MYLAN LABS LTD	150MG	A 209986	001	Feb 07, 2024	Jan	NFTG
AB	TYBOST						
AB	+! GILEAD SCIENCES INC	150MG	N 203094	001	Sep 24, 2014	Jan	CFTG

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

GOPRELTO

+!	NODEN PHARMA	4%	N 209963	001	Dec 14, 2017	Jan	CAHN
----	--------------	----	----------	-----	--------------	-----	------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

>A>	AA	!	GENUS	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A 040660	001	Dec 07, 2006	Apr	CAHN
>D>	AA	!	PHARM ASSOC	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A 040660	001	Dec 07, 2006	Apr	CAHN
			PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE						
			@ HIKMA	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A 040674	001	Dec 23, 2014	Mar	DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

	@ HIKMA	10MG/5ML; 6.25MG/5ML	A 040151	001	Aug 26, 1997	Mar	DISC
--	---------	----------------------	----------	-----	--------------	-----	------

COLCHICINE

CAPSULE;ORAL

COLCHICINE

>A>	AB	ANNORA PHARMA	0.6MG	A 217620	001	Apr 29, 2024	Apr	NEWA
>A>	AB	AUROBINDO PHARMA LTD	0.6MG	A 215463	001	Apr 29, 2024	Apr	NEWA
>A>	AB	GRANULES	0.6MG	A 210757	001	Apr 29, 2024	Apr	NEWA

TABLET;ORAL

COLCHICINE

>D>	AB	MYLAN	0.6MG	A 209470	001	Sep 16, 2019	Apr	DISC
>A>		@	0.6MG	A 209470	001	Sep 16, 2019	Apr	DISC

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDESUSPENSION/DROPS;OTIC
COLY-MYCIN S

>A>	+	ENDO OPERATIONS	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001			Apr	CAHN
>D>	+	ENDO PHARMS INC	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001			Apr	CAHN

CORTICOTROPININJECTABLE;INJECTION
ACTHAR GEL (AUTOINJECTOR)

+	!	MALLINCKRODT ARD	40 UNITS/0.5ML	N008372	003	Feb 29, 2024		Mar	NEWA
+	!		80 UNITS/ML	N008372	004	Feb 29, 2024		Mar	NEWA

CUPRIC CHLORIDEINJECTABLE;INJECTION
CUPRIC CHLORIDE

>A>	AP	SOMERSET	EQ 0.4MG COPPER/ML	A216113	001	Apr 30, 2024		Apr	NEWA
>A>	AP	STIRA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024		Apr	NEWA

CYCLOPENTOLATE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
CYCLOPENTOLATE HYDROCHLORIDE

@	SAPTALIS PHARMS	0.5%		A205937	001	Dec 09, 2015		Mar	CAHN
---	-----------------	------	--	---------	-----	--------------	--	-----	------

CYCLOPHOSPHAMIDEINJECTABLE;INJECTION
CYCLOPHOSPHAMIDE

AP		HIKMA	500MG/VIAL	A216958	001	Dec 18, 2023		Jan	CAHN
AP			1GM/VIAL	A216958	002	Dec 18, 2023		Jan	CAHN
AP			2GM/VIAL	A216958	003	Dec 18, 2023		Jan	CAHN

SOLUTION;INTRAVENOUS
CYCLOPHOSPHAMIDE

+	@	BAXTER HLTHCARE CORP	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023		Jan	CAHN
+	@		1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023		Jan	CAHN

CYPROHEPTADINE HYDROCHLORIDESYRUP;ORAL
CYPROHEPTADINE HYDROCHLORIDE

>D>	AA	PATRIN	2MG/5ML	A204823	001	Dec 27, 2016		Apr	DISC
>A>		@	2MG/5ML	A204823	001	Dec 27, 2016		Apr	DISC
		@	PHARM ASSOC	A091295	001	Mar 28, 2013		Feb	DISC

CYSTEINE HYDROCHLORIDESOLUTION;INTRAVENOUS
ELCYS

+	@	EXELA PHARMA	2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023		Jan	DISC
---	---	--------------	-----------------------	---------	-----	--------------	--	-----	------

DACTINOMYCININJECTABLE;INJECTION
COSMEGEN

+	@	RECORDATI RARE	0.5MG/VIAL	N050682	001			Jan	DISC
AP	!	EUGIA PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017		Jan	CHRS

DANICOPANTABLET;ORAL
VOYDEYA

+		ALEXION PHARMS INC	50MG	N218037	001	Mar 29, 2024		Mar	NEWA
+	!		100MG	N218037	002	Mar 29, 2024		Mar	NEWA

DAPSONEGEL;TOPICAL
DAPSONE

		@	PADAGIS ISRAEL	5%	A215087	001	Oct 31, 2023	Jan	DISC
		@		7.5%	A212657	001	Nov 01, 2023	Jan	DISC
>A>	AB		ZYDUS	7.5%	A214019	001	May 08, 2024	Apr	NEWA

DEFERASIROXGRANULE; ORAL
DEFERASIROX

>A>	AB	MYLAN	90MG	A213146	001	May 03, 2024	Apr	NEWA
>A>	AB		180MG	A213146	002	May 03, 2024	Apr	NEWA
>A>	AB		360MG	A213146	003	May 03, 2024	Apr	NEWA

TABLET; ORAL
DEFERASIROX

	AB	MYLAN	90MG	A211395	001	Mar 22, 2024	Mar	NEWA
	AB		180MG	A211395	002	Mar 22, 2024	Mar	NEWA
	AB		360MG	A211395	003	Mar 22, 2024	Mar	NEWA

DEFLAZACORTSUSPENSION; ORAL
DEFLAZACORT

>A>	AB	TRIS PHARMA INC	22.75MG/ML	A217813	001	Apr 25, 2024	Apr	NFTG
>D>	+	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr	CFTG
>A>	AB	EMFLAZA	22.75MG/ML	N208685	001	Feb 09, 2017	Apr	CFTG

TABLET; ORAL
DEFLAZACORT

	AB	AUROBINDO PHARMA LTD	6MG	A217123	001	Feb 09, 2024	Feb	NFTG
	AB		18MG	A217123	002	Feb 09, 2024	Feb	NFTG
	AB		30MG	A217123	003	Feb 09, 2024	Feb	NFTG
	AB		36MG	A217123	004	Feb 09, 2024	Feb	NFTG
	AB	EMFLAZA						
	AB	+ PTC THERAP	6MG	N208684	001	Feb 09, 2017	Feb	CFTG
	AB	+	18MG	N208684	002	Feb 09, 2017	Feb	CFTG
	AB	+	30MG	N208684	003	Feb 09, 2017	Feb	CFTG
	AB	+	36MG	N208684	004	Feb 09, 2017	Feb	CFTG

DEOXYCHOLIC ACIDSOLUTION; SUBCUTANEOUS
KYBELLA

AP	+	ABBVIE	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Jan	CAHN
----	---	--------	--------------------	---------	-----	--------------	-----	------

DESIPRAMINE HYDROCHLORIDETABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

	AB	CHARTWELL RX	10MG	A072103	002	May 24, 1988	Mar	CAHN
	AB		25MG	A072103	003	May 24, 1988	Mar	CAHN
	AB		50MG	A072103	004	May 24, 1988	Mar	CAHN
	AB		75MG	A072103	005	Jun 20, 1988	Mar	CAHN
	AB		100MG	A072103	001	Jun 20, 1988	Mar	CAHN
	AB		150MG	A072103	006	Jun 20, 1988	Mar	CAHN

DESLORATADINETABLET; ORAL
DESLORATADINE
@ CHARTWELL RX

		5MG	A078364	001	Dec 03, 2010	Jan	CAHN
--	--	-----	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATETABLET; ORAL
DESMOPRESSIN ACETATE

		@ ACTAVIS LABS FL INC	0.1MG	A076470	001	Jul 01, 2005	Feb	DISC
		@	0.2MG	A076470	002	Jul 01, 2005	Feb	DISC
	AB	AUROBINDO PHARMA	0.1MG	A213095	001	Mar 21, 2024	Mar	NEWA
	AB		0.2MG	A213095	002	Mar 21, 2024	Mar	NEWA

DESOGESTREL; ETHINYL ESTRADIOLTABLET; ORAL-28
DESOGESTREL AND ETHINYL ESTRADIOL

>D>		@ MYLAN LABS LTD	0.15MG; 0.03MG	A202085	001	May 20, 2015	Apr	CAHN
>D>		@ NAARI PTE LTD	0.15MG; 0.03MG	A207067	001	Sep 13, 2018	Apr	CMFD
>A>	AB		0.15MG; 0.03MG	A207067	001	Sep 13, 2018	Apr	CMFD
>A>		@ XIROMED	0.15MG; 0.03MG	A202085	001	May 20, 2015	Apr	CAHN

DESONIDE

OINTMENT; TOPICAL

DESONIDE

@	HIKMA	0.05%	A208836	001	Mar 27, 2017	Mar	DISC
---	-------	-------	---------	-----	--------------	-----	------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

@	COSETTE	0.25%	A209595	001	Mar 04, 2020	Mar	DISC
---	---------	-------	---------	-----	--------------	-----	------

@	SAPTALIS PHARMS	0.05%	A203787	001	Jan 06, 2017	Feb	CAHN
---	-----------------	-------	---------	-----	--------------	-----	------

@		0.25%	A203234	001	Jun 12, 2015	Feb	CAHN
---	--	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

DESOXIMETASONE

>D>	AB	COSETTE	0.25%	A206740	001	Dec 23, 2016	Apr	DISC
-----	----	---------	-------	---------	-----	--------------	-----	------

>A>		@	0.25%	A206740	001	Dec 23, 2016	Apr	DISC
-----	--	---	-------	---------	-----	--------------	-----	------

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

>A>	BP	KEY THERAP	1.5MG	A088237	001	Apr 28, 1983	Apr	CAHN
-----	----	------------	-------	---------	-----	--------------	-----	------

@	PANGEA	0.25MG	A088149	001	Apr 28, 1983	Jan	CAHN
---	--------	--------	---------	-----	--------------	-----	------

>D>	BP	XSPIRE PHARMA	1.5MG	A088237	001	Apr 28, 1983	Apr	CAHN
-----	----	---------------	-------	---------	-----	--------------	-----	------

AB	ZYDUS LIFESCIENCES	0.5MG	A216282	001	Feb 07, 2024	Mar	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

AB		0.75MG	A216282	002	Feb 07, 2024	Mar	CAHN
----	--	--------	---------	-----	--------------	-----	------

AB		1.5MG	A216282	003	Feb 07, 2024	Mar	CAHN
----	--	-------	---------	-----	--------------	-----	------

AB		2MG	A216283	001	Feb 07, 2024	Mar	CAHN
----	--	-----	---------	-----	--------------	-----	------

AB		4MG	A216282	004	Feb 07, 2024	Mar	CAHN
----	--	-----	---------	-----	--------------	-----	------

AB		6MG	A216282	005	Feb 07, 2024	Mar	CAHN
----	--	-----	---------	-----	--------------	-----	------

AB	ZYDUS PHARMS	0.5MG	A216282	001	Feb 07, 2024	Jan	NEWA
----	--------------	-------	---------	-----	--------------	-----	------

AB		0.75MG	A216282	002	Feb 07, 2024	Jan	NEWA
----	--	--------	---------	-----	--------------	-----	------

AB		1.5MG	A216282	003	Feb 07, 2024	Jan	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		2MG	A216283	001	Feb 07, 2024	Jan	NEWA
----	--	-----	---------	-----	--------------	-----	------

AB		4MG	A216282	004	Feb 07, 2024	Jan	NEWA
----	--	-----	---------	-----	--------------	-----	------

AB		6MG	A216282	005	Feb 07, 2024	Jan	NEWA
----	--	-----	---------	-----	--------------	-----	------

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

@	GENEYORK PHARMS	EQ 4MG PHOSPHATE/ML	A214891	001	Jul 28, 2023	Feb	DISC
---	-----------------	---------------------	---------	-----	--------------	-----	------

@		EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Feb	DISC
---	--	----------------------	---------	-----	--------------	-----	------

AP	MICRO LABS	EQ 10MG PHOSPHATE/ML	A217797	001	Mar 27, 2024	Mar	NEWA
----	------------	----------------------	---------	-----	--------------	-----	------

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

+	@	PAI HOLDINGS PHARM	2MG/5ML	A088251	001	Mar 23, 1984	Mar	DISC
---	---	--------------------	---------	---------	-----	--------------	-----	------

POLMON

!	CAPELLON PHARMS LLC	2MG/5ML	A202520	001	Jul 16, 2018	Mar	CTEC
---	---------------------	---------	---------	-----	--------------	-----	------

AA	!		2MG/5ML	A202520	001	Jul 16, 2018	Mar	CHRS
----	---	--	---------	---------	-----	--------------	-----	------

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

DEXLANSOPRAZOLE

AB	MYLAN	30MG	A205205	001	Jan 19, 2024	Jan	NEWA
----	-------	------	---------	-----	--------------	-----	------

AB		60MG	A205205	002	Jan 19, 2024	Jan	NEWA
----	--	------	---------	-----	--------------	-----	------

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	AZURITY	2.5MG	A090533	001	Oct 25, 2011	Mar	CAHN
----	---------	-------	---------	-----	--------------	-----	------

AA		5MG	A090533	002	Oct 25, 2011	Mar	CAHN
----	--	-----	---------	-----	--------------	-----	------

AA		7.5MG	A090533	003	Oct 25, 2011	Mar	CAHN
----	--	-------	---------	-----	--------------	-----	------

AA		10MG	A090533	004	Oct 25, 2011	Mar	CAHN
----	--	------	---------	-----	--------------	-----	------

AA		15MG	A090533	005	Oct 25, 2011	Mar	CAHN
----	--	------	---------	-----	--------------	-----	------

AA		20MG	A090533	006	Oct 25, 2011	Mar	CAHN
----	--	------	---------	-----	--------------	-----	------

AA		30MG	A090533	007	Oct 25, 2011	Mar	CAHN
----	--	------	---------	-----	--------------	-----	------

@	TRIS PHARMA INC	5MG	A206095	001	Aug 18, 2022	Jan	DISC
---	-----------------	-----	---------	-----	--------------	-----	------

@		10MG	A206095	002	Aug 18, 2022	Jan	DISC
---	--	------	---------	-----	--------------	-----	------

DEXTROSE

INJECTABLE; INJECTION

>A>		DEXTROSE 5%						
>A>	AP	AM REGENT	50MG/ML	A217263	001	Apr 08, 2024	Apr	CTNA
>D>		DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	AP	AM REGENT	50MG/ML	A217263	001	Apr 08, 2024	Apr	CTNA
	AP		50MG/ML	A217263	001	Apr 08, 2024	Mar	NEWA

DIAZEPAM

>A>		FILM; BUCCAL						
>A>		LIBERVANT						
>A>	+	AQUESTIVE	5MG	N218623	001	Apr 26, 2024	Apr	NEWA
>A>	+		7.5MG	N218623	002	Apr 26, 2024	Apr	NEWA
>A>	+		10MG	N218623	003	Apr 26, 2024	Apr	NEWA
>A>	+		12.5MG	N218623	004	Apr 26, 2024	Apr	NEWA
>A>	+	!	15MG	N218623	005	Apr 26, 2024	Apr	NEWA

INJECTABLE; INJECTION

DIAZEPAM

>A>	AP	ALEMBIC	10MG/2ML (5MG/ML)	A218450	001	Apr 25, 2024	Apr	NEWA
		@ HIKMA	5MG/ML (5MG/ML)	A070311	002	Dec 16, 1985	Jan	NEWA
		@	10MG/2ML (5MG/ML)	A070311	003	Dec 16, 1985	Jan	NEWA
	AP		50MG/10ML (5MG/ML)	A070311	001	Dec 16, 1985	Jan	C POT

DICHLORPHENAMIDE

TABLET; ORAL

ORMALVI

AB		TORRENT	50MG	A215924	001	Dec 29, 2022	Feb	CTNA
----	--	---------	------	---------	-----	--------------	-----	------

DICLOFENAC SODIUM

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AB	!	LUPIN PHARMS	2%	A208021	001	Sep 20, 2022	Mar	CHRS
		PENNSAID						
	+	@ HORIZON	2%	N204623	001	Jan 16, 2014	Mar	DISC

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENTYL

>D>	AP	+	!	ABBVIE	10MG/ML	N008370	001	Oct 15, 1984	Apr	DISC
>A>		+	@		10MG/ML	N008370	001	Oct 15, 1984	Apr	DISC

DICYCLOMINE HYDROCHLORIDE

>D>	AP			FOSUN PHARMA	10MG/ML	A210979	001	Jul 02, 2018	Apr	CHRS
>A>	AP		!		10MG/ML	A210979	001	Jul 02, 2018	Apr	CHRS

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

>A>	AA	!		ENDO OPERATIONS	10MG/5ML	A040169	001	Mar 24, 2005	Apr	CAHN
>D>	AA	!		GENERICS	10MG/5ML	A040169	001	Mar 24, 2005	Apr	CAHN

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

>A>	AB			ANNORA PHARMA	20MG	A217566	001	May 07, 2024	Apr	NEWA
-----	----	--	--	---------------	------	---------	-----	--------------	-----	------

DIGOXIN

ELIXIR; ORAL

DIGOXIN

AA		VISTAPHARM LLC	0.05MG/ML	A213000	001	Oct 04, 2019	Feb	CAHN
----	--	----------------	-----------	---------	-----	--------------	-----	------

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED; NASAL

DIHYDROERGOTAMINE MESYLATE

@ ANNEAL

TRUDHESA

+!

JN BIDCO

0.725MG/SPRAY

A214105	001	Jan 04, 2022	Mar	DISC
N213436	001	Sep 02, 2021	Feb	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

>A>	AB3			ENDO OPERATIONS	120MG	A074984	001	Dec 20, 1999	Apr	CAHN
>A>	AB3				180MG	A074984	002	Dec 20, 1999	Apr	CAHN
>A>	AB3				240MG	A074984	003	Dec 20, 1999	Apr	CAHN
>A>	AB3				300MG	A074984	004	Dec 20, 1999	Apr	CAHN

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

>D>	AB3	PAR PHARM	120MG	A074984	001	Dec 20, 1999	Apr	CAHN
>D>	AB3		180MG	A074984	002	Dec 20, 1999	Apr	CAHN
>D>	AB3		240MG	A074984	003	Dec 20, 1999	Apr	CAHN
>D>	AB3		300MG	A074984	004	Dec 20, 1999	Apr	CAHN
		@ SUN PHARM	360MG	A090492	005	Oct 28, 2011	Feb	DISC

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

AP		HIKMA	5MG/ML	A078538	001	Dec 17, 2008	Mar	CAHN
		@ HIKMA FARMACEUTICA	5MG/ML	A202651	001	Aug 09, 2012	Mar	DISC

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP		GLAND PHARMA LTD	50MG/ML	A218448	001	Mar 20, 2024	Mar	NEWA
----	--	------------------	---------	---------	-----	--------------	-----	------

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

		@ GENUS	25MG	A040898	001	Apr 23, 2008	Jan	CAHN
		@	50MG	A040898	002	Apr 23, 2008	Jan	CAHN
		@	75MG	A040898	003	Apr 23, 2008	Jan	CAHN

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP		ACIC PHARMS	80MG/4ML (20MG/ML)	A216677	002	Feb 28, 2024	Feb	NEWA
AP			20MG/ML (20MG/ML)	A216677	001	Feb 28, 2024	Feb	NEWA

SOLUTION; INTRAVENOUS

DOCETAXEL

>D>	+	@ AVYXA HOLDINGS	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Apr	CTNA
		+ @	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Jan	CAHN
>D>	+	@	80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Apr	CTNA
		+ @	80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Jan	CAHN
>D>	+	@	160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Apr	CTNA
		+ @	160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Jan	CAHN
		DOCIVYX						
>A>	+	! AVYXA HOLDINGS	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Apr	CMFD
>A>	+	@	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Apr	CTNA
>A>	+	!	80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Apr	CMFD
>A>	+	@	80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Apr	CTNA
>A>	+	!	160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Apr	CMFD
>A>	+	@	160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Apr	CTNA

DOLUTEGRAVIR SODIUM

TABLET; ORAL

TIVICAY

		+ @ VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016	Jan	DISC
		+ @	EQ 25MG BASE	N204790	003	Jun 09, 2016	Jan	DISC

DONEPEZIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

AB	!	MACLEODS PHARMS LTD	10MG	A201787	002	Dec 14, 2012	Mar	CHRS
		@ SANDOZ	5MG	A091198	001	May 10, 2011	Mar	DISC
		@	10MG	A091198	002	May 10, 2011	Mar	DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

		@ HIKMA	EQ 2% BASE	A077846	001	Oct 28, 2008	Mar	DISC
--	--	---------	------------	---------	-----	--------------	-----	------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

		@ HIKMA	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	Mar	DISC
--	--	---------	-------------------------	---------	-----	--------------	-----	------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB	AUROBINDO PHARMA USA	EQ 1MG BASE	A075509	001	Oct 19, 2000	Mar	CMFD
AB		EQ 2MG BASE	A075509	002	Oct 19, 2000	Mar	CMFD
AB		EQ 4MG BASE	A075509	003	Oct 19, 2000	Mar	CMFD
AB		EQ 8MG BASE	A075509	004	Oct 19, 2000	Mar	CMFD

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

>A>	@ ENDO OPERATIONS	EQ 10MG BASE	A071422	002	Nov 09, 1987	Apr	CAHN
>A>	@	EQ 25MG BASE	A071422	003	Nov 09, 1987	Apr	CAHN
>A>	@	EQ 50MG BASE	A071422	004	Nov 09, 1987	Apr	CAHN
>A>	@	EQ 75MG BASE	A071422	005	Nov 09, 1987	Apr	CAHN
>A>	@	EQ 100MG BASE	A071422	001	Nov 09, 1987	Apr	CAHN
>A> AB	!	EQ 150MG BASE	A071422	006	Nov 09, 1987	Apr	CAHN
>D>	@ PAR PHARM	EQ 10MG BASE	A071422	002	Nov 09, 1987	Apr	CAHN
>D>	@	EQ 25MG BASE	A071422	003	Nov 09, 1987	Apr	CAHN
>D>	@	EQ 50MG BASE	A071422	004	Nov 09, 1987	Apr	CAHN
>D>	@	EQ 75MG BASE	A071422	005	Nov 09, 1987	Apr	CAHN
>D>	@	EQ 100MG BASE	A071422	001	Nov 09, 1987	Apr	CAHN
>D> AB	!	EQ 150MG BASE	A071422	006	Nov 09, 1987	Apr	CAHN

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

	@ AMNEAL	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	Jan	DISC
	@	4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	Jan	DISC
AP		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jan	CMFD

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

>D> AB	COSETTE	EQ 50MG BASE	A204446	001	May 28, 2015	Apr	DISC
>A>	@	EQ 50MG BASE	A204446	001	May 28, 2015	Apr	DISC
>D> AB		EQ 75MG BASE	A204446	002	May 28, 2015	Apr	DISC
>A>	@	EQ 75MG BASE	A204446	002	May 28, 2015	Apr	DISC
>D> AB		EQ 100MG BASE	A204446	003	May 28, 2015	Apr	DISC
>A>	@	EQ 100MG BASE	A204446	003	May 28, 2015	Apr	DISC
AB	DR REDDYS	40MG	A218034	001	Apr 08, 2024	Mar	NFTG
AB	LUPIN	40MG	A216631	001	Apr 08, 2024	Mar	NFTG
AB	ORACEA						
AB	+! GALDERMA LABS LP	40MG	N050805	001	May 26, 2006	Mar	CFTG

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

ACTICLATE CAP

+ @ CHARTWELL RX

EQ 75MG BASE

N208253 001 Apr 26, 2016 Jan CAHN

INJECTABLE; INJECTION

DOXYCYCLINE HYCLATE

AP LUPIN LTD

EQ 100MG BASE/VIAL

A217794 001 Mar 14, 2024 Mar NEWA

TABLET; ORAL

ACTICLATE

AB + CHARTWELL RX

EQ 75MG BASE

N205931 001 Jul 25, 2014 Jan CAHN

AB +!

EQ 150MG BASE

N205931 002 Jul 25, 2014 Jan CAHN

DOXYCYCLINE HYCLATE

>A> AB	NOSTRUM LABS INC	EQ 100MG BASE	A209560	001	Apr 15, 2024	Apr	NEWA
>A>	@ TORRENT	EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr	DISC
>A> AB		EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr	NEWA
>A>	@	EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr	DISC
>A> AB		EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr	NEWA

TABLET, DELAYED RELEASE; ORAL

DORYX

+ @ MAYNE PHARMA

EQ 75MG BASE

N050795 001 May 06, 2005 Feb DISC

+ @

EQ 150MG BASE

N050795 003 Jun 20, 2008 Feb DISC

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

>A>	AB	ENDO OPERATIONS	10MG;10MG	A208518	001	Dec 06, 2017	Apr	CAHN
>D>	AB	PAR PHARM INC	10MG;10MG	A208518	001	Dec 06, 2017	Apr	CAHN

DRONABINOL

CAPSULE;ORAL

DRONABINOL

	@	HIKMA	2.5MG	A079217	001	Jun 20, 2014	Mar	DISC
	@		5MG	A079217	002	Jun 20, 2014	Mar	DISC
	@		10MG	A079217	003	Jun 20, 2014	Mar	DISC

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

DRONEDARONE HYDROCHLORIDE

AB		LUPIN	EQ 400MG BASE	A205904	001	Jan 31, 2024	Jan	NFTG
		MULTAQ						
AB	+	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009	Jan	CFTG

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

>D>	AB	UPSHER SMITH LABS	100MG	A213661	001	Feb 18, 2021	Apr	DISC
>A>		@	100MG	A213661	001	Feb 18, 2021	Apr	DISC
>D>	AB		200MG	A213661	002	Feb 18, 2021	Apr	DISC
>A>		@	200MG	A213661	002	Feb 18, 2021	Apr	DISC
>D>	AB		300MG	A213661	003	Feb 18, 2021	Apr	DISC
>A>		@	300MG	A213661	003	Feb 18, 2021	Apr	DISC

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DRIZALMA SPRINKLE

>D>	+	@	SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr	CMFD
>A>		+		EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr	CMFD
>D>	+	@		EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr	CMFD
>A>		+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr	CMFD
>D>	+	@		EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr	CMFD
>A>		+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr	CMFD
>D>	+	@		EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr	CMFD
>A>		+	!	EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr	CMFD

DULOXETINE HYDROCHLORIDE

	@	ANCHEN PHARMS	EQ 20MG BASE	A090780	001	Oct 28, 2015	Feb	DISC
	@		EQ 30MG BASE	A090780	002	Oct 28, 2015	Feb	DISC
	@		EQ 60MG BASE	A090780	003	Oct 28, 2015	Feb	DISC
	@	MARKSANS PHARMA	EQ 20MG BASE	A090723	001	Dec 11, 2013	Feb	DISC
	@		EQ 30MG BASE	A090723	002	Dec 11, 2013	Feb	DISC
	@		EQ 60MG BASE	A090723	003	Dec 11, 2013	Feb	DISC

DUTASTERIDE

CAPSULE;ORAL

AVODART

AB	+	!	WAYLIS THERAP	0.5MG	N021319	001	Nov 20, 2001	Mar	CAHN
			DUTASTERIDE						
AB			CHARTWELL	0.5MG	A200899	001	Nov 20, 2015	Mar	CAHN
		@	VINTAGE	0.5MG	A202421	001	Nov 20, 2015	Feb	DISC

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

>D>	AB	ANCHEN PHARMS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Apr	CAHN	
>A>	AB	ENDO OPERATIONS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Apr	CAHN	
		JALYN							
>A>	AB	+	!	WAYLIS THERAP	N022460	001	Jun 14, 2010	Apr	CAHN
>D>	AB	+	!	WOODWARD	N022460	001	Jun 14, 2010	Apr	CAHN

EDARAVONE

SOLUTION; INTRAVENOUS

EDARAVONE

>A>	AP	DR REDDYS	60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr	NEWA
>A>	AP	GLAND PHARMA LTD	30MG/100ML (0.3MG/ML)	A216199	001	May 06, 2024	Apr	NFTG
>A>	AP		60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr	NFTG
>A>	AP	HIKMA	30MG/100ML (0.3MG/ML)	A215508	001	May 06, 2024	Apr	NFTG
>A>	AP	LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr	NEWA
		RADICAVA						
>D>	+	! MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr	CFTG
>A>	AP	+	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr	CFTG
>D>	+	!	60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	CFTG
>A>	AP	+	60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	CFTG

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@ STRIDES PHARMA 600MG; 200MG; 300MG

A201802 001 Oct 03, 2023 Mar DISC

ELTROMBOPAG OLAMINE

FOR SUSPENSION; ORAL

ELTROMBOPAG OLAMINE

>A>	AB	ANNORA PHARMA	EQ 12.5MG ACID/PACKET	A216620	001	Apr 18, 2024	Apr	NFTG
>A>	AB		EQ 25MG ACID/PACKET	A216620	002	Apr 18, 2024	Apr	NFTG
		PROMACTA KIT						
>D>	+	NOVARTIS	EQ 12.5MG ACID/PACKET	N207027	002	Sep 27, 2018	Apr	CFTG
>A>	AB	+	EQ 12.5MG ACID/PACKET	N207027	002	Sep 27, 2018	Apr	CFTG
>D>	+	!	EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015	Apr	CFTG
>A>	AB	+	EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015	Apr	CFTG

ENALAPRIL MALEATE

FOR SOLUTION; ORAL

EPANED KIT

+ @ AZURITY 1MG/ML

N204308 001 Aug 13, 2013 Mar CAHN

SOLUTION; ORAL

ENALAPRIL MALEATE

AB AMNEAL 1MG/ML A212894 001 Jun 29, 2022 Mar CMFD

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>D>	AB	COSETTE	5MG; 12.5MG	A075727	001	Sep 18, 2001	Apr	DISC
>A>		@	5MG; 12.5MG	A075727	001	Sep 18, 2001	Apr	DISC
>D>	AB		10MG; 25MG	A075727	002	Sep 18, 2001	Apr	DISC
>A>		@	10MG; 25MG	A075727	002	Sep 18, 2001	Apr	DISC

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

EPHEDRINE SULFATE

>A>	+	ENDO OPERATIONS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Apr	CAHN
>A>	+	!	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Apr	CAHN
>D>	+	OPERAND PHARMS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Apr	CAHN
>D>	+	!	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Apr	CAHN

EPINEPHRINE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

EPINEPHRINE

>A>	+	BPI LABS	1MG/ML (1MG/ML)	N205029	005	Mar 04, 2024	Apr	NEWA
		+	30MG/30ML (1MG/ML)	N205029	004	Feb 14, 2024	Feb	NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE W/ EPINEPHRINE

+ @ FRESENIUS KABI USA 0.01MG/ML; 2%

N006488 003 Feb CRLD

EPLERENONE

TABLET; ORAL

EPLERENONE

		@ PRASCO	25MG	A203896	001	Feb 02, 2017	Mar	DISC
		@	50MG	A203896	002	Feb 02, 2017	Mar	DISC
AB		SLATE RUN PHARMA	25MG	A212765	001	Aug 10, 2020	Feb	CAHN

	TABLET;ORAL							
	EPLERENONE							
AB		50MG		A212765	002	Aug 10, 2020	Feb	CAHN
	<u>EPLONTERSEN SODIUM</u>							
	SOLUTION;SUBCUTANEOUS							
	WAINUA (AUTOINJECTOR)							
	+	ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Feb	CTNA
	+		EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Jan	CAHN
	<u>EPOPROSTENOL SODIUM</u>							
	INJECTABLE;INJECTION							
	EPOPROSTENOL SODIUM							
AP1	MEITHEAL		EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Jan	CAHN
AP1			EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Jan	CAHN
	<u>ERGOTAMINE TARTRATE</u>							
	TABLET;SUBLINGUAL							
	ERGOMAR							
	!	PANGEA	2MG	A087693	001	Feb 24, 1983	Feb	CAHN
	<u>ERIBULIN MESYLATE</u>							
	SOLUTION;INTRAVENOUS							
	ERIBULIN MESYLATE							
AP	GLAND PHARMA LTD		1MG/2ML (0.5MG/ML)	A218047	001	Apr 05, 2024	Mar	NFTG
	HALAVEN							
AP	+	EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010	Mar	CFTG
	<u>ERLOTINIB HYDROCHLORIDE</u>							
	TABLET;ORAL							
	ERLOTINIB HYDROCHLORIDE							
>D>	AB	NATCO PHARMA LTD	EQ 25MG BASE	A208488	001	Nov 05, 2019	Apr	DISC
>A>	@		EQ 25MG BASE	A208488	001	Nov 05, 2019	Apr	DISC
	<u>ERTAPENEM SODIUM</u>							
	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS							
	ERTAPENEM SODIUM							
	@	SUN PHARM	EQ 1GM BASE/VIAL	A209145	001	May 02, 2023	Jan	DISC
	<u>ERYTHROMYCIN</u>							
	CAPSULE, DELAYED REL PELLETS;ORAL							
	ERYTHROMYCIN							
AB	AZURITY		250MG	A062746	001	Dec 22, 1986	Mar	CAHN
	OINTMENT;OPHTHALMIC							
	ERYTHROMYCIN							
AT	!	BAUSCH AND LOMB	0.5%	A064067	001	Jul 29, 1994	Mar	CHRS
	@	PADAGIS US	0.5%	A062447	001	Sep 26, 1983	Mar	DISC
	TABLET;ORAL							
	ERYTHROMYCIN							
AB	AZURITY		250MG	A061621	001		Mar	CAHN
AB			500MG	A061621	002		Mar	CAHN
	TABLET, DELAYED RELEASE;ORAL							
	ERY-TAB							
AB	AZURITY		250MG	A062298	001		Mar	CAHN
AB			333MG	A062298	003	Mar 29, 1982	Mar	CAHN
AB	!		500MG	A062298	002		Mar	CAHN
	<u>ERYTHROMYCIN ETHYLSUCCINATE</u>							
	TABLET;ORAL							
	E.E.S. 400							
	@	AZURITY	EQ 400MG BASE	A061905	001		Mar	CAHN
BX	!		EQ 400MG BASE	A061905	002	Aug 12, 1982	Mar	CAHN
	ERYTHROMYCIN ETHYLSUCCINATE							
BX	!	AZURITY	EQ 400MG BASE	A061904	001		Mar	CAHN

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

@ AZURITY	EQ 125MG BASE	A 060359	002		Mar CAHN
!	EQ 250MG BASE	A 060359	001		Mar CAHN
@	EQ 500MG BASE	A 060359	003		Mar CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

@ PHARM ASSOC	EQ 5MG BASE	A 077512	001	Sep 12, 2012	Mar DISC
@	EQ 10MG BASE	A 077512	002	Sep 12, 2012	Mar DISC
@	EQ 20MG BASE	A 077512	003	Sep 12, 2012	Mar DISC

ESLICARBAZEPINE ACETATE

TABLET; ORAL

ESLICARBAZEPINE ACETATE

>D> AB	APOTEX	200MG	A 211236	001	Dec 07, 2023	Apr DISC
>A>	@	200MG	A 211236	001	Dec 07, 2023	Apr DISC
>D> AB		400MG	A 211236	002	Dec 07, 2023	Apr DISC
>A>	@	400MG	A 211236	002	Dec 07, 2023	Apr DISC
>D> AB		600MG	A 211236	003	Dec 07, 2023	Apr DISC
>A>	@	600MG	A 211236	003	Dec 07, 2023	Apr DISC
>D> AB		800MG	A 211236	004	Dec 07, 2023	Apr DISC
>A>	@	800MG	A 211236	004	Dec 07, 2023	Apr DISC
AB	LUPIN LTD	200MG	A 211246	001	Mar 27, 2024	Mar NEWA
AB		400MG	A 211246	002	Mar 27, 2024	Mar NEWA
AB		600MG	A 211246	003	Mar 27, 2024	Mar NEWA
AB		800MG	A 211246	004	Mar 27, 2024	Mar NEWA
	@ TORRENT	200MG	A 211227	001	Feb 27, 2024	Mar DISC
AB		200MG	A 211227	001	Feb 27, 2024	Feb NEWA
	@	400MG	A 211227	002	Feb 27, 2024	Mar DISC
AB		400MG	A 211227	002	Feb 27, 2024	Feb NEWA
	@	600MG	A 211227	003	Feb 27, 2024	Mar DISC
AB		600MG	A 211227	003	Feb 27, 2024	Feb NEWA
	@	800MG	A 211227	004	Feb 27, 2024	Mar DISC
AB		800MG	A 211227	004	Feb 27, 2024	Feb NEWA

ESTRADIOL

GEL, METERED; TRANSDERMAL

ESTRADIOL

>A> AB	SOLARIS PHARMA CORP	0.06% (1.25GM/ACTIVATION)	A 216160	001	Apr 22, 2024	Apr NFTG
	ESTROGEL					
>D>	+! ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N 021166	002	Feb 09, 2004	Apr CFTG
>A> AB	+!	0.06% (1.25GM/ACTIVATION)	N 021166	002	Feb 09, 2004	Apr CFTG

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR

LUNELLE

+ @ PHARMACIA AND UPJOHN	5MG/0.5ML; 25MG/0.5ML	N 020874	001	Oct 05, 2000	Feb CRLD
--------------------------	-----------------------	----------	-----	--------------	----------

ESTRADIOL VALERATE

INJECTABLE; INJECTION

DELESTROGEN

>A> AO	+! ENDO OPERATIONS	10MG/ML	N 009402	002		Apr CAHN
>A> AO	+!	20MG/ML	N 009402	004		Apr CAHN
>A> AO	+!	40MG/ML	N 009402	003		Apr CAHN
>D> AO	+! PAR STERILE PRODUCTS	10MG/ML	N 009402	002		Apr CAHN
>D> AO	+!	20MG/ML	N 009402	004		Apr CAHN
>D> AO	+!	40MG/ML	N 009402	003		Apr CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

>D>	@ NAARI PTE LTD	1MG; 0.5MG	A 210233	001	Feb 28, 2018	Apr CMFD
>A> AB		1MG; 0.5MG	A 210233	001	Feb 28, 2018	Apr CMFD

ESZOPICLONE

TABLET; ORAL

LUNESTA

>A>	AB	+	WAYLIS THERAP	1MG	N021476	001	Dec 15, 2004	Apr	CAHN
>A>	AB	+		2MG	N021476	002	Dec 15, 2004	Apr	CAHN
>A>	AB	+		3MG	N021476	003	Dec 15, 2004	Apr	CAHN
>D>	AB	+	WOODWARD	1MG	N021476	001	Dec 15, 2004	Apr	CAHN
>D>	AB	+		2MG	N021476	002	Dec 15, 2004	Apr	CAHN
>D>	AB	+		3MG	N021476	003	Dec 15, 2004	Apr	CAHN

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

ETHACRYNATE SODIUM

>A>	AP		ENDO OPERATIONS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Apr	CAHN
>D>	AP		PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Apr	CAHN
	AP		STERIMAX	EQ 50MG BASE/VIAL	A208663	001	Jun 09, 2020	Mar	CAHN

ETHACRYNIC ACID

TABLET; ORAL

ETHACRYNIC ACID

>D>	AB		PAR PHARM INC	25MG	A208501	001	Jul 21, 2017	Apr	DISC
>A>		@		25MG	A208501	001	Jul 21, 2017	Apr	DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

>D>	AB		MYLAN LABS LTD	0.03MG;0.15MG	A200490	001	Apr 21, 2015	Apr	CAHN
>A>	AB		XIROMED	0.03MG;0.15MG	A200490	001	Apr 21, 2015	Apr	CAHN
	AB3		MINZOYA						
			LUPIN LTD	0.02MG;0.1MG	A217087	001	Feb 15, 2024	Feb	NEWA

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

>D>		@	MYLAN LABS LTD	0.02MG;0.1MG	A202247	001	Dec 08, 2014	Apr	CAHN
>A>		@	XIROMED	0.02MG;0.1MG	A202247	001	Dec 08, 2014	Apr	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

CYCLAFEM 0.5/35

>A>		@	ENDO OPERATIONS	0.035MG;0.5MG	A203413	001	Dec 16, 2015	Apr	CAHN
>D>		@	VINTAGE PHARMS	0.035MG;0.5MG	A203413	001	Dec 16, 2015	Apr	CAHN
			NORETHINDRONE AND ETHINYL ESTRADIOL						
>D>		@	MYLAN LABS LTD	0.035MG;0.4MG	A200897	001	May 11, 2015	Apr	CAHN
>D>		@		0.05MG;1MG	A203006	001	Aug 05, 2013	Apr	CAHN
>A>		@	XIROMED	0.035MG;0.4MG	A200897	001	May 11, 2015	Apr	CAHN
>A>		@		0.05MG;1MG	A203006	001	Aug 05, 2013	Apr	CAHN

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		+	TEVA BRANDED PHARM	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Mar	CAHN
----	--	---	--------------------	---------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

@ AMNEAL PHARMS 0.02MG;1MG

A214292 001 Jul 20, 2021 Feb DISC

TABLET; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

>D>		@	MYLAN LABS LTD	0.0025MG;0.5MG	A207260	001	Feb 02, 2017	Apr	CAHN
>D>		@		0.005MG;1MG	A207259	001	Dec 27, 2016	Apr	CAHN
>A>		@	XIROMED	0.0025MG;0.5MG	A207260	001	Feb 02, 2017	Apr	CAHN
>A>		@		0.005MG;1MG	A207259	001	Dec 27, 2016	Apr	CAHN

TABLET; ORAL-28

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

>D>	AB		MYLAN	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Apr	CAHN
>A>	AB		XIROMED	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Apr	CAHN

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB			EPIC PHARMA LLC	250MG	A040686	001	May 28, 2008	Jan	CAHN
----	--	--	-----------------	-------	---------	-----	--------------	-----	------

ETODOLACTABLET;ORAL
ETODOLAC

>A>	AB	IPCA LABS LTD	400MG	A204729	001	May 01, 2024	Apr	NEWA
>A>	AB		500MG	A204729	002	May 01, 2024	Apr	NEWA

EZETIMIBETABLET;ORAL
EZETIMIBE

>A>	AB	MACLEODS PHARMS LTD	10MG	A211159	001	Apr 29, 2024	Apr	NEWA
-----	----	---------------------	------	---------	-----	--------------	-----	------

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

AB		AUROBINDO PHARMA USA	10MG;10MG	A200082	001	Dec 17, 2020	Mar	CMFD
AB			10MG;20MG	A200082	002	Dec 17, 2020	Mar	CMFD
AB			10MG;40MG	A200082	003	Dec 17, 2020	Mar	CMFD
AB			10MG;80MG	A200082	004	Dec 17, 2020	Mar	CMFD

FAMOTIDINEFOR SUSPENSION;ORAL
FAMOTIDINE

AB		CEROVENE INC	40MG/5ML	A217605	001	Jan 16, 2024	Jan	NEWA
----	--	--------------	----------	---------	-----	--------------	-----	------

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

FAMOTIDINE AND IBUPROFEN

		@ TORRENT	26.6MG;800MG	A215925	001	Mar 18, 2024	Mar	NEWA
AB	!	ALKEM LABS LTD	26.6MG;800MG	A211890	001	Aug 03, 2021	Feb	CHRS

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

>D>	AB	LUPIN LTD	40MG	A205406	001	Jan 17, 2024	Apr	DISC
>A>		@	40MG	A205406	001	Jan 17, 2024	Apr	DISC
	AB		40MG	A205406	001	Jan 17, 2024	Jan	NEWA
>D>	AB		80MG	A205406	002	Jan 17, 2024	Apr	DISC
>A>		@	80MG	A205406	002	Jan 17, 2024	Apr	DISC
	AB		80MG	A205406	002	Jan 17, 2024	Jan	NEWA

FEDRATINIB HYDROCHLORIDE

CAPSULE;ORAL

INREBIC

+!		BRISTOL-MYERS	EQ 100MG BASE	N212327	001	Aug 16, 2019	Feb	CAHN
----	--	---------------	---------------	---------	-----	--------------	-----	------

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

>A>	AB	ENDO OPERATIONS	2.5MG	A200815	001	Oct 28, 2011	Apr	CAHN
>A>	AB		5MG	A200815	002	Oct 28, 2011	Apr	CAHN
>A>	AB		10MG	A200815	003	Oct 28, 2011	Apr	CAHN
>D>	AB	VINTAGE PHARMS LLC	2.5MG	A200815	001	Oct 28, 2011	Apr	CAHN
>D>	AB		5MG	A200815	002	Oct 28, 2011	Apr	CAHN
>D>	AB		10MG	A200815	003	Oct 28, 2011	Apr	CAHN

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

AB		CHARTWELL	67MG	A211407	001	Jan 31, 2024	Mar	CAHN
AB			134MG	A211407	002	Jan 31, 2024	Mar	CAHN
AB			200MG	A211407	003	Jan 31, 2024	Mar	CAHN
		@ INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017	Mar	DISC
		@	134MG	A207378	002	Mar 28, 2017	Mar	DISC
		@	200MG	A207378	003	Mar 28, 2017	Mar	DISC
AB		YOUNGTECH PHARMS INC	67MG	A211407	001	Jan 31, 2024	Jan	NEWA
AB			134MG	A211407	002	Jan 31, 2024	Jan	NEWA
AB			200MG	A211407	003	Jan 31, 2024	Jan	NEWA

TABLET;ORAL

FENOFIBRATE

AB	!	AUROBINDO PHARMA	145MG	A205118	002	May 05, 2016	Mar	CHRS
----	---	------------------	-------	---------	-----	--------------	-----	------

		TABLET;ORAL							
		FENOFIBRATE							
>A>	AB	YICHANG HUMANWELL	54MG	A218548	001	Apr 24, 2024	Apr	NEWA	
>A>	AB		160MG	A218548	002	Apr 24, 2024	Apr	NEWA	
		TRICOR							
		+ @ ABBVIE	145MG	N021656	002	Nov 05, 2004	Mar	DISC	
<u>FENOPROFEN CALCIUM</u>									
		CAPSULE;ORAL							
		NALFON							
>A>	AB	+ KEY THERAP	EQ 200MG BASE	N017604	003		Apr	CAHN	
>A>		@	EQ 300MG BASE	N017604	002		Apr	CAHN	
>A>	AB	+!	EQ 400MG BASE	N017604	004	Jul 21, 2009	Apr	CAHN	
>D>	AB	+ XSPIRE PHARMA	EQ 200MG BASE	N017604	003		Apr	CAHN	
>D>		@	EQ 300MG BASE	N017604	002		Apr	CAHN	
>D>	AB	+!	EQ 400MG BASE	N017604	004	Jul 21, 2009	Apr	CAHN	
		TABLET;ORAL							
		FENOPROFEN CALCIUM							
>A>		! KEY THERAP	EQ 600MG BASE	A072267	001	Aug 17, 1988	Apr	CAHN	
>D>		! XSPIRE PHARMA	EQ 600MG BASE	A072267	001	Aug 17, 1988	Apr	CAHN	
<u>FESOTERODINE FUMARATE</u>									
		TABLET, EXTENDED RELEASE;ORAL							
		FESOTERODINE FUMARATE							
>D>	AB	ANI PHARMS	4MG	A204504	001	Jan 04, 2023	Apr	DISC	
>A>		@	4MG	A204504	001	Jan 04, 2023	Apr	DISC	
>D>	AB		8MG	A204504	002	Jan 04, 2023	Apr	DISC	
>A>		@	8MG	A204504	002	Jan 04, 2023	Apr	DISC	
<u>FIDAXOMICIN</u>									
		TABLET;ORAL							
		DIFICID							
AB		+! CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Jan	CFTG	
AB		FIDAXOMICIN							
AB		ACTAVIS LABS FL	200MG	A208443	001	Jan 16, 2024	Jan	NEWA	
<u>FINASTERIDE</u>									
		TABLET;ORAL							
		FINASTERIDE							
		@ CIPLA	1MG	A077335	001	Nov 20, 2014	Mar	DISC	
<u>FINASTERIDE; TADALAFIL</u>									
		CAPSULE;ORAL							
		ENTADFI							
AB		+! BLUE WATER BIOTECH	5MG;5MG	N215423	001	Dec 09, 2021	Mar	CFTG	
<u>FINGOLIMOD HYDROCHLORIDE</u>									
		CAPSULE;ORAL							
		FINGOLIMOD HYDROCHLORIDE							
AB		AUROBINDO PHARMA LTD	EQ 0.5MG BASE	A207983	001	Feb 28, 2024	Feb	NEWA	
AB		BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Feb	CMFD	
<u>FLUDARABINE PHOSPHATE</u>									
		INJECTABLE;INJECTION							
		FLUDARABINE PHOSPHATE							
		@ RISING	50MG/VIAL	A200648	001	Oct 16, 2012	Feb	CAHN	
<u>FLUOCINOLONE ACETONIDE</u>									
		OIL;TOPICAL							
		FLUOCINOLONE ACETONIDE							
		@ SAPTALIS PHARMS	0.01%	A091514	001	Jun 25, 2015	Feb	CAHN	
AT		TARO	0.01%	A209336	001	May 19, 2016	Jan	CAHN	
		OIL/DROPS;OTIC							
		FLUOCINOLONE ACETONIDE							
		@ SAPTALIS PHARMS	0.01%	A202705	001	Sep 09, 2016	Feb	CAHN	

FLUOCINONIDECREAM; TOPICAL
FLUOCINONIDE

@ PADAGIS ISRAEL 0.1% A090256 001 Jan 14, 2014 Jan DISC

GEL; TOPICAL
FLUOCINONIDE

>D>	AB	COSETTE	0.05%	A072537	001	Feb 07, 1989	Apr	DISC
>A>		@	0.05%	A072537	001	Feb 07, 1989	Apr	DISC
		@ PADAGIS US	0.05%	A209030	001	Jun 19, 2018	Jan	CAHN

SOLUTION; TOPICAL
FLUOCINONIDE

>D>	AT	COSETTE	0.05%	A071535	001	Dec 02, 1988	Apr	DISC
>A>		@	0.05%	A071535	001	Dec 02, 1988	Apr	DISC

FLUOROURACILINJECTABLE; INJECTION
FLUOROURACIL

>D>		@ EUGIA PHARMA SPECLTS	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Apr	CMFD
>A>	AP		500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Apr	CMFD
>D>		@	1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Apr	CMFD
>A>	AP		1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Apr	CMFD
>D>		@	2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012	Apr	CMFD
>A>	AP		2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012	Apr	CMFD
>D>		@	5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012	Apr	CMFD
>A>	AP		5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012	Apr	CMFD

FLUOXETINE HYDROCHLORIDECAPSULE; ORAL
FLUOXETINE HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 40MG BASE A076990 001 Dec 13, 2004 Jan DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

@ BAJAJ EQ 20MG BASE/5ML A075920 001 Jan 29, 2002 Mar CAHN

@ SAPTALIS PHARMS EQ 20MG BASE/5ML A075525 001 Jun 27, 2002 Mar CAHN

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

>A>	AB	ENDO OPERATIONS	EQ 10MG BASE	A203836	001	Aug 19, 2016	Apr	CAHN
>A>	AB		EQ 20MG BASE	A203836	002	Aug 19, 2016	Apr	CAHN
>A>	AB		EQ 60MG BASE	A209419	001	Nov 16, 2017	Apr	CAHN
>D>	AB	PAR FORM	EQ 10MG BASE	A203836	001	Aug 19, 2016	Apr	CAHN
>D>	AB		EQ 20MG BASE	A203836	002	Aug 19, 2016	Apr	CAHN
>D>	AB	PAR PHARM INC	EQ 60MG BASE	A209419	001	Nov 16, 2017	Apr	CAHN
	AB	STRIDES PHARMA	EQ 10MG BASE	A212684	001	Apr 05, 2024	Mar	NEWA
	AB		EQ 20MG BASE	A212684	002	Apr 05, 2024	Mar	NEWA
		@ TEVA	EQ 10MG BASE	A075872	001	Jan 29, 2002	Jan	DISC
		@	EQ 20MG BASE	A075872	002	Jan 04, 2019	Jan	DISC
		@ TEVA PHARMS USA	EQ 60MG BASE	A211051	001	Dec 03, 2018	Jan	DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

>A>	AB	ENDO OPERATIONS	EQ 25MG BASE;EQ 3MG BASE	A077742	001	Nov 02, 2012	Apr	CAHN
>A>	AB		EQ 25MG BASE;EQ 6MG BASE	A077742	002	Nov 02, 2012	Apr	CAHN
>A>	AB		EQ 25MG BASE;EQ 12MG BASE	A077742	003	Nov 02, 2012	Apr	CAHN
>A>	AB		EQ 50MG BASE;EQ 6MG BASE	A077742	004	Nov 02, 2012	Apr	CAHN
>A>	AB		EQ 50MG BASE;EQ 12MG BASE	A077742	005	Nov 02, 2012	Apr	CAHN
>D>	AB	PAR PHARM	EQ 25MG BASE;EQ 3MG BASE	A077742	001	Nov 02, 2012	Apr	CAHN
>D>	AB		EQ 25MG BASE;EQ 6MG BASE	A077742	002	Nov 02, 2012	Apr	CAHN
>D>	AB		EQ 25MG BASE;EQ 12MG BASE	A077742	003	Nov 02, 2012	Apr	CAHN
>D>	AB		EQ 50MG BASE;EQ 6MG BASE	A077742	004	Nov 02, 2012	Apr	CAHN
>D>	AB		EQ 50MG BASE;EQ 12MG BASE	A077742	005	Nov 02, 2012	Apr	CAHN

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

>A>	AO	ENDO OPERATIONS	25MG/ML	A203732	001	Jul 03, 2014	Apr	CAHN
>D>	AO	PAR STERILE PRODUCTS	25MG/ML	A203732	001	Jul 03, 2014	Apr	CAHN

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL		FLUPHENAZINE HYDROCHLORIDE					
	@ TORRENT	1MG		A217094	001	Jan 22, 2024	Jan DISC
AB		1MG		A217094	001	Jan 22, 2024	Jan NEWA
	@	2.5MG		A217094	002	Jan 22, 2024	Jan DISC
AB		2.5MG		A217094	002	Jan 22, 2024	Jan NEWA
	@	5MG		A217094	003	Jan 22, 2024	Jan DISC
AB		5MG		A217094	003	Jan 22, 2024	Jan NEWA
	@	10MG		A217094	004	Jan 22, 2024	Jan DISC
AB		10MG		A217094	004	Jan 22, 2024	Jan NEWA
AB	ZAMEER PHARMS	1MG		A215141	001	Oct 20, 2021	Feb CAHN
AB		2.5MG		A215141	002	Oct 20, 2021	Feb CAHN
AB		5MG		A215141	003	Oct 20, 2021	Feb CAHN
AB		10MG		A215141	004	Oct 20, 2021	Feb CAHN

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL		FLUTICASONE PROPIONATE					
	@ HIKMA	0.05MG/SPRAY		A077570	001	Jan 16, 2008	Mar DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL		FLUVOXAMINE MALEATE					
>D>	AB	ANCHEN PHARMS	100MG	A091476	001	Mar 13, 2013	Apr CAHN
>D>	AB		150MG	A091476	002	Mar 13, 2013	Apr CAHN
>A>	AB	ENDO OPERATIONS	100MG	A091476	001	Mar 13, 2013	Apr CAHN
>A>	AB		150MG	A091476	002	Mar 13, 2013	Apr CAHN
TABLET; ORAL		FLUVOXAMINE MALEATE					
AB		BIONPHARMA	25MG	A217917	001	Jan 22, 2024	Jan NEWA
AB			50MG	A217917	002	Jan 22, 2024	Jan NEWA
AB			100MG	A217917	003	Jan 22, 2024	Jan NEWA

FOSAMPRENAVIR CALCIUM

TABLET; ORAL		FOSAMPRENAVIR CALCIUM					
AB	!	MYLAN	EQ 700MG BASE	A204060	001	Apr 15, 2016	Jan CHRS
		LEXIVA					
	+	@ VIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Jan DISC

FOSCARNET SODIUM

INJECTABLE; INJECTION		FOSCARNET SODIUM					
AP		AMNEAL	2.4GM/100ML	A216602	001	Mar 01, 2024	Feb NEWA

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL		FOSFOMYCIN TROMETHAMINE					
AA		AMNEAL	EQ 3GM BASE/PACKET	A216600	001	Mar 25, 2024	Mar NEWA

FROVATRIPTAN SUCCINATE

TABLET; ORAL		FROVA						
>A>	AB	!	ENDO OPERATIONS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Apr CAHN
>D>	AB	!	ENDO PHARMS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Apr CAHN

FUROSEMIDE

INJECTABLE; INJECTION		FUROSEMIDE					
AP		SABA ILAC SANAYIVE	10MG/ML	A215856	001	Apr 02, 2024	Mar NEWA

GABAPENTIN

SOLUTION; ORAL		GABAPENTIN					
AA		ANNORA PHARMA	250MG/5ML	A217682	001	Jan 17, 2024	Jan NEWA
TABLET; ORAL		GABAPENTIN					
AB1		ACI	600MG	A203244	002	Jul 12, 2013	Jan CTEC
AB1			800MG	A203244	001	Jul 12, 2013	Jan CTEC
AB1		ACTAVIS ELIZABETH	600MG	A075694	001	Oct 21, 2004	Jan CTEC

TABLET;ORAL
GABAPENTIN

AB1		800MG	A075694	002	Oct 21, 2004	Jan CTEC
AB1	ALKEM LABS LTD	600MG	A206402	001	Dec 23, 2015	Jan CTEC
AB1		800MG	A206402	002	Dec 23, 2015	Jan CTEC
AB2	ANNORA PHARMA	300MG	A218075	001	Feb 26, 2024	Feb NEWA
AB2		600MG	A218075	002	Feb 26, 2024	Feb NEWA
AB1	APOTEX	100MG	A077894	001	Oct 10, 2006	Jan CTEC
AB1		300MG	A077894	002	Oct 10, 2006	Jan CTEC
AB1		400MG	A077894	003	Oct 10, 2006	Jan CTEC
AB1	ASCENT PHARMS INC	600MG	A214957	001	Oct 01, 2021	Jan CTEC
AB1		800MG	A214957	002	Oct 01, 2021	Jan CTEC
AB1	AUROBINDO PHARMA LTD	600MG	A200651	001	Oct 06, 2011	Jan CTEC
AB1		800MG	A200651	002	Oct 06, 2011	Jan CTEC
AB1	CSPC OUYI	600MG	A207057	001	Oct 26, 2017	Jan CTEC
AB1		800MG	A207057	002	Oct 26, 2017	Jan CTEC
AB1	GLENMARK PHARMS LTD	600MG	A077662	001	Aug 18, 2006	Jan CTEC
AB1		800MG	A077662	002	Aug 18, 2006	Jan CTEC
AB1	GRANULES	600MG	A217116	001	Mar 28, 2023	Jan CTEC
AB1		800MG	A217116	002	Mar 28, 2023	Jan CTEC
AB2	HUMANWELL	300MG	A216252	001	Feb 26, 2024	Feb NEWA
AB2		600MG	A216252	002	Feb 26, 2024	Feb NEWA
	@ INVAGEN PHARMS	600MG	A202764	001	Oct 16, 2012	Mar DISC
AB1		600MG	A202764	001	Oct 16, 2012	Jan CTEC
	@	800MG	A202764	002	Oct 16, 2012	Mar DISC
AB1		800MG	A202764	002	Oct 16, 2012	Jan CTEC
AB1	IVAX SUB TEVA PHARMS	100MG	A076017	001	Apr 28, 2004	Jan CTEC
AB1		300MG	A076017	002	Apr 28, 2004	Jan CTEC
AB1		400MG	A076017	003	Apr 28, 2004	Jan CTEC
AB1	LAURUS	600MG	A217965	001	Apr 08, 2024	Mar NEWA
AB1		800MG	A217965	002	Apr 08, 2024	Mar NEWA
AB1	RISING	600MG	A217995	001	Jul 19, 2023	Jan CTEC
AB1		800MG	A217995	002	Jul 19, 2023	Jan CTEC
AB1	RUBICON	600MG	A077661	004	Sep 13, 2006	Jan CTEC
AB1		800MG	A077661	005	Sep 13, 2006	Jan CTEC
AB1	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan CTEC
AB1		800MG	A205101	002	Feb 04, 2016	Jan CTEC
AB1	STRIDES PHARMA	600MG	A211313	001	Mar 04, 2024	Feb NEWA
AB1		800MG	A211313	002	Mar 04, 2024	Feb NEWA
AB1	SUN PHARM INDS LTD	600MG	A077525	001	Aug 24, 2006	Jan CTEC
AB1		800MG	A077525	002	Aug 24, 2006	Jan CTEC
AB2	ZYDUS PHARMS	300MG	A203934	001	Jan 24, 2024	Jan NEWA
AB2		600MG	A203934	002	Jan 24, 2024	Jan NEWA
AB1	ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011	Jan CTEC
AB1		800MG	A078926	002	Feb 11, 2011	Jan CTEC

GRALISE

AB2	+! ALMATICA	300MG	N022544	001	Jan 28, 2011	Jan CTEC
AB2	+	600MG	N022544	002	Jan 28, 2011	Jan CTEC
BX	+	600MG	N022544	002	Jan 28, 2011	Jan CHRS
	+!	900MG	N022544	005	Apr 18, 2023	Jan CHRS

NEURONTIN

AB1	+ VIATRIS	600MG	N020882	001	Oct 09, 1998	Jan CTEC
AB1	+!	800MG	N020882	002	Oct 09, 1998	Jan CTEC

GADODIAMIDE

INJECTABLE; INJECTION
OMNISCAN

+	@ GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007	Mar CRLD
+	@	28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007	Mar DISC

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

@	HIKMA	0.5%	A203189	001	Sep 03, 2014	Mar DISC
---	-------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

>D>	AP	ACCORD HLTHCARE	EQ 200MG BASE/VIAL	A091594	001	Jul 25, 2011	Apr DISC
>A>	@		EQ 200MG BASE/VIAL	A091594	001	Jul 25, 2011	Apr DISC
>D>	AP		EQ 1GM BASE/VIAL	A091594	002	Jul 25, 2011	Apr DISC
>A>	@		EQ 1GM BASE/VIAL	A091594	002	Jul 25, 2011	Apr DISC
>D>	AP		EQ 2GM BASE/VIAL	A091594	003	Jul 25, 2011	Apr DISC

	INJECTABLE; INJECTION							
	GEMCITABINE HYDROCHLORIDE							
>A>	@	EQ 2GM BASE/VIAL	A091594	003	Jul 25, 2011	Apr	DISC	
	<u>GENTAMICIN SULFATE</u>							
	SOLUTION/DROPS; OPHTHALMIC							
	GENTAK							
	@ SAPTALIS PHARMS	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Feb	CAHN	
	<u>GIVINOSTAT HYDROCHLORIDE</u>							
	SUSPENSION; ORAL							
	DUVYZAT							
	+! ITALFARMACO SPA	EQ 8.86MG BASE/ML	N217865	001	Mar 21, 2024	Mar	NEWA	
	<u>GLUCAGON HYDROCHLORIDE</u>							
>D>	INJECTABLE; INJECTION							
>D>	GLUCAGEN							
>D>	+! NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998	Apr	CDFR	
>A>	POWDER; INTRAMUSCULAR, INTRAVENOUS							
>A>	GLUCAGEN							
>A>	+! NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998	Apr	CDFR	
	POWDER; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
	GLUCAGEN							
>A>	+! NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	002	Jun 22, 1998	Apr	CMS1	
	GLUCAGON							
>A>	+! FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	002	Sep 19, 2019	Apr	CMS1	
	<u>GLYBURIDE; METFORMIN HYDROCHLORIDE</u>							
	TABLET; ORAL							
	GLYBURIDE AND METFORMIN HYDROCHLORIDE							
AB	HERITAGE PHARMS	1.25MG; 250MG	A079009	001	Jun 03, 2009	Feb	CMFD	
AB		2.5MG; 500MG	A079009	002	Jun 03, 2009	Feb	CMFD	
AB		5MG; 500MG	A079009	003	Jun 03, 2009	Feb	CMFD	
	<u>GLYCOPYRROLATE</u>							
	INJECTABLE; INJECTION							
	GLYCOPYRROLATE							
AP	NIVAGEN PHARMS INC	0.2MG/ML	A212591	001	Oct 13, 2021	Feb	CAHN	
	<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE</u>							
	SOLUTION; INTRAVENOUS							
	PREVDUO							
	+! AZURITY	0.6MG/3ML (0.2MG/ML); 3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb	CAHN	
	<u>GRISEOFULVIN, MICROSIZE</u>							
	TABLET; ORAL							
	FULVICIN-U/F							
AB	CHARTWELL RX	250MG	A060569	002		Jan	CTEC	
		250MG	A060569	002		Jan	CAIN	
AB		500MG	A060569	001		Jan	CTEC	
		500MG	A060569	001		Jan	CAIN	
	GRISEOFULVIN							
AB	SANDOZ	250MG	A091592	001	Aug 07, 2013	Jan	CTEC	
	<u>GRISEOFULVIN, ULTRAMICROSIZE</u>							
	TABLET; ORAL							
	FULVICIN P/G							
AB	CHARTWELL RX	125MG	A061996	001		Jan	CTEC	
		125MG	A061996	001		Jan	CAIN	
AB		250MG	A061996	002		Jan	CTEC	
		250MG	A061996	002		Jan	CAIN	
	FULVICIN P/G 165							
	CHARTWELL RX	165MG	A061996	003	Apr 06, 1982	Jan	CAIN	
	FULVICIN P/G 330							
	CHARTWELL RX	330MG	A061996	004	Apr 06, 1982	Jan	CAIN	

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB	XIROMED	EQ 1MG BASE	A218326	001	Feb 23, 2024	Feb	NEWA
AB		EQ 2MG BASE	A218326	002	Feb 23, 2024	Feb	NEWA

HALCINONIDE

OINTMENT; TOPICAL

HALOG

	+ @ SUN PHARM INDS INC	0.1%	N017824	001		Jan	DISC
--	------------------------	------	---------	-----	--	-----	------

SOLUTION; TOPICAL

HALOG

	+ @ SUN PHARM INDS INC	0.1%	N017823	001		Jan	DISC
--	------------------------	------	---------	-----	--	-----	------

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

>A>	AB	AUROBINDO PHARMA LTD	0.5MG	A218789	001	Apr 19, 2024	Apr	NEWA
>A>	AB		1MG	A218789	002	Apr 19, 2024	Apr	NEWA
>A>	AB		2MG	A218789	003	Apr 19, 2024	Apr	NEWA
>A>	AB		5MG	A218789	004	Apr 19, 2024	Apr	NEWA
>A>	AB		10MG	A218789	005	Apr 19, 2024	Apr	NEWA
>A>	AB		20MG	A218789	006	Apr 19, 2024	Apr	NEWA
	AB	CHARTWELL RX	0.5MG	A071209	002	Nov 17, 1986	Jan	CAHN
	AB		1MG	A071209	003	Nov 17, 1986	Jan	CAHN
		@	2MG	A071209	004	Nov 17, 1986	Jan	CAHN
	AB		5MG	A071209	001	Nov 17, 1986	Jan	CAHN
	AB		10MG	A071210	001	Mar 11, 1988	Jan	CAHN
	AB		20MG	A071211	001	Mar 11, 1988	Jan	CAHN
>A>	AB	MANKIND PHARMA	0.5MG	A216918	001	Apr 11, 2024	Apr	NEWA
>A>	AB		1MG	A216918	002	Apr 11, 2024	Apr	NEWA
>A>	AB		2MG	A216918	003	Apr 11, 2024	Apr	NEWA
>A>	AB		5MG	A216918	004	Apr 11, 2024	Apr	NEWA
>A>	AB		10MG	A216918	005	Apr 11, 2024	Apr	NEWA
>A>	AB		20MG	A216918	006	Apr 11, 2024	Apr	NEWA

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

	@ TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jan	DISC
	@	EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jan	DISC

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

AA	RUBICON	EQ 2MG BASE/ML	A218371	001	Jan 31, 2024	Jan	NEWA
----	---------	----------------	---------	-----	--------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5%

+	!	FRESENIUS KABI USA	40 UNITS/ML	N017029	021	Aug 24, 2017	Mar	NEWA
---	---	--------------------	-------------	---------	-----	--------------	-----	------

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

+	!	FRESENIUS KABI USA	50 UNITS/ML	N017029	022	Aug 24, 2017	Mar	NEWA
---	---	--------------------	-------------	---------	-----	--------------	-----	------

+	!		100 UNITS/ML	N017029	023	Aug 24, 2017	Mar	NEWA
---	---	--	--------------	---------	-----	--------------	-----	------

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%

+	!	FRESENIUS KABI USA	50 UNITS/ML	N017029	024	Aug 24, 2017	Mar	NEWA
---	---	--------------------	-------------	---------	-----	--------------	-----	------

+	!		100 UNITS/ML	N017029	025	Aug 24, 2017	Mar	NEWA
---	---	--	--------------	---------	-----	--------------	-----	------

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

>A>	+	!	ENDO OPERATIONS	50MG	N022058	001	May 03, 2007	Apr	CAHN
>D>	+	!	ENDO PHARM	50MG	N022058	001	May 03, 2007	Apr	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	!	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Mar	CHRS
>A>		@ GENUS	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Apr	CAHN
>D>		@ PAI HOLDINGS PHARM	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Apr	CAHN
		@	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Mar	DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION		HYDRALAZINE HYDROCHLORIDE					
AP	ADRASTEIA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Feb	CAHN
TABLET; ORAL		HYDRALAZINE HYDROCHLORIDE					
@	INVAGEN PHARMS	10MG	A090255	001	Dec 15, 2008	Mar	DISC
@		25MG	A090255	002	Dec 15, 2008	Mar	DISC
@		50MG	A090255	003	Dec 15, 2008	Mar	DISC
@		100MG	A090255	004	Dec 15, 2008	Mar	DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL		ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE					
AB	I3 PHARMS	37.5MG; 20MG	A215988	001	Jan 17, 2024	Jan	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL		LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE					
@	GRANULES	12.5MG; 50MG	A218015	001	Sep 29, 2023	Mar	DISC
@		12.5MG; 100MG	A218015	002	Sep 29, 2023	Mar	DISC
@		25MG; 100MG	A218015	003	Sep 29, 2023	Mar	DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL		QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
@	INVAGEN PHARMS	12.5MG; EQ 10MG BASE	A201356	001	Apr 20, 2011	Mar	DISC
@		12.5MG; EQ 20MG BASE	A201356	002	Apr 20, 2011	Mar	DISC
@		25MG; EQ 20MG BASE	A201356	003	Apr 20, 2011	Mar	DISC

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION		DILAUDID					
AP	+! FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	Feb	CFTG
AP	+!	0.5MG/0.5ML	N019034	007	Feb 10, 2017	Feb	CFTG
	+!	0.5MG/0.5ML	N019034	007	Feb 10, 2017	Jan	NEWA
HYDROMORPHONE HYDROCHLORIDE							
AP	HIKMA	0.2MG/ML	A216899	001	Feb 09, 2024	Feb	NFTG
AP		0.5MG/0.5ML	A216899	002	Feb 09, 2024	Feb	NFTG
AP		1MG/ML	A216899	003	Feb 09, 2024	Feb	NEWA
AP		2MG/ML	A216899	004	Feb 09, 2024	Feb	NEWA
SOLUTION; ORAL		HYDROMORPHONE HYDROCHLORIDE					
@	GENUS	5MG/5ML	A207108	001	Apr 22, 2020	Jan	CAHN
TABLET; ORAL		HYDROMORPHONE HYDROCHLORIDE					
@	GENUS	2MG	A077471	002	Dec 09, 2009	Jan	CAHN
@		4MG	A077471	003	Dec 09, 2009	Jan	CAHN
@		8MG	A077471	001	Dec 09, 2009	Jan	CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL		HYDROXYCHLOROQUINE SULFATE					
>D>	@ CREEKWOOD PHARMS	200MG	A040150	001	Jan 27, 1996	Apr	CMFD
>A>	AB	200MG	A040150	001	Jan 27, 1996	Apr	CMFD
	@	200MG	A040150	001	Jan 27, 1996	Jan	CAHN
AB	SENORES PHARMS	200MG	A212902	001	May 14, 2020	Feb	CAHN
AB	TEVA PHARMS	200MG	A040081	001	Sep 30, 1994	Feb	CMFD

HYDROXYUREA

CAPSULE; ORAL		HYDROXYUREA					
AB	QILU	500MG	A218021	001	Mar 06, 2024	Feb	NEWA
SOLUTION; ORAL		XROMI					
>A>	+!	NOVA LABS LTD	N216593	001	Apr 04, 2024	Apr	NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@	INVAGEN PHARMS	10MG	A040812	001	Mar 12, 2008	Mar	DISC
@		25MG	A040812	002	Mar 12, 2008	Mar	DISC
@		50MG	A040812	003	Mar 12, 2008	Mar	DISC

IBRUTINIB

TABLET; ORAL

IMBRUVICA

+!	PHARMACYCLICS LLC	420MG	N210563	003	Feb 16, 2018	Jan	CHRS
----	-------------------	-------	---------	-----	--------------	-----	------

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

IBUTILIDE FUMARATE

AP	AVET LIFESCIENCES	0.1MG/ML	A204146	001	Apr 01, 2024	Mar	NEWA
----	-------------------	----------	---------	-----	--------------	-----	------

ICOSAPENT ETHYL

CAPSULE; ORAL

ICOSAPENT ETHYL

AB	ASCENT PHARMS INC	1GM	A216811	002	Feb 16, 2024	Feb	NEWA
>D>	AB	ZYDUS	A217656	001	Apr 20, 2023	Apr	CAHN
>D>	AB		A217656	002	Apr 20, 2023	Apr	CAHN
>A>	AB	ZYDUS LIFESCIENCES	A217656	001	Apr 20, 2023	Apr	CAHN
>A>	AB		A217656	002	Apr 20, 2023	Apr	CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

@	RISING	1MG/ML	A200144	001	Oct 11, 2012	Feb	CAHN
---	--------	--------	---------	-----	--------------	-----	------

ILOPROST

SOLUTION; INHALATION

VENTAVIS

+	@	ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005	Mar	DISC
+	@		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009	Mar	DISC

SOLUTION; INTRAVENOUS

AURLUMYN

+!	EICOS SCI	100MCG/ML (100MCG/ML)	N217933	001	Feb 13, 2024	Feb	NEWA
----	-----------	-----------------------	---------	-----	--------------	-----	------

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

>D>	AB	LEADING	50MG	A040903	003	Oct 24, 2012	Apr	CHRS
>A>	AB	!	50MG	A040903	003	Oct 24, 2012	Apr	CHRS
>D>	AB	+ SPECGX LLC	10MG	A087846	002	May 22, 1984	Apr	DISC
>A>		+ @	10MG	A087846	002	May 22, 1984	Apr	DISC
>D>	AB	+	25MG	A087846	003	May 22, 1984	Apr	DISC
>A>		+ @	25MG	A087846	003	May 22, 1984	Apr	DISC
>D>		TOFRANIL						
>D>	AB	+! SPECGX LLC	50MG	A087846	001	May 22, 1984	Apr	DISC
>A>		+ @	50MG	A087846	001	May 22, 1984	Apr	DISC

INDOMETHACIN

SUPPOSITORY; RECTAL

INDOMETHACIN

>D>	AB	ZYDUS	50MG	A216184	001	Aug 02, 2023	Apr	CAHN
>A>	AB	ZYDUS LIFESCIENCES	50MG	A216184	001	Aug 02, 2023	Apr	CAHN

SUSPENSION; ORAL

INDOCIN

AB	+!	ZYLA	25MG/5ML	N018332	001	Oct 10, 1985	Jan	CTEC
----	----	------	----------	---------	-----	--------------	-----	------

INDOMETHACIN

AB		NOVITIUM PHARMA	25MG/5ML	A217883	001	Jan 12, 2024	Jan	NEWA
----	--	-----------------	----------	---------	-----	--------------	-----	------

IOBENGUANE I-131

SOLUTION; INTRAVENOUS

AZEDRA

+	@	PROGENICS PHARMS INC	15mCi/ML	N209607	001	Jul 30, 2018	Feb	DISC
---	---	----------------------	----------	---------	-----	--------------	-----	------

IOPAMIDOLINJECTABLE; INJECTION
IOPAMIDOL

AP		HAINAN POLY	51%	A217134	002	Apr 09, 2024	Mar	NEWA
AP			61%	A217134	003	Apr 09, 2024	Mar	NEWA
AP			76%	A217134	004	Apr 09, 2024	Mar	NEWA
		ISOVUE-250						
AP	+!	BRACCO	51%	N018735	007	Jul 06, 1992	Mar	CTEC
		ISOVUE-300						
AP	+!	BRACCO	61%	N018735	002	Dec 31, 1985	Mar	CTEC
		ISOVUE-370						
AP	+!	BRACCO	76%	N018735	003	Dec 31, 1985	Mar	CTEC

ISOPROTERENOL HYDROCHLORIDEINJECTABLE; INJECTION
ISOPROTERENOL HYDROCHLORIDE
@ CIPLA 0.2MG/ML

A210322 001 Jun 12, 2018 Mar DISC

ISOSORBIDE DINITRATETABLET; ORAL
ISOSORBIDE DINITRATE

>A>	AB	ENDO OPERATIONS	40MG	A211290	001	Nov 23, 2021	Apr	CAHN
>D>	AB	PAR PHARM INC	40MG	A211290	001	Nov 23, 2021	Apr	CAHN

ISOSORBIDE MONONITRATETABLET; ORAL
MONOKET

AB	+	OMNIVIUM PHARMS	10MG	N020215	002	Jun 30, 1993	Jan	CAHN
AB	+!		20MG	N020215	001	Jun 30, 1993	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

AB		CHARTWELL MOLECULAR	120MG	A075155	003	Aug 04, 2000	Mar	CHRS
AB	!	RICONPHARMA LLC	120MG	A210918	003	Nov 05, 2018	Mar	CHRS
AB		SHANDONG	30MG	A214115	002	Feb 08, 2024	Feb	NEWA
AB			60MG	A214115	003	Feb 08, 2024	Feb	NEWA
AB			120MG	A214115	001	Apr 29, 2022	Mar	CMFD
AB		ZYDUS PHARMS	30MG	A218255	001	Feb 15, 2024	Feb	NEWA
AB			60MG	A218255	002	Feb 15, 2024	Feb	NEWA
AB			120MG	A218255	003	Feb 15, 2024	Feb	NEWA

ISOTRETINOINCAPSULE; ORAL
ISOTRETINOIN

AB2		AUROBINDO PHARMA	10MG	A218194	001	Jan 29, 2024	Jan	NEWA
AB2			20MG	A218194	002	Jan 29, 2024	Jan	NEWA
AB2			25MG	A218194	003	Jan 29, 2024	Jan	NEWA
AB2			30MG	A218194	004	Jan 29, 2024	Jan	NEWA
AB2			35MG	A218194	005	Jan 29, 2024	Jan	NEWA
AB2			40MG	A218194	006	Jan 29, 2024	Jan	NEWA

ITRACONAZOLECAPSULE; ORAL
ITRACONAZOLE

>D>		@ PAR PHARM INC	100MG	A205724	001	Dec 13, 2016	Apr	CAHN
>A>		@ RISING	100MG	A205724	001	Dec 13, 2016	Apr	CAHN

IVERMECTINCREAM; TOPICAL
IVERMECTIN

AB		ZYDUS LIFESCIENCES	1%	A215210	001	Aug 02, 2022	Mar	CAHN
----	--	--------------------	----	---------	-----	--------------	-----	------

KETOCONAZOLEAEROSOL, FOAM; TOPICAL
EXTINA

	+	@ MYLAN	2%	N021738	001	Jun 12, 2007	Feb	DISC
--	---	---------	----	---------	-----	--------------	-----	------

KETOCONAZOLE

AB	!	XIROMED	2%	A213601	001	May 21, 2021	Feb	CHRS
----	---	---------	----	---------	-----	--------------	-----	------

TABLET; ORAL

KETOCONAZOLE

AB		SENORES PHARMS	200MG	A075912	001	Jan 10, 2002	Feb	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINESOLUTION/DROPS;OPHTHALMIC
KETOROLAC TROMETHAMINE

AT	CAPLIN	0.5%		A218204	001	Mar 26, 2024	Mar	NEWA
----	--------	------	--	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDETABLET;ORAL
LABETALOL HYDROCHLORIDE

>A>	AB	ENDO OPERATIONS	100MG	A200908	001	Jul 10, 2012	Apr	CAHN
>A>	AB	!	200MG	A200908	002	Jul 10, 2012	Apr	CAHN
>A>	AB		300MG	A200908	003	Jul 10, 2012	Apr	CAHN
>D>	AB	PAR FORM	100MG	A200908	001	Jul 10, 2012	Apr	CAHN
>D>	AB	!	200MG	A200908	002	Jul 10, 2012	Apr	CAHN
>D>	AB		300MG	A200908	003	Jul 10, 2012	Apr	CAHN

LACOSAMIDESOLUTION;INTRAVENOUS
LACOSAMIDE

AP	DR REDDYS	200MG/20ML (10MG/ML)		A217718	001	Mar 25, 2024	Mar	NEWA
AP	HAINAN POLY	200MG/20ML (10MG/ML)		A217311	001	Feb 13, 2024	Feb	NEWA
AP	HIKMA	200MG/20ML (10MG/ML)		A216806	001	Apr 05, 2024	Mar	NEWA

SOLUTION;ORAL
LACOSAMIDE

>D>	AA	AMNEAL PHARMS	10MG/ML	A204839	001	Mar 27, 2024	Apr	DISC
>A>		@	10MG/ML	A204839	001	Mar 27, 2024	Apr	DISC
	AA		10MG/ML	A204839	001	Mar 27, 2024	Mar	NEWA
	AA	AUROBINDO PHARMA LTD	10MG/ML	A209224	001	Jan 24, 2024	Jan	NEWA

TABLET;ORAL
LACOSAMIDE

AB	MEDLEY PHARMS	50MG		A218014	001	Apr 02, 2024	Mar	NEWA
AB		100MG		A218014	002	Apr 02, 2024	Mar	NEWA
AB		150MG		A218014	003	Apr 02, 2024	Mar	NEWA
AB		200MG		A218014	004	Apr 02, 2024	Mar	NEWA

LACTULOSESOLUTION;ORAL
LACTULOSE

		@ HIKMA	10GM/15ML	A074076	001	Jul 03, 1995	Mar	DISC
AA	!	PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	Mar	CHRS

SOLUTION;ORAL, RECTAL
LACTULOSE

		@ PAI HOLDINGS PHARM	10GM/15ML	A074077	001	Jul 03, 1995	Feb	DISC
--	--	----------------------	-----------	---------	-----	--------------	-----	------

LAMIVUDINESOLUTION;ORAL
EPIVIR-HBV

>D>		!	GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998	Apr	DISC
>A>		+	@	5MG/ML	N021004	001	Dec 08, 1998	Apr	DISC

TABLET;ORAL
EPIVIR-HBV

>D>	AB	!	GLAXOSMITHKLINE	100MG	N021003	001	Dec 08, 1998	Apr	DISC
>A>		+	@	100MG	N021003	001	Dec 08, 1998	Apr	DISC

LAMIVUDINE

>D>	AB	APOTEX	100MG	A202941	001	Jan 02, 2014	Apr	CHRS
>A>	AB	!	100MG	A202941	001	Jan 02, 2014	Apr	CHRS
		@ MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Jan	DISC
		@	300MG	A078545	002	Mar 05, 2019	Jan	DISC

LAMIVUDINE; ZIDOVUDINETABLET;ORAL
COMBIVIR

		+	@ VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997	Jan	DISC
--	--	---	-----------------	-------------	---------	-----	--------------	-----	------

LAMIVUDINE AND ZIDOVUDINE

AB	!	HETERO LABS LTD III	150MG;300MG	A079124	001	Sep 17, 2015	Jan	CHRS
----	---	---------------------	-------------	---------	-----	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	GLENMARK PHARMS LTD	25MG	A090169	001	May 12, 2012	Mar	CAHN
AB		100MG	A090169	002	May 12, 2012	Mar	CAHN
AB		150MG	A090169	003	May 12, 2012	Mar	CAHN
AB		200MG	A090169	004	May 12, 2012	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

	@ ANCHEN PHARMS	25MG	A201374	001	Dec 26, 2012	Feb	DISC	
	@	50MG	A201374	002	Dec 26, 2012	Feb	DISC	
	@	100MG	A201374	003	Dec 26, 2012	Feb	DISC	
	@	200MG	A201374	004	Dec 26, 2012	Feb	DISC	
	@	250MG	A201374	005	Dec 26, 2012	Feb	DISC	
	@	300MG	A201374	006	Dec 26, 2012	Feb	DISC	
>A>	AB	ENDO OPERATIONS	25MG	A201791	001	Jan 18, 2013	Apr	CAHN
>A>	AB		50MG	A201791	002	Jan 18, 2013	Apr	CAHN
>A>	AB		100MG	A201791	003	Jan 18, 2013	Apr	CAHN
>A>	AB		200MG	A201791	004	Jan 18, 2013	Apr	CAHN
>A>	AB		250MG	A201791	005	Jan 18, 2013	Apr	CAHN
>A>	AB		300MG	A201791	006	Jan 18, 2013	Apr	CAHN
>D>	AB	PAR PHARM	25MG	A201791	001	Jan 18, 2013	Apr	CAHN
>D>	AB		50MG	A201791	002	Jan 18, 2013	Apr	CAHN
>D>	AB		100MG	A201791	003	Jan 18, 2013	Apr	CAHN
>D>	AB		200MG	A201791	004	Jan 18, 2013	Apr	CAHN
>D>	AB		250MG	A201791	005	Jan 18, 2013	Apr	CAHN
>D>	AB		300MG	A201791	006	Jan 18, 2013	Apr	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

LAMOTRIGINE

>A>	AB	ENDO OPERATIONS	25MG	A204158	001	Oct 27, 2015	Apr	CAHN
>A>	AB		50MG	A204158	002	Oct 27, 2015	Apr	CAHN
>A>	AB		100MG	A204158	003	Oct 27, 2015	Apr	CAHN
>A>	AB		200MG	A204158	004	Oct 27, 2015	Apr	CAHN
>D>	AB	PAR PHARM	25MG	A204158	001	Oct 27, 2015	Apr	CAHN
>D>	AB		50MG	A204158	002	Oct 27, 2015	Apr	CAHN
>D>	AB		100MG	A204158	003	Oct 27, 2015	Apr	CAHN
>D>	AB		200MG	A204158	004	Oct 27, 2015	Apr	CAHN

LEFAMULIN ACETATE

SOLUTION; INTRAVENOUS

XENLETA

>D>	+	@ NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Apr	CMFD
>A>	+	!	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Apr	CMFD

LENALIDOMIDE

CAPSULE; ORAL

LENALIDOMIDE

AB	QILU	2.5MG	A217265	001	Feb 22, 2024	Feb	NEWA
AB		5MG	A217265	002	Feb 22, 2024	Feb	NEWA
AB		10MG	A217265	003	Feb 22, 2024	Feb	NEWA
AB		15MG	A217265	004	Feb 22, 2024	Feb	NEWA
AB		20MG	A217265	005	Feb 22, 2024	Feb	NEWA
AB		25MG	A217265	006	Feb 22, 2024	Feb	NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

>D>	AN	MYLAN SPECIALITY LP	EQ 0.25% BASE	A078309	001	Mar 20, 2009	Apr	CHRS	
>A>	AN	!	EQ 0.25% BASE	A078309	001	Mar 20, 2009	Apr	CHRS	
>D>	AN	TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr	CHRS	
>A>	AN	!	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr	CHRS	
>D>	AN		EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr	CHRS	
>A>	AN	!	EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr	CHRS	
>D>	AN		EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr	CHRS	
>A>	AN	!	EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr	CHRS	
>D>		XOPENEX							
>D>	AN	+	! HIKMA	EQ 0.0103% BASE	N020837	003	Jan 30, 2002	Apr	DISC
>A>		+	@	EQ 0.0103% BASE	N020837	003	Jan 30, 2002	Apr	DISC
>D>	AN	+	!	EQ 0.021% BASE	N020837	001	Mar 25, 1999	Apr	DISC
>A>		+	@	EQ 0.021% BASE	N020837	001	Mar 25, 1999	Apr	DISC

SOLUTION; INHALATION									
XOPENEX									
>D>	AN	+	EQ 0.042% BASE	N020837	002	Mar 25, 1999	Apr	DISC	
>A>		+ @	EQ 0.042% BASE	N020837	002	Mar 25, 1999	Apr	DISC	
>D>	AN	+	EQ 0.25% BASE	N020837	004	Jul 18, 2003	Apr	DISC	
>A>		+ @	EQ 0.25% BASE	N020837	004	Jul 18, 2003	Apr	DISC	
<u>LEVAMLODIPINE MALEATE</u>									
TABLET; ORAL									
CONJUPRI									
		+	CSPC OUYI EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Mar	CMFD	
		+	!	EQ 5MG BASE	N212895	003	Dec 19, 2019	Mar	CMFD
<u>LEVETIRACETAM</u>									
INJECTABLE; INTRAVENOUS									
LEVETIRACETAM									
AP			ADRASTEA PHARMA 500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN	
LEVETIRACETAM IN SODIUM CHLORIDE									
AP			B BRAUN MEDICAL INC 500MG/100ML (5MG/ML)	A209705	001	Feb 27, 2024	Feb	NEWA	
AP			1GM/100ML (10MG/ML)	A209705	002	Feb 27, 2024	Feb	NEWA	
AP			1.5GM/100ML (15MG/ML)	A209705	003	Feb 27, 2024	Feb	NEWA	
AP			BAXTER HLTHCARE CORP 500MG/100ML (5MG/ML)	A217059	001	Oct 02, 2023	Feb	CTNA	
AP			1GM/100ML (10MG/ML)	A217059	002	Oct 02, 2023	Feb	CTNA	
AP			1.5GM/100ML (15MG/ML)	A217059	003	Oct 02, 2023	Feb	CTNA	
		@	FRESENIUS KABI USA 500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Mar	DISC	
		@	1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Mar	DISC	
		@	1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Mar	DISC	
AP			HIKMA 500MG/100ML (5MG/ML)	A211356	001	Feb 12, 2024	Feb	NEWA	
AP			1GM/100ML (10MG/ML)	A211356	002	Feb 12, 2024	Feb	NEWA	
AP			1.5GM/100ML (15MG/ML)	A211356	003	Feb 12, 2024	Feb	NEWA	
		+	@ HQ SPCLT PHARMA 250MG/50ML (5MG/ML)	N202543	004	Dec 14, 2020	Feb	DISC	
SOLUTION; ORAL									
LEVETIRACETAM									
		@	HIKMA 100MG/ML	A090601	001	Feb 28, 2012	Mar	DISC	
TABLET; ORAL									
LEVETIRACETAM									
		@	GRANULES 250MG	A217878	001	Jun 13, 2023	Mar	DISC	
		@	500MG	A217878	002	Jun 13, 2023	Mar	DISC	
		@	750MG	A217878	003	Jun 13, 2023	Mar	DISC	
		@	1GM	A217878	004	Jun 13, 2023	Mar	DISC	
		@	INVAGEN PHARMS 250MG	A078234	001	Jan 15, 2009	Mar	DISC	
		@	500MG	A078234	002	Jan 15, 2009	Mar	DISC	
		@	750MG	A078234	003	Jan 15, 2009	Mar	DISC	
TABLET, EXTENDED RELEASE; ORAL									
LEVETIRACETAM									
		@	ANCHEN PHARMS 500MG	A091360	001	Oct 04, 2011	Feb	DISC	
		@	750MG	A091360	002	Oct 04, 2011	Feb	DISC	
<u>LEVOCARNITINE</u>									
SOLUTION; ORAL									
LEVOCARNITINE									
		@	HIKMA 1GM/10ML	A077399	001	Oct 25, 2007	Mar	DISC	
<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>									
TABLET; ORAL									
LEVOCETIRIZINE DIHYDROCHLORIDE									
>A>	AB		IPCA LABS LTD 5MG	A204626	001	May 06, 2024	Apr	NEWA	
<u>LEVOFLOXACIN</u>									
INJECTABLE; INJECTION									
LEVOFLOXACIN									
>D>	AP		BAXTER HLTHCARE CORP EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr	DISC	
>A>		@	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr	DISC	
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER									
AP			KNACK EQ 250MG/50ML (EQ 5MG/ML)	A216164	001	Jan 29, 2024	Jan	NEWA	
AP			EQ 500MG/100ML (EQ 5MG/ML)	A216164	002	Jan 29, 2024	Jan	NEWA	
AP			EQ 750MG/150ML (EQ 5MG/ML)	A216164	003	Jan 29, 2024	Jan	NEWA	
SOLUTION/DROPS; OPHTHALMIC									
LEVOFLOXACIN									
		@	SAPTALIS PHARMS 0.5%	A090268	001	Dec 20, 2010	Mar	CAHN	

TABLET;ORAL

LEVOFLOXACIN

>D>	AB	CELLTRION	250MG	A090367	001	Jun 20, 2011	Apr	DISC
>A>	@		250MG	A090367	001	Jun 20, 2011	Apr	DISC
>D>	AB		500MG	A090367	002	Jun 20, 2011	Apr	DISC
>A>	@		500MG	A090367	002	Jun 20, 2011	Apr	DISC
>D>	AB		750MG	A090367	003	Jun 20, 2011	Apr	DISC
>A>	@		750MG	A090367	003	Jun 20, 2011	Apr	DISC

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS
FUSILEV

+!	ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar	CTEC
	LEVOLEUCOVORIN CALCIUM						
@	MEITHEAL	EQ 50MG BASE/VIAL	A211003	001	Aug 22, 2019	Mar	DISC

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOTHYROXINE SODIUM

AB1,	WATSON LABS TEVA	0.025MG	A207588	001	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							
AB1,		0.05MG	A207588	002	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							
AB1,		0.075MG	A207588	003	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							
AB1,		0.088MG	A207588	004	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							
AB1,		0.1MG	A207588	005	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							
AB1,		0.112MG	A207588	006	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							
AB1,		0.125MG	A207588	007	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							
AB1,		0.137MG	A207588	008	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							
AB1,		0.15MG	A207588	009	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							
AB1,		0.175MG	A207588	010	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							
AB1,		0.2MG	A207588	011	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							
AB1,		0.3MG	A207588	012	May 10, 2022	Feb	CTEC
AB2,							
AB3,							
AB4							

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

>D>	AT	COSETTE	5%	A211019	001	Dec 12, 2018	Apr	DISC
>A>	@		5%	A211019	001	Dec 12, 2018	Apr	DISC

LIDOCAINE HYDROCHLORIDE

	INJECTABLE; INJECTION					
	LIDOCAINE HYDROCHLORIDE					
>A>	AP	FRESENIUS KABI USA	1%	A088586	002	Apr CMS1
>A>	AP		2%	A088586	003	Apr CMS1
	SOLUTION; ORAL					
	LIDOCAINE HYDROCHLORIDE VISCOUS					
AT		PAI HOLDINGS PHARM	2%	A218138	001	Feb 20, 2024 Feb NEWA
	SOLUTION; TOPICAL					
	LIDOCAINE HYDROCHLORIDE					
>A>	AT	THE J MOLNER	4%	A218411	001	Apr 29, 2024 Apr NEWA

LIDOCAINE; PRILOCAINE

	CREAM; TOPICAL					
	LIDOCAINE AND PRILOCAINE					
	@	HIKMA	2.5%; 2.5%	A076290	001	Sep 25, 2003 Mar DISC

LIFITEGRAST

	SOLUTION/DROPS; OPHTHALMIC					
	XIIDRA					
AB	+	BAUSCH AND LOMB INC	5%	N208073	001	Jul 11, 2016 Jan CAHN

LIOTHYRONINE SODIUM

	TABLET; ORAL					
	LIOTHYRONINE SODIUM					
AB		BIOCON PHARMA	EQ 0.005MG BASE	A218070	001	Feb 06, 2024 Mar CAHN
AB			EQ 0.005MG BASE	A218070	001	Feb 06, 2024 Feb CAHN
AB			EQ 0.025MG BASE	A218070	002	Feb 06, 2024 Mar CAHN
AB			EQ 0.025MG BASE	A218070	002	Feb 06, 2024 Feb CAHN
AB			EQ 0.05MG BASE	A218070	003	Feb 06, 2024 Mar CAHN
AB			EQ 0.05MG BASE	A218070	003	Feb 06, 2024 Feb CAHN
AB		CARNEGIE	EQ 0.005MG BASE	A218070	001	Feb 06, 2024 Jan NEWA
AB			EQ 0.025MG BASE	A218070	002	Feb 06, 2024 Jan NEWA
AB			EQ 0.05MG BASE	A218070	003	Feb 06, 2024 Jan NEWA

LIRAGLUTIDE

	SOLUTION; SUBCUTANEOUS					
	SAXENDA					
	+	NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014 Mar CAIN
	VICTOZA					
	+	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010 Mar CAIN

LISDEXAMFETAMINE DIMESYLATE

	CAPSULE; ORAL					
	LISDEXAMFETAMINE DIMESYLATE					
	@	ACTAVIS ELIZABETH	10MG	A202802	001	Aug 25, 2023 Feb DISC
	@		20MG	A202802	002	Aug 25, 2023 Feb DISC
	@		30MG	A202802	003	Aug 25, 2023 Feb DISC
	@		40MG	A202802	004	Aug 25, 2023 Feb DISC
	@		50MG	A202802	005	Aug 25, 2023 Feb DISC
	@		60MG	A202802	006	Aug 25, 2023 Feb DISC
	@		70MG	A202802	007	Aug 25, 2023 Feb DISC
AB		HIKMA	10MG	A202827	007	Jan 17, 2024 Jan NEWA
	TABLET, CHEWABLE; ORAL					
	LISDEXAMFETAMINE DIMESYLATE					
AB		MSN	10MG	A218306	001	Feb 02, 2024 Jan NEWA
AB			20MG	A218306	002	Feb 02, 2024 Jan NEWA
AB			30MG	A218306	003	Feb 02, 2024 Jan NEWA
AB			40MG	A218306	004	Feb 02, 2024 Jan NEWA
AB			50MG	A218306	005	Feb 02, 2024 Jan NEWA
AB			60MG	A218306	006	Feb 02, 2024 Jan NEWA
	@	TEVA PHARMS	10MG	A215415	001	Aug 25, 2023 Feb DISC
	@		20MG	A215415	002	Aug 25, 2023 Feb DISC
	@		30MG	A215415	003	Aug 25, 2023 Feb DISC
	@		40MG	A215415	004	Aug 25, 2023 Feb DISC
	@		50MG	A215415	005	Aug 25, 2023 Feb DISC
	@		60MG	A215415	006	Aug 25, 2023 Feb DISC

LITHIUM CITRATE

SYRUP;ORAL		LITHIUM CITRATE							
	@ PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML		A070755	001	May 21, 1986	Feb	DISC	
AA	! RUBICON	EQ 300MG CARBONATE/5ML		A218036	001	Aug 14, 2023	Mar	NEWA	
	!	EQ 300MG CARBONATE/5ML		A218036	001	Aug 14, 2023	Mar	CTEC	
AA	!	EQ 300MG CARBONATE/5ML		A218036	001	Aug 14, 2023	Feb	CHRS	
AA	SAPTALIS PHARMS	EQ 300MG CARBONATE/5ML		A217183	001	Mar 18, 2024	Mar	NEWA	
AA		EQ 300MG CARBONATE/5ML		A217183	001	Feb 29, 2024	Feb	NEWA	

LOMITAPIDE MESYLATE

CAPSULE;ORAL		JUXTAPID							
	+ CHIESI	EQ 5MG BASE		N203858	001	Dec 21, 2012	Jan	CAHN	
	+	EQ 10MG BASE		N203858	002	Dec 21, 2012	Jan	CAHN	
	+	EQ 20MG BASE		N203858	003	Dec 21, 2012	Jan	CAHN	
	+	EQ 30MG BASE		N203858	004	Apr 23, 2015	Jan	CAHN	
	+ @	EQ 40MG BASE		N203858	005	Apr 23, 2015	Jan	CAHN	
	+ @	EQ 60MG BASE		N203858	006	Apr 23, 2015	Jan	CAHN	

LOMUSTINE

CAPSULE;ORAL		GLEOSTINE							
	+ @ LATINA PHARMA	5MG		N017588	004	Dec 19, 2014	Feb	CAHN	
	+	10MG		N017588	001		Feb	CAHN	
	+	40MG		N017588	002		Feb	CAHN	
	+!	100MG		N017588	003		Feb	CAHN	

LOPINAVIR; RITONAVIR

TABLET;ORAL		LOPINAVIR AND RITONAVIR							
AB	MYLAN LABS LTD	100MG;25MG		A079074	001	Feb 07, 2024	Jan	NEWA	
AB		200MG;50MG		A079074	002	Feb 07, 2024	Jan	NEWA	

LORAZEPAM

CONCENTRATE;ORAL		LORAZEPAM							
	@ HIKMA	2MG/ML		A200169	001	Jan 30, 2012	Mar	DISC	
INJECTABLE;INJECTION		LORAZEPAM							
>D>	@ DAVA PHARMS INC	2MG/ML		A074793	001	Mar 16, 2000	Apr	CAHN	
>D>	@	4MG/ML		A074793	002	Mar 16, 2000	Apr	CAHN	
>A>	@ ENDO OPERATIONS	2MG/ML		A074793	001	Mar 16, 2000	Apr	CAHN	
>A>	@	4MG/ML		A074793	002	Mar 16, 2000	Apr	CAHN	

LOSARTAN POTASSIUM

TABLET;ORAL		LOSARTAN POTASSIUM							
	@ AIPING PHARM INC	25MG		A090544	001	Oct 06, 2010	Feb	CAHN	
	@	50MG		A090544	002	Oct 06, 2010	Feb	CAHN	
	@	100MG		A090544	003	Oct 06, 2010	Feb	CAHN	
AB	CHARTWELL RX	25MG		A077424	001	Oct 06, 2010	Jan	CAHN	
AB		50MG		A077424	002	Oct 06, 2010	Jan	CAHN	
AB		100MG		A077424	003	Oct 06, 2010	Jan	CAHN	

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC		LOTEPREDNOL ETABONATE							
>A>	AB HIKMA	0.5%		A213956	001	Nov 29, 2023	Apr	CAHN	
>D>	AB SLAYBACK PHARMA LLC	0.5%		A213956	001	Nov 29, 2023	Apr	CAHN	
SUSPENSION/DROPS;OPHTHALMIC		LOTEPREDNOL ETABONATE							
>A>	AB LUPIN LTD	0.5%		A215719	001	Apr 24, 2024	Apr	NEWA	

LUBIPROSTONE

CAPSULE;ORAL		LUBIPROSTONE							
>D>	@ ANCHEN PHARMS	8MCG		A201442	001	Jun 27, 2022	Apr	CAHN	
>D>	@	24MCG		A201442	002	Jun 27, 2022	Apr	CAHN	
>A>	@ ENDO OPERATIONS	8MCG		A201442	001	Jun 27, 2022	Apr	CAHN	
>A>	@	24MCG		A201442	002	Jun 27, 2022	Apr	CAHN	

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

AB	SLATE RUN PHARMA	20MG	A212091	001	Dec 28, 2020	Feb	CAHN
AB		40MG	A212091	002	Dec 28, 2020	Feb	CAHN
AB		60MG	A212091	003	Dec 28, 2020	Feb	CAHN
AB		80MG	A212091	004	Dec 28, 2020	Feb	CAHN
AB		120MG	A212091	005	Dec 28, 2020	Feb	CAHN

MACITENTAN

TABLET; ORAL

>D> MACITENTAN

>D> AB	APOTEX	10MG	A211195	001	Jan 09, 2024	Apr	DISC
>A>	@	10MG	A211195	001	Jan 09, 2024	Apr	DISC
>D> AB	OPSUMIT						
>D> AB	+! ACTELION	10MG	N204410	001	Oct 18, 2013	Apr	CTEC
>A>	+!	10MG	N204410	001	Oct 18, 2013	Apr	CTEC

MACITENTAN; TADALAFIL

TABLET; ORAL

OPSYNVI

+	ACTELION	10MG;20MG	N218490	001	Mar 22, 2024	Mar	NEWA
+	!	10MG;40MG	N218490	002	Mar 22, 2024	Mar	NEWA

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

AA	TARO	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A206431	001	Mar 19, 2024	Mar	NEWA
----	------	---------------------------------	---------	-----	--------------	-----	------

MARAVIROC

TABLET; ORAL

SELZENTRY

+	@ VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016	Jan	DISC
+	@	75MG	N022128	004	Nov 04, 2016	Jan	DISC

>A> MAVORIXAFOR

>A> CAPSULE; ORAL

>A> XOLREMDI

>A>	+! X4 PHARMS	100MG	N218709	001	Apr 26, 2024	Apr	NEWA
-----	--------------	-------	---------	-----	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011	Mar	CHRS
AA	!	50MG	A201451	003	Feb 23, 2011	Feb	CMFD
	@ INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Mar	DISC
	@	25MG	A200432	002	Feb 17, 2022	Mar	DISC
	@	50MG	A200432	003	Feb 17, 2022	Mar	DISC

TABLET, CHEWABLE; ORAL

MECLIZINE HYDROCHLORIDE

@	INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Mar	DISC
---	----------------	------	---------	-----	--------------	-----	------

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

AB	HONG KONG	150MG/ML	A076553	001	Jul 28, 2004	Jan	CAHN
----	-----------	----------	---------	-----	--------------	-----	------

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

@	CHARTWELL	125MG/ML	A204688	001	Dec 01, 2017	Mar	CAHN
@	HIKMA	40MG/ML	A203960	001	Jun 09, 2017	Mar	DISC

MELOXICAM

TABLET; ORAL

MELOXICAM

>D>	@ SCIEGEN PHARMS INC	7.5MG	A077920	001	Jul 19, 2006	Apr	CMFD
>A> AB		7.5MG	A077920	001	Jul 19, 2006	Apr	CMFD
>D>	@	15MG	A077920	002	Jul 19, 2006	Apr	CMFD
>A> AB		15MG	A077920	002	Jul 19, 2006	Apr	CMFD
AB	! ZYDUS PHARMS USA	15MG	A077921	002	Jul 19, 2006	Jan	CTEC

TABLET;ORAL

MOBIC

+ @	BOEHRINGER INGELHEIM	7.5MG	N020938	001	Apr 13, 2000	Jan	DISC
+ @		15MG	N020938	002	Aug 23, 2000	Jan	DISC

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

>D>	@	ANCHEN PHARMS	7MG	A205784	001	Jun 09, 2017	Apr	CAHN
>D>	@		14MG	A205784	002	Jun 09, 2017	Apr	CAHN
>D>	@		21MG	A205784	003	Jun 09, 2017	Apr	CAHN
>D>	@		28MG	A205784	004	Jun 09, 2017	Apr	CAHN
>A>	@	ENDO OPERATIONS	7MG	A205784	001	Jun 09, 2017	Apr	CAHN
>A>	@		14MG	A205784	002	Jun 09, 2017	Apr	CAHN
>A>	@		21MG	A205784	003	Jun 09, 2017	Apr	CAHN
>A>	@		28MG	A205784	004	Jun 09, 2017	Apr	CAHN
AB		XIAMEN LP PHARM CO	21MG	A213985	004	Feb 06, 2024	Jan	NEWA

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB		RENATA	5MG	A209527	001	May 07, 2018	Jan	CAHN
AB			10MG	A209527	002	May 07, 2018	Jan	CAHN

MEPERIDINE HYDROCHLORIDE

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

AA	!	EPIC PHARMA LLC	50MG	A040331	001	May 28, 1999	Feb	CTEC
	!		50MG	A040331	001	May 28, 1999	Feb	CHRS
AA		GENUS	50MG	A040893	001	Jun 24, 2009	Feb	CMFD
	@		50MG	A040893	001	Jun 24, 2009	Jan	CAHN
	@		75MG	A040893	002	Jun 24, 2009	Jan	CAHN
	@		100MG	A040893	003	Jun 24, 2009	Jan	CAHN
	@		150MG	A040893	004	Jun 24, 2009	Jan	CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

@	DAEWOONG PHARM CO	500MG/VIAL	A204854	001	Dec 18, 2015	Feb	DISC
@		1GM/VIAL	A204854	002	Dec 18, 2015	Feb	DISC

MESALAMINE

TABLET, DELAYED RELEASE;ORAL

MESALAMINE

AB		ANNORA PHARMA	1.2GM	A216334	001	Feb 05, 2024	Jan	NEWA
----	--	---------------	-------	---------	-----	--------------	-----	------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

@	RISING	100MG/ML	A203364	001	Jul 18, 2014	Feb	CAHN
---	--------	----------	---------	-----	--------------	-----	------

METAPROTERENOL SULFATE

SYRUP;ORAL

METAPROTERENOL SULFATE

!	GENUS	10MG/5ML	A073632	001	Jul 22, 1992	Jan	CAHN
---	-------	----------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB3		MACLEODS PHARMS LTD	1GM	A211163	001	Mar 13, 2024	Mar	NEWA
-----	--	---------------------	-----	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

@	CHARTWELL RX	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Jan	CAHN
@		850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Jan	CAHN

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

>D>	AA	VISTAPHARM	10MG/ML	A040088	001	Nov 30, 1994	Apr	CAHN
>A>	AA	VISTAPHARM LLC	10MG/ML	A040088	001	Nov 30, 1994	Apr	CAHN

		SOLUTION;ORAL							
		METHADONE HYDROCHLORIDE							
>D>	AA	VISTAPHARM	5MG/5ML	A090707	001	Jun 30, 2010	Apr	CAHN	
>D>	AA		10MG/5ML	A090707	002	Jun 30, 2010	Apr	CAHN	
>A>	AA	VISTAPHARM LLC	5MG/5ML	A090707	001	Jun 30, 2010	Apr	CAHN	
>A>	AA		10MG/5ML	A090707	002	Jun 30, 2010	Apr	CAHN	
		TABLET;ORAL							
		METHADONE HYDROCHLORIDE							
>D>		@ VISTAPHARM	5MG	A040241	001	May 29, 1998	Apr	CAHN	
>D>	AA		10MG	A040241	002	May 29, 1998	Apr	CAHN	
>D>	AA		10MG	A204166	001	Mar 16, 2020	Apr	CAHN	
>A>		@ VISTAPHARM LLC	5MG	A040241	001	May 29, 1998	Apr	CAHN	
>A>	AA		10MG	A040241	002	May 29, 1998	Apr	CAHN	
>A>	AA		10MG	A204166	001	Mar 16, 2020	Apr	CAHN	
		<u>METHENAMINE HIPPURATE</u>							
		TABLET;ORAL							
		METHENAMINE HIPPURATE							
>A>	AB	JUBILANT CADISTA	1GM	A217675	001	Dec 01, 2023	Apr	CAHN	
>D>	AB	LYRUS LIFE SCIENCES	1GM	A217675	001	Dec 01, 2023	Apr	CAHN	
		<u>METHOCARBAMOL</u>							
		TABLET;ORAL							
		METHOCARBAMOL							
AA		DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb	CAHN	
AA			750MG	A203550	002	Feb 08, 2017	Feb	CAHN	
AA		HANGZHOU BINJIANG	500MG	A200958	001	Oct 21, 2011	Mar	CAHN	
AA			750MG	A200958	002	Oct 21, 2011	Mar	CAHN	
AB	!		1GM	A200958	003	Dec 06, 2021	Mar	CAHN	
		<u>METHOTREXATE SODIUM</u>							
		TABLET;ORAL							
		METHOTREXATE SODIUM							
>D>	AB	LOTUS PHARM CO LTD	EQ 2.5MG BASE	A209787	001	Apr 23, 2021	Apr	DISC	
>A>		@	EQ 2.5MG BASE	A209787	001	Apr 23, 2021	Apr	DISC	
		<u>METHSCOPOLAMINE BROMIDE</u>							
		TABLET;ORAL							
		METHSCOPOLAMINE BROMIDE							
AA		AACE PHARMS	2.5MG	A216786	001	Feb 01, 2024	Jan	NEWA	
AA			5MG	A216786	002	Feb 01, 2024	Jan	NEWA	
		<u>METHYLDOPA</u>							
		TABLET;ORAL							
		METHYLDOPA							
		@ CHARTWELL RX	250MG	N018934	001	Jun 29, 1984	Feb	DISC	
			250MG	N018934	001	Jun 29, 1984	Jan	CMFD	
		@	500MG	N018934	002	Jun 29, 1984	Feb	DISC	
		!	500MG	N018934	002	Jun 29, 1984	Jan	CMFD	
		<u>METHYLENE BLUE</u>							
		SOLUTION;INTRAVENOUS							
		METHYLENE BLUE							
>D>	AP	ZYDUS	10MG/2ML (5MG/ML)	A215636	001	Dec 05, 2023	Apr	CAHN	
>D>	AP		50MG/10ML (5MG/ML)	A215636	002	Dec 05, 2023	Apr	CAHN	
>A>	AP	ZYDUS LIFESCIENCES	10MG/2ML (5MG/ML)	A215636	001	Dec 05, 2023	Apr	CAHN	
>A>	AP		50MG/10ML (5MG/ML)	A215636	002	Dec 05, 2023	Apr	CAHN	
		<u>METHYLPHENIDATE HYDROCHLORIDE</u>							
		SOLUTION;ORAL							
		METHYLPHENIDATE HYDROCHLORIDE							
		@ BRECKENRIDGE	5MG/5ML	A201466	001	Nov 12, 2013	Mar	DISC	
		@	10MG/5ML	A201466	002	Nov 12, 2013	Mar	DISC	
		TABLET;ORAL							
		METHYLPHENIDATE HYDROCHLORIDE							
AB		CEDIPROF INC	5MG	A208737	001	Feb 01, 2019	Mar	CMFD	
AB			10MG	A208737	002	Feb 01, 2019	Mar	CMFD	
AB			20MG	A208737	003	Feb 01, 2019	Mar	CMFD	

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

>A>	AB	ENDO OPERATIONS	4MG	A040183	001	Dec 22, 1998	Apr	CAHN
		@ PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb	DISC
>D>	AB	VINTAGE PHARMS	4MG	A040183	001	Dec 22, 1998	Apr	CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

>A>	AB	ENDO OPERATIONS	40MG/ML	A214297	001	Jan 21, 2022	Apr	CAHN
>A>	AB		80MG/ML	A214297	002	Jan 21, 2022	Apr	CAHN
	AB	HONG KONG	40MG/ML	A040557	001	Feb 23, 2005	Jan	CAHN
	AB		80MG/ML	A040557	002	Feb 23, 2005	Jan	CAHN
>D>	AB	PAR STERILE PRODUCTS	40MG/ML	A214297	001	Jan 21, 2022	Apr	CAHN
>D>	AB		80MG/ML	A214297	002	Jan 21, 2022	Apr	CAHN
		@ TEVA PHARMS USA	40MG/ML	A040620	001	Oct 27, 2006	Jan	DISC
		@	80MG/ML	A040620	002	Oct 27, 2006	Jan	DISC

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>A>	AA	!	GENUS	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	Apr	CAHN
>D>	AA	!	PHARM ASSOC	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	Apr	CAHN

METOLAZONE

TABLET; ORAL

METOLAZONE

>A>	AB	LEADING	2.5MG	A218606	001	Apr 17, 2024	Apr	NEWA
>A>	AB		5MG	A218606	002	Apr 17, 2024	Apr	NEWA
>A>	AB		10MG	A218606	003	Apr 17, 2024	Apr	NEWA

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

@ GRANULES

@

@

@

EQ 25MG TARTRATE

EQ 50MG TARTRATE

EQ 100MG TARTRATE

EQ 200MG TARTRATE

A216509	001	Aug 07, 2023	Mar	DISC
A216509	002	Aug 07, 2023	Mar	DISC
A216509	003	Aug 07, 2023	Mar	DISC
A216509	004	Aug 07, 2023	Mar	DISC

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

>D>	AP	HOSPIRA	1MG/ML	A074133	001	Dec 21, 1993	Apr	DISC
>A>		@	1MG/ML	A074133	001	Dec 21, 1993	Apr	DISC

METRONIDAZOLE

GEL; VAGINAL

METRONIDAZOLE

AB ENCUBE

NUVESSA

AB +! CHEMO RESEARCH SL

TABLET; ORAL

METRONIDAZOLE

@ FLAMINGO PHARMS

@

250MG

500MG

A216795	001	Mar 18, 2024	Mar	NFTG
N205223	001	Mar 24, 2014	Mar	CFTG
A207309	001	May 16, 2016	Mar	DISC
A207309	002	May 16, 2016	Mar	DISC

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

>D>	AB	CARNEGIE	150MG	A215315	001	Aug 26, 2022	Apr	CAHN
>D>	AB		200MG	A215315	002	Aug 26, 2022	Apr	CAHN
>D>	AB		250MG	A215315	003	Aug 26, 2022	Apr	CAHN
>A>	AB	ZENARA	150MG	A215315	001	Aug 26, 2022	Apr	CAHN
>A>	AB		200MG	A215315	002	Aug 26, 2022	Apr	CAHN
>A>	AB		250MG	A215315	003	Aug 26, 2022	Apr	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

@ FRESENIUS KABI USA EQ 5MG BASE/ML A208878 001 Mar 28, 2017 Jan DISC

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
MIDODRINE HYDROCHLORIDE

>A> AB ENDO OPERATIONS 2.5MG A207169 001 Oct 29, 2018 Apr CAHN
>A> AB 5MG A207169 002 Oct 29, 2018 Apr CAHN
>A> AB 10MG A207169 003 Oct 29, 2018 Apr CAHN
>D> AB PAR PHARM INC 2.5MG A207169 001 Oct 29, 2018 Apr CAHN
>D> AB 5MG A207169 002 Oct 29, 2018 Apr CAHN
>D> AB 10MG A207169 003 Oct 29, 2018 Apr CAHN

MIDOSTAURIN

CAPSULE; ORAL
MIDOSTAURIN

>A> AB TEVA PHARMS 25MG A216076 001 Apr 29, 2024 Apr NFTG
RYDAFT
>D> +! NOVARTIS 25MG N207997 001 Apr 28, 2017 Apr CFTG
>A> AB +! 25MG N207997 001 Apr 28, 2017 Apr CFTG

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
MINOCYCLINE HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 45MG BASE A091118 001 Sep 25, 2014 Jan DISC
@ EQ 65MG BASE A091118 003 Dec 03, 2019 Jan DISC
@ EQ 80MG BASE A091118 004 Sep 25, 2014 Jan DISC
@ EQ 90MG BASE A091118 005 Sep 25, 2014 Jan DISC
@ EQ 105MG BASE A091118 006 Sep 25, 2014 Jan DISC
@ EQ 115MG BASE A091118 007 Dec 03, 2019 Jan DISC
@ EQ 135MG BASE A091118 008 Sep 25, 2014 Jan DISC
@ ZYDUS PHARMS EQ 45MG BASE A203553 001 Nov 16, 2017 Jan DISC
@ EQ 55MG BASE A203553 002 Jun 16, 2023 Jan DISC
@ EQ 65MG BASE A203553 003 Jun 16, 2023 Jan DISC
@ EQ 80MG BASE A203553 004 Nov 16, 2017 Jan DISC
@ EQ 90MG BASE A203553 005 Nov 16, 2017 Jan DISC
@ EQ 105MG BASE A203553 006 Nov 16, 2017 Jan DISC
@ EQ 115MG BASE A203553 007 Jun 16, 2023 Jan DISC
@ EQ 135MG BASE A203553 008 Nov 16, 2017 Jan DISC

MINOXIDIL

TABLET; ORAL
MINOXIDIL

>A> AB ENDO OPERATIONS 2.5MG A071826 001 Nov 14, 1988 Apr CAHN
>A> AB 10MG A071839 001 Nov 14, 1988 Apr CAHN
>D> AB PAR PHARM 2.5MG A071826 001 Nov 14, 1988 Apr CAHN
>D> AB 10MG A071839 001 Nov 14, 1988 Apr CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL
MIRABEGRON

AB ALKEM LABS LTD 25MG A215948 001 Feb 12, 2024 Feb NEWA
AB 50MG A215948 002 Feb 12, 2024 Feb NEWA
AB ZYDUS PHARMS 25MG A209488 001 Sep 29, 2022 Mar CMFD
AB 50MG A209488 002 Sep 29, 2022 Mar CMFD

MIRTAZAPINE

TABLET; ORAL
MIRTAZAPINE

AB AIPING PHARM INC 15MG A076219 001 Jun 19, 2003 Feb CAHN
AB 30MG A076219 002 Jun 19, 2003 Feb CAHN
AB 45MG A076219 003 Jun 19, 2003 Feb CAHN

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP FRESENIUS KABI USA 5MG/VIAL A211269 001 Apr 05, 2024 Mar NEWA
AP 20MG/VIAL A211269 002 Apr 05, 2024 Mar NEWA
AP 40MG/VIAL A211269 003 Apr 05, 2024 Mar NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION
MITOXANTRONE HYDROCHLORIDE
@ RISING

EQ 20MG BASE/10ML (EQ 2MG BASE/ML) A201014 001 Dec 11, 2012 Mar CAHN

>D> MOBOCERTINIB SUCCINATE

>D> CAPSULE; ORAL
>D> EXKIVITY

>D> +! TAKEDA PHARMS USA EQ 40MG BASE N215310 001 Sep 15, 2021 Apr DISC
>A> + @ EQ 40MG BASE N215310 001 Sep 15, 2021 Apr DISC

MOMETASONE FUROATE

LOTION; TOPICAL
MOMETASONE FUROATE

>D> AB COSETTE 0.1% A077678 001 Nov 21, 2007 Apr DISC
>A> @ 0.1% A077678 001 Nov 21, 2007 Apr DISC

SPRAY, METERED; NASAL
MOMETASONE FUROATE

AB AUROBINDO PHARMA 0.05MG/SPRAY A215878 001 Mar 18, 2024 Mar NEWA

MONTELUKAST SODIUM

GRANULE; ORAL
MONTELUKAST SODIUM
@ TEVA PHARMS

EQ 4MG BASE/PACKET A090955 001 Aug 03, 2012 Jan DISC

MORPHINE SULFATE

INJECTABLE; INJECTION
MORPHINE SULFATE

>D> AP HOSPIRA 0.5MG/ML A071849 001 May 11, 1988 Apr DISC
>A> @ 0.5MG/ML A071849 001 May 11, 1988 Apr DISC

SOLUTION; ORAL
MORPHINE SULFATE

@ HIKMA 100MG/5ML A208809 001 Jul 06, 2017 Mar DISC
AA WINDER LABS LLC 10MG/5ML A211454 001 Feb 12, 2021 Jan CMFD
AA 20MG/5ML A211454 002 Feb 12, 2021 Jan CMFD
AA 100MG/5ML A211454 003 Feb 12, 2021 Jan CMFD

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
VIGAMOX

AT1 +! HARROW EYE EQ 0.5% BASE N021598 001 Apr 15, 2003 Jan CAHN

MYCOPHENOLATE MOFETIL

TABLET; ORAL
MYCOPHENOLATE MOFETIL

@ AMNEAL 500MG A090606 001 Jul 16, 2010 Feb DISC
AB AUROBINDO PHARMA 500MG A217937 001 Feb 20, 2024 Feb NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

>A> AP ENDO OPERATIONS 500MG/VIAL A203575 001 Oct 28, 2016 Apr CAHN
>D> AP PAR STERILE PRODUCTS 500MG/VIAL A203575 001 Oct 28, 2016 Apr CAHN

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE; ORAL
MYCOPHENOLIC SODIUM

>D> AB AIRIS PHARMA PVT LTD EQ 180MG BASE A217031 001 Nov 29, 2023 Apr CAHN
>D> AB EQ 360MG BASE A217031 002 Nov 29, 2023 Apr CAHN
AB AUROBINDO PHARMA LTD EQ 180MG BASE A218603 001 Feb 27, 2024 Feb NEWA
AB EQ 360MG BASE A218603 002 Feb 27, 2024 Feb NEWA
>A> AB SKG PHARMA EQ 180MG BASE A217031 001 Nov 29, 2023 Apr CAHN
>A> AB EQ 360MG BASE A217031 002 Nov 29, 2023 Apr CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HYDROCHLORIDE

AP FRESENIUS KABI USA 0.4MG/ML A213573 001 Apr 02, 2024 Mar NEWA
AP 1MG/ML A213573 002 Apr 02, 2024 Mar NEWA
AP HIKMA 0.4MG/ML A212300 002 Mar 07, 2024 Mar NEWA
AP MANKIND PHARMA 0.4MG/ML A218404 001 Feb 29, 2024 Feb NEWA

SPRAY;NASAL
 >A> REZENOPY
 >A> +! SUMMIT BIOSCI 10MG/SPRAY N215487 001 Apr 19, 2024 Apr NEWA
 SPRAY, METERED;NASAL
 REXTOVY
 >D> + @ AMPHASTAR PHARMS INC 4MG/SPRAY N208969 001 Mar 07, 2023 Apr CMFD
 >A> +! 4MG/SPRAY N208969 001 Mar 07, 2023 Apr CMFD

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
 NALTREXONE
 @ TEVA PHARMS USA INC 380MG/VIAL A213195 001 Jul 06, 2023 Jan DISC
 VIVITROL
 +! ALKERMES 380MG/VIAL N021897 001 Apr 13, 2006 Jan CTEC

NAPROXEN

TABLET;ORAL
 NAPROXEN
 @ INVAGEN PHARMS 250MG A091305 001 Aug 24, 2011 Mar DISC
 @ 375MG A091305 002 Aug 24, 2011 Mar DISC
 @ 500MG A091305 003 Aug 24, 2011 Mar DISC

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL
 NEBIVOLOL HYDROCHLORIDE
 AB APOTEX EQ 10MG BASE A209741 001 Feb 27, 2024 Feb NEWA
 AB EQ 20MG BASE A209741 002 Feb 27, 2024 Feb NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS
 NEOSTIGMINE METHYLSULFATE
 >A> AP ENDO OPERATIONS 5MG/10ML (0.5MG/ML) A208405 001 Apr 26, 2017 Apr CAHN
 >A> AP 10MG/10ML (1MG/ML) A208405 002 Apr 26, 2017 Apr CAHN
 AP NIVAGEN PHARMS INC 5MG/10ML (0.5MG/ML) A212627 001 Nov 03, 2022 Jan CAHN
 AP 10MG/10ML (1MG/ML) A212627 002 Nov 03, 2022 Jan CAHN
 >D> AP PAR STERILE PRODUCTS 5MG/10ML (0.5MG/ML) A208405 001 Apr 26, 2017 Apr CAHN
 >D> AP 10MG/10ML (1MG/ML) A208405 002 Apr 26, 2017 Apr CAHN

NESIRITIDE

FOR SOLUTION;INTRAVENOUS
 NATRECOR
 + @ SCIOS LLC 1.5MG/VIAL N020920 001 Aug 10, 2001 Mar CAIN

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL
 NICARDIPINE HYDROCHLORIDE
 AB SKG PHARMA 20MG A218202 001 Apr 10, 2024 Mar NEWA
 AB 30MG A218202 002 Apr 10, 2024 Mar NEWA
 INJECTABLE;INJECTION
 NICARDIPINE HYDROCHLORIDE
 AP RK PHARMA 25MG/10ML (2.5MG/ML) A090664 001 Nov 17, 2009 Feb CMFD
 INJECTABLE;INTRAVENOUS
 CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER
 >D> +! CHIESI 40MG/200ML (0.2MG/ML) N019734 004 Nov 07, 2008 Apr CFTG
 >A> AP +! 40MG/200ML (0.2MG/ML) N019734 004 Nov 07, 2008 Apr CFTG
 CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER
 >D> +! CHIESI 20MG/200ML (0.1MG/ML) N019734 003 Jul 31, 2008 Apr CFTG
 >A> AP +! 20MG/200ML (0.1MG/ML) N019734 003 Jul 31, 2008 Apr CFTG
 >A> NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE
 >A> AP INFORLIFE 40MG/200ML (0.2MG/ML) A203978 002 Apr 17, 2024 Apr NFTG
 >A> NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE
 >A> AP INFORLIFE 20MG/200ML (0.1MG/ML) A203978 001 Apr 17, 2024 Apr NFTG

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL
 NILOTINIB HYDROCHLORIDE
 >D> AB APOTEX EQ 50MG BASE A203640 001 Jan 05, 2024 Apr DISC
 >A> @ EQ 50MG BASE A203640 001 Jan 05, 2024 Apr DISC
 >D> AB EQ 150MG BASE A203640 002 Jan 05, 2024 Apr DISC
 >A> @ EQ 150MG BASE A203640 002 Jan 05, 2024 Apr DISC
 >D> AB EQ 200MG BASE A203640 003 Jan 05, 2024 Apr DISC

CAPSULE;ORAL

NIOLOTINIB HYDROCHLORIDE

>A>	@	EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr	DISC
	TASIGNA						
>D>	AB +	NOVARTIS EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr	CTEC
>A>	+	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr	CTEC
>D>	AB +	EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr	CTEC
>A>	+	EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr	CTEC
>D>	AB +!	EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr	CTEC
>A>	+	EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr	CTEC

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

	+ @	GLAXOSMITHKLINE EQ 100MG BASE	N208447	001	Mar 27, 2017	Feb	DISC
--	-----	-------------------------------	---------	-----	--------------	-----	------

NIROGACESTAT HYDROBROMIDE

TABLET;ORAL

OGSIVEO

>D>	+!	SPRINGWORKS EQ 50MG BASE	N217677	001	Nov 27, 2023	Apr	CHRS
>A>	+	EQ 50MG BASE	N217677	001	Nov 27, 2023	Apr	CHRS
>A>	+	EQ 100MG BASE	N217677	002	Apr 04, 2024	Apr	NEWA
>A>	+!	EQ 150MG BASE	N217677	003	Apr 04, 2024	Apr	NEWA

NITISINONE

CAPSULE;ORAL

NITISINONE

>D>	AB	TORRENT 2MG	A215908	001	Jan 09, 2023	Apr	DISC
>A>	@	2MG	A215908	001	Jan 09, 2023	Apr	DISC
>D>	AB	5MG	A215908	002	Jan 09, 2023	Apr	DISC
>A>	@	5MG	A215908	002	Jan 09, 2023	Apr	DISC
>D>	AB	10MG	A215908	003	Jan 09, 2023	Apr	DISC
>A>	@	10MG	A215908	003	Jan 09, 2023	Apr	DISC
>D>	AB	20MG	A215908	004	Jan 09, 2023	Apr	DISC
>A>	@	20MG	A215908	004	Jan 09, 2023	Apr	DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

@	ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Feb	DISC
@		50MG	A091095	002	Jun 18, 2015	Feb	DISC
@		100MG	A091095	003	Jun 18, 2015	Feb	DISC

NITROGLYCERIN

OINTMENT;INTRA-ANAL

NITROGLYCERIN

AB		COSETTE 0.4%	A216103	001	Feb 16, 2024	Feb	NFTG
		RECTIV					
AB	+!	ABBVIE 0.4%	N021359	001	Jun 21, 2011	Feb	CFTG

NOREPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+!	LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Jan	CMFD
+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Jan	CMFD
+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Jan	CMFD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

@	RISING	EQ 10MG BASE	A074234	001	Jul 26, 1993	Feb	CAHN
@		EQ 25MG BASE	A074234	002	Jul 26, 1993	Feb	CAHN
@		EQ 50MG BASE	A074234	003	Jul 26, 1993	Feb	CAHN
@		EQ 75MG BASE	A074234	004	Jul 26, 1993	Feb	CAHN

NYSTATINPOWDER; TOPICAL
NYSTATIN

AT	ADRASTEIA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Mar	CAHN
----	------------------	------------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDECREAM; TOPICAL
MYKACET

>D>	AT	COSETTE	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Apr	DISC
>A>		@	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Apr	DISC

OINTMENT; TOPICAL
MYKACET

>D>	AT	COSETTE	100,000 UNITS/GM;0.1%	A062733	001	Mar 06, 1987	Apr	DISC
>A>		@	100,000 UNITS/GM;0.1%	A062733	001	Mar 06, 1987	Apr	DISC

OCTREOTIDE ACETATEINJECTABLE; INJECTION
OCTREOTIDE ACETATE

>A>	AP	SHUANGCHENG	EQ 0.1MG BASE/ML	A217860	001	May 02, 2024	Apr	NEWA
	AB	TEVA PHARMS USA INC	EQ 10MG BASE/VIAL	A210317	001	Dec 05, 2023	Jan	CTEC
	AB		EQ 20MG BASE/VIAL	A210317	002	Dec 05, 2023	Jan	CTEC
	AB		EQ 30MG BASE/VIAL	A210317	003	Dec 05, 2023	Jan	CTEC
		SANDOSTATIN LAR						
	AB	+ NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998	Jan	CTEC
	AB	+	EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998	Jan	CTEC
	AB	+	EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998	Jan	CTEC

ODEVIXIBATCAPSULE; ORAL
BYLVAY

+	IPSEN	0.4MG	N215498	002	Jul 20, 2021	Jan	CAHN
+	!	1.2MG	N215498	004	Jul 20, 2021	Jan	CAHN

CAPSULE, PELLETS; ORAL
BYLVAY

+	IPSEN	0.2MG	N215498	001	Jul 20, 2021	Jan	CAHN
+	!	0.6MG	N215498	003	Jul 20, 2021	Jan	CAHN

OFLOXACINSOLUTION/DROPS; OPHTHALMIC
OFLOXACIN

AT	AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb	NEWA	
>A>	AT	CAPLIN	0.3%	A217904	001	Apr 12, 2024	Apr	NEWA

SOLUTION/DROPS; OTIC
OFLOXACIN

@	HIKMA	0.3%	A076616	001	Mar 17, 2008	Mar	DISC
---	-------	------	---------	-----	--------------	-----	------

OLANZAPINETABLET; ORAL
OLANZAPINE

@	INDOCO	2.5MG	A206155	001	Jul 31, 2020	Mar	DISC
@		5MG	A206155	002	Jul 31, 2020	Mar	DISC
@		7.5MG	A206155	003	Jul 31, 2020	Mar	DISC
@		10MG	A206155	004	Jul 31, 2020	Mar	DISC
@		15MG	A206155	005	Jul 31, 2020	Mar	DISC
@		20MG	A206155	006	Jul 31, 2020	Mar	DISC

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

AB	BRECKENRIDGE	5MG	A206227	001	Jan 25, 2024	Jan	NEWA
AB		20MG	A206227	002	Jan 25, 2024	Jan	NEWA
AB		40MG	A206227	003	Jan 25, 2024	Jan	NEWA
AB	CHARTWELL RX	5MG	A206227	001	Jan 25, 2024	Mar	CAHN
AB		20MG	A206227	002	Jan 25, 2024	Mar	CAHN
AB		40MG	A206227	003	Jan 25, 2024	Mar	CAHN

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
 OLOPATADINE HYDROCHLORIDE
 >D> SOMERSET THERAPS LLC EQ 0.1% BASE A206306 001 Dec 07, 2015 Apr CMKT
 SPRAY, METERED;NASAL
 OLOPATADINE HYDROCHLORIDE
 @ HIKMA 0.665MG/SPRAY A213757 001 Aug 19, 2020 Mar DISC

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
 OMEGA-3-ACID ETHYL ESTERS
 AB CHARTWELL 1GM CONTAINS AT LEAST 900MG OF THE A206455 001 Aug 07, 2019 Mar CAHN
 ETHYL ESTERS OF OMEGA-3 FATTY
 ACIDS

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
 OMEPRAZOLE AND SODIUM BICARBONATE
 AB ! AJANTA PHARMA LTD 40MG;1.1GM A204228 002 Jul 15, 2016 Mar CHRS
 ZEGERID
 + @ SALIX 20MG;1.1GM N021849 001 Feb 27, 2006 Mar DISC
 + @ 40MG;1.1GM N021849 002 Feb 27, 2006 Mar DISC
 FOR SUSPENSION;ORAL
 OMEPRAZOLE AND SODIUM BICARBONATE
 AB ! AJANTA PHARMA LTD 40MG/PACKET;1.68GM/PACKET A205545 002 Jul 27, 2016 Mar CHRS
 ZEGERID
 + @ SALIX 20MG/PACKET;1.68GM/PACKET N021636 001 Jun 15, 2004 Mar DISC
 + @ 40MG/PACKET;1.68GM/PACKET N021636 002 Dec 21, 2004 Mar DISC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
 ONDANSETRON
 @ SUN PHARM INDS LTD 4MG A078602 001 Feb 24, 2011 Jan DISC
 @ 8MG A078602 002 Feb 24, 2011 Jan DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
 ONDANSETRON HYDROCHLORIDE
 >A> @ AM REGENT EQ 2MG BASE/ML A077582 001 Dec 26, 2006 Apr CAHN
 >D> @ LUITPOLD EQ 2MG BASE/ML A077582 001 Dec 26, 2006 Apr CAHN
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE
 >A> @ AM REGENT EQ 2MG BASE/ML A077387 001 Dec 26, 2006 Apr CAHN
 >D> @ LUITPOLD EQ 2MG BASE/ML A077387 001 Dec 26, 2006 Apr CAHN
 SOLUTION;ORAL
 ONDANSETRON HYDROCHLORIDE
 @ PHARM ASSOC EQ 4MG BASE/5ML A078127 001 Jun 25, 2007 Feb DISC

OPICAPONE

CAPSULE;ORAL
 ONGENTYS
 >A> + AMNEAL 25MG N212489 001 Apr 24, 2020 Apr CAHN
 >A> +! 50MG N212489 002 Apr 24, 2020 Apr CAHN
 >D> + NEUROCRINE 25MG N212489 001 Apr 24, 2020 Apr CAHN
 >D> +! 50MG N212489 002 Apr 24, 2020 Apr CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
 OSELTAMIVIR PHOSPHATE
 >A> AB LAURUS EQ 30MG BASE A218565 001 May 01, 2024 Apr NEWA
 >A> AB EQ 45MG BASE A218565 002 May 01, 2024 Apr NEWA
 >A> AB EQ 75MG BASE A218565 003 May 01, 2024 Apr NEWA

OSPEMIFENE

TABLET;ORAL
 OSPEMIFENE
 AB HETERO LABS LTD V 60MG A215574 001 Feb 13, 2024 Feb NFTG
 OSPHENA
 AB +! DUCHESNAY 60MG N203505 001 Feb 26, 2013 Feb CFTG

OXALIPLATININJECTABLE; INTRAVENOUS
OXALIPLATIN

AP	KINDOS	50MG/10ML (5MG/ML)	A217348	001	Jan 11, 2024	Jan	NEWA
AP		100MG/20ML (5MG/ML)	A217348	002	Jan 11, 2024	Jan	NEWA

OXAPROZINTABLET; ORAL
OXAPROZIN
@ TEVA

		600MG	A075849	001	Jul 03, 2002	Jan	DISC
--	--	-------	---------	-----	--------------	-----	------

OXCARBAZEPINESUSPENSION; ORAL
OXCARBAZEPINE

AB	ALKEM LABS LTD	300MG/5ML	A213183	001	Mar 18, 2023	Mar	NEWA
>A>	AB	BIOCON PHARMA	A218278	001	Mar 01, 2024	Apr	CAHN
AB	CARNEGIE	300MG/5ML	A218278	001	Mar 01, 2024	Feb	NEWA
AB	MEDLEY PHARMS	300MG/5ML	A217782	001	Feb 14, 2024	Feb	NEWA
>D>	AB	RISING	A218278	001	Mar 01, 2024	Apr	CAHN
AB		300MG/5ML	A218278	001	Mar 01, 2024	Mar	CAHN

TABLET; ORAL
OXCARBAZEPINE

AB	RUBICON	150MG	A207717	001	Mar 05, 2024	Feb	NEWA
AB		300MG	A207717	002	Mar 05, 2024	Feb	NEWA
AB		600MG	A207717	003	Mar 05, 2024	Feb	NEWA
	@ ZYDUS	150MG	A211747	001	Jul 03, 2023	Jan	DISC
	@	300MG	A211747	002	Jul 03, 2023	Jan	DISC
	@	600MG	A211747	003	Jul 03, 2023	Jan	DISC

TABLET, EXTENDED RELEASE; ORAL
OXCARBAZEPINE

AB	AJANTA PHARMA LTD	150MG	A217659	001	Feb 22, 2024	Feb	NEWA
AB		300MG	A217659	002	Feb 22, 2024	Feb	NEWA
AB		600MG	A217659	003	Feb 22, 2024	Feb	NEWA
	OXTELLAR XR						
AB	+ SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012	Feb	CTEC
AB	+	300MG	N202810	002	Oct 19, 2012	Feb	CTEC
AB	+!	600MG	N202810	003	Oct 19, 2012	Feb	CTEC

OXYBUTYNIN CHLORIDESYRUP; ORAL
OXYBUTYNIN CHLORIDE
@ PHARM ASSOC

		5MG/5ML	A075137	001	Dec 18, 1998	Feb	DISC
--	--	---------	---------	-----	--------------	-----	------

TABLET; ORAL
OXYBUTYNIN CHLORIDE
@ EYWA

		5MG	A211062	001	Feb 06, 2019	Mar	DISC
--	--	-----	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDESOLUTION; ORAL
OXYCODONE HYDROCHLORIDE

	@ HIKMA	5MG/5ML	A208817	001	Aug 10, 2017	Mar	DISC
	@	100MG/5ML	A208795	001	Aug 07, 2017	Mar	DISC
>D>	+ @ VISTAPHARM	5MG/5ML	N201194	001	Jan 12, 2012	Apr	CAHN
>A>	+ @ VISTAPHARM LLC	5MG/5ML	N201194	001	Jan 12, 2012	Apr	CAHN
	@ XTTRIUM LABS INC	5MG/5ML	A206456	001	Jun 16, 2015	Mar	CAHN

OZANIMOD HYDROCHLORIDECAPSULE; ORAL
ZEPOSIA

+	BRISTOL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	Jan	CAHN
+		EQ 0.46MG BASE	N209899	002	Mar 25, 2020	Jan	CAHN
+	!	EQ 0.92MG BASE	N209899	003	Mar 25, 2020	Jan	CAHN

PACLITAXELPOWDER; INTRAVENOUS
ABRAXANE

AB	+! BRISTOL-MYERS	100MG/VIAL	N021660	001	Jan 07, 2005	Jan	CTEC
	PACLITAXEL						
>D>	+! AM REGENT	100MG/VIAL	N211875	001	Jul 27, 2022	Apr	CTEC
>A>	AB	+! 100MG/VIAL	N211875	001	Jul 27, 2022	Apr	CTEC
AB	+! TEVA PHARMS INC	100MG/VIAL	N216338	001	May 11, 2023	Jan	CMFD

PALBOCICLIBTABLET; ORAL
IBRANCE

+	PFIZER	75MG	N212436	001	Nov 01, 2019	Jan	CTEC
+		100MG	N212436	002	Nov 01, 2019	Jan	CTEC
+	!	125MG	N212436	003	Nov 01, 2019	Jan	CTEC

PALIPERIDONETABLET, EXTENDED RELEASE; ORAL
INVEGA

+	@ JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008	Mar	DISC
---	------------------	-------	---------	-----	--------------	-----	------

PALONOSETRON HYDROCHLORIDESOLUTION; INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

>A>	@ AVYXA HOLDINGS	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Apr	CAHN
>A>	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Apr	CAHN
>D>	@ AVYXA PHARMA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Apr	CAHN
>D>	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Apr	CAHN

PANTOPRAZOLE SODIUMINJECTABLE; INTRAVENOUS
PANTOPRAZOLE SODIUM

AP	HANGZHOU ZHONGMEI	EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Mar	CAHN
	@ SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Feb	DISC

SOLUTION; INTRAVENOUS
PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

+	!	BAXTER HLTHCARE CORP	EQ 40MG BASE/100ML (EQ 0.4MG BASE/ML)	N217512	001	Feb 14, 2024	Feb	NEWA
+	!		EQ 40MG BASE/50ML (EQ 0.8MG BASE/ML)	N217512	002	Feb 14, 2024	Feb	NEWA
+	!		EQ 80MG BASE/100ML (EQ 0.8MG BASE/ML)	N217512	003	Feb 14, 2024	Feb	NEWA

TABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

>A>	AB	MANKIND PHARMA	EQ 20MG BASE	A215880	002	Apr 25, 2024	Apr	NEWA
-----	----	----------------	--------------	---------	-----	--------------	-----	------

PATIROMER SORBITE CALCIUMPOWDER; ORAL
VELTASSA

+	@ VIFOR PHARMA	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Feb	DISC
---	----------------	--------------------	---------	-----	--------------	-----	------

PAZOPANIB HYDROCHLORIDETABLET; ORAL
PAZOPANIB HYDROCHLORIDE

>A>	AB	NOVUGEN	EQ 200MG BASE	A218231	001	Apr 23, 2024	Apr	NEWA
-----	----	---------	---------------	---------	-----	--------------	-----	------

PEGULICIANINE ACETATEPOWDER; INTRAVENOUS
LUMISIGHT

>A>	+	!	LUMICELL	EQ 40MG BASE/VIAL	N214511	001	Apr 17, 2024	Apr	NEWA
-----	---	---	----------	-------------------	---------	-----	--------------	-----	------

PENICILLAMINECAPSULE; ORAL
PENICILLAMINE

>A>	AB	ENDO OPERATIONS	250MG	A211231	001	Dec 23, 2019	Apr	CAHN
>D>	AB	PAR PHARM INC	250MG	A211231	001	Dec 23, 2019	Apr	CAHN

TABLET; ORAL
PENICILLAMINE

>A>	AB	ENDO OPERATIONS	250MG	A211196	001	Dec 23, 2019	Apr	CAHN
>D>	AB	PAR PHARM INC	250MG	A211196	001	Dec 23, 2019	Apr	CAHN

PENICILLIN V POTASSIUMTABLET; ORAL
PENICILLIN V POTASSIUM

AB	!	AUROBINDO PHARMA	EQ 500MG BASE	A065435	002	Apr 29, 2008	Jan	CHRS
	@	SANDOZ	EQ 250MG BASE	A064071	001	Nov 30, 1995	Jan	DISC
	@		EQ 500MG BASE	A064071	002	Nov 30, 1995	Jan	DISC

PENTOBARBITAL

ELIXIR;ORAL
NEMBUTAL

>D>	@ AKORN	18.2MG/5ML	A 083244	001		Apr	CAHN
>A>	@ SAPTALIS PHARMS	18.2MG/5ML	A 083244	001		Apr	CAHN

PENTOBARBITAL SODIUM

SUPPOSITORY;RECTAL
NEMBUTAL

@ SAPTALIS PHARMS	30MG	A 083247	001	Jan 25, 1982	Mar	CAHN
@	60MG	A 083247	002	Jan 25, 1982	Mar	CAHN
@	120MG	A 083247	003	Jan 25, 1982	Mar	CAHN
@	200MG	A 083247	004	Jan 25, 1982	Mar	CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

AB	ANI PHARMS	400MG	A 074878	001	Jul 09, 1997	Jan	CMFD
----	------------	-------	----------	-----	--------------	-----	------

PERMETHRIN

CREAM;TOPICAL
PERMETHRIN

@ DR REDDYS LABS EU	5%	A 209732	001	Aug 01, 2023	Jan	DISC
---------------------	----	----------	-----	--------------	-----	------

PERPHENAZINE

TABLET;ORAL
PERPHENAZINE

>A> AB	ENDO OPERATIONS	2MG	A 040226	001	Dec 31, 1998	Apr	CAHN
>A> AB		4MG	A 040226	002	Dec 31, 1998	Apr	CAHN
>A> AB		8MG	A 040226	003	Dec 31, 1998	Apr	CAHN
>A> AB		16MG	A 040226	004	Dec 31, 1998	Apr	CAHN
>A> AB	MACLEODS PHARMS LTD	2MG	A 212545	001	May 06, 2024	Apr	NEWA
>A> AB		4MG	A 212545	002	May 06, 2024	Apr	NEWA
>A> AB		8MG	A 212545	003	May 06, 2024	Apr	NEWA
>A> AB		16MG	A 212545	004	May 06, 2024	Apr	NEWA
>D> AB	VINTAGE PHARMS	2MG	A 040226	001	Dec 31, 1998	Apr	CAHN
>D> AB		4MG	A 040226	002	Dec 31, 1998	Apr	CAHN
>D> AB		8MG	A 040226	003	Dec 31, 1998	Apr	CAHN
>D> AB		16MG	A 040226	004	Dec 31, 1998	Apr	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL
ADIPEX-P

+ @ TEVA	37.5MG	A 088023	001	Aug 02, 1983	Feb	DISC
@ INVAGEN PHARMS	15MG	A 202858	001	Feb 14, 2014	Mar	DISC
@	30MG	A 202858	002	Feb 14, 2014	Mar	DISC
@	30MG	A 204414	001	May 05, 2014	Mar	DISC
@	37.5MG	A 202846	001	Feb 05, 2014	Mar	DISC
AA ! NUVO PHARM	37.5MG	A 205017	001	Sep 25, 2014	Feb	CHRS

TABLET;ORAL
PHENTERMINE HYDROCHLORIDE

@ INVAGEN PHARMS	37.5MG	A 202942	001	Feb 05, 2014	Mar	DISC
------------------	--------	----------	-----	--------------	-----	------

PHENTOLAMINE MESYLATE

SOLUTION;OPHTHALMIC
RYZUMVI

+! FAMYGEN LIFE SCI	EQ 0.75% BASE	N 217064	001	Sep 25, 2023	Jan	CAHN
---------------------	---------------	----------	-----	--------------	-----	------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS
PHENYLEPHRINE HYDROCHLORIDE

>A>	@ ENDO OPERATIONS	10MG/ML (10MG/ML)	A 210025	001	Dec 21, 2018	Apr	CAHN
>A> AP1		50MG/5ML (10MG/ML)	A 210025	002	Dec 21, 2018	Apr	CAHN
>A> AP1		100MG/10ML (10MG/ML)	A 210025	003	Dec 21, 2018	Apr	CAHN
AP1	HAINAN POLY	10MG/ML (10MG/ML)	A 218412	001	Mar 14, 2024	Mar	NEWA
AP1		50MG/5ML (10MG/ML)	A 218412	002	Mar 14, 2024	Mar	NEWA
AP1		100MG/10ML (10MG/ML)	A 218412	003	Mar 14, 2024	Mar	NEWA
>D>	@ PAR STERILE PRODUCTS	10MG/ML (10MG/ML)	A 210025	001	Dec 21, 2018	Apr	CAHN
>D> AP1		50MG/5ML (10MG/ML)	A 210025	002	Dec 21, 2018	Apr	CAHN
>D> AP1		100MG/10ML (10MG/ML)	A 210025	003	Dec 21, 2018	Apr	CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

>A>	AA	!	GENUS	5MG/5ML; 6.25MG/5ML	A 040654	001	Dec 07, 2006	Apr	CAHN
		@	HIKMA	5MG/5ML; 6.25MG/5ML	A 040675	001	Dec 23, 2014	Mar	DISC
>D>	AA	!	PHARM ASSOC	5MG/5ML; 6.25MG/5ML	A 040654	001	Dec 07, 2006	Apr	CAHN

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

>D>	AB	@	PAI HOLDINGS PHARM	125MG/5ML	A 040420	001	Apr 19, 2002	Feb	DISC
>A>		@	VISTAPHARM	125MG/5ML	A 040342	001	Jan 31, 2001	Apr	DISC
>D>	AB	@		125MG/5ML	A 040342	001	Jan 31, 2001	Apr	DISC
>A>		@		125MG/5ML	A 040342	002	Aug 18, 2005	Apr	DISC
>A>		@		125MG/5ML	A 040342	002	Aug 18, 2005	Apr	DISC

TABLET, CHEWABLE; ORAL

PHENYTOIN

>D>	AB		TARO	50MG	A 200565	001	Apr 17, 2014	Apr	CAHN
>A>	AB			50MG	A 200565	001	Apr 17, 2014	Apr	CAHN

PIMAVANSERIN TARTRATE

CAPSULE; ORAL

NUPLAZID

AB	+	!	ACADIA PHARMS INC	EQ 34MG BASE	N 210793	001	Jun 28, 2018	Jan	CFTG
		@	PIMAVANSERIN						
		@	MSN	EQ 34MG BASE	A 214925	001	Jan 16, 2024	Feb	DISC
AB				EQ 34MG BASE	A 214925	001	Jan 16, 2024	Jan	NEWA
AB			ZYDUS	EQ 34MG BASE	A 214493	001	Jan 16, 2024	Jan	CAHN
AB			ZYDUS PHARMS	EQ 34MG BASE	A 214493	001	Jan 16, 2024	Jan	NEWA

TABLET; ORAL

NUPLAZID

AB	+	!	ACADIA PHARMS INC	EQ 10MG BASE	N 207318	002	Jun 28, 2018	Jan	CFTG
		@	PIMAVANSERIN						
AB			ZYDUS	EQ 10MG BASE	A 214502	001	Jan 16, 2024	Jan	CAHN
AB			ZYDUS PHARMS	EQ 10MG BASE	A 214502	001	Jan 16, 2024	Jan	NEWA

PIMOZIDE

TABLET; ORAL

PIMOZIDE

>A>			ENDO OPERATIONS	1MG	A 204521	001	Sep 28, 2015	Apr	CAHN
>A>		!		2MG	A 204521	002	Sep 28, 2015	Apr	CAHN
>D>			PAR PHARM	1MG	A 204521	001	Sep 28, 2015	Apr	CAHN
>D>		!		2MG	A 204521	002	Sep 28, 2015	Apr	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

>D>	AP		ASTRAL	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A 212287	001	Jul 29, 2019	Apr	DISC
>A>		@		EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A 212287	001	Jul 29, 2019	Apr	DISC
>D>	AP			EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A 212287	002	Jul 29, 2019	Apr	DISC
>A>		@		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A 212287	002	Jul 29, 2019	Apr	DISC
>D>	AP			EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A 212287	003	Jul 29, 2019	Apr	DISC
>A>		@		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A 212287	003	Jul 29, 2019	Apr	DISC
>D>	AP		EUGIA PHARMA	EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL	A 217409	002	Oct 12, 2023	Apr	DISC
>A>		@		EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL	A 217409	002	Oct 12, 2023	Apr	DISC
>D>	AP			EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A 217409	001	Oct 12, 2023	Apr	DISC
>A>		@		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A 217409	001	Oct 12, 2023	Apr	DISC
		@	FRESENIUS KABI USA	EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL	A 206204	001	May 11, 2018	Feb	DISC

PIROXICAM

CAPSULE;ORAL

PIROXICAM

@	FLAMINGO PHARMS	10MG	A207938	001	Sep 09, 2016	Mar	DISC
@		20MG	A207938	002	Sep 09, 2016	Mar	DISC

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

>A>	AB	HETERO LABS LTD V	EQ 1MG BASE	A205977	001	Apr 30, 2024	Apr	NEWA
>A>	AB		EQ 2MG BASE	A205977	002	Apr 30, 2024	Apr	NEWA
>A>	AB		EQ 4MG BASE	A205977	003	Apr 30, 2024	Apr	NEWA

PIVMECILLINAM HYDROCHLORIDE

>A> TABLET;ORAL

>A> PIVYA

>A>	+	UTILITY THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Apr	NEWA
-----	---	----------------	---------------	---------	-----	--------------	-----	------

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

PLERIXAFOR

>A>	AP	GLAND PHARMA LTD	24MG/1.2ML (20MG/ML)	A206644	001	May 03, 2024	Apr	NEWA
-----	----	------------------	----------------------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

>D> FOR SOLUTION;ORAL

>D> COLYTE WITH FLAVOR PACKS

>D>	AA	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr	DISC
>A>		@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr	DISC

>D> PEG 3350 AND ELECTROLYTES

>D>	AA	NOVEL LABS INC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009	Apr	CTEC
>A>			240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009	Apr	CTEC

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

AP		ADRASTEIA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb	CAHN
----	--	------------------	----------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

@	ANCHEN PHARMS	8MEQ	A202886	001	Dec 26, 2013	Feb	DISC
@		10MEQ	A202886	002	Dec 26, 2013	Feb	DISC

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA		STRIDES PHARMA	20MEQ/15ML	A211665	002	Jan 16, 2024	Jan	NEWA
----	--	----------------	------------	---------	-----	--------------	-----	------

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

@	TORRENT	5MEQ	A213986	001	Feb 06, 2024	Feb	DISC
AB		5MEQ	A213986	001	Feb 06, 2024	Jan	NEWA
@		10MEQ	A213986	002	Feb 06, 2024	Feb	DISC
AB		10MEQ	A213986	002	Feb 06, 2024	Jan	NEWA
@		15MEQ	A213986	003	Feb 06, 2024	Feb	DISC
AB		15MEQ	A213986	003	Feb 06, 2024	Jan	NEWA

PRALSETINIB

CAPSULE;ORAL

GAVRETO

+	!	BLUEPRINT MEDICINES	100MG	N213721	001	Sep 04, 2020	Feb	CAHN
---	---	---------------------	-------	---------	-----	--------------	-----	------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		GLENMARK PHARMS LTD	0.125MG	A 090781	001	Oct 08, 2010	Mar	CAHN
AB	!		0.25MG	A 090781	002	Oct 08, 2010	Mar	CAHN
AB			0.5MG	A 090781	003	Oct 08, 2010	Mar	CAHN
AB			0.75MG	A 090781	006	Sep 11, 2015	Mar	CAHN
AB			1MG	A 090781	004	Oct 08, 2010	Mar	CAHN
AB			1.5MG	A 090781	005	Oct 08, 2010	Mar	CAHN

PRAZIQUANTEL

TABLET;ORAL

PRAZIQUANTEL

>A>	AB	ENDO OPERATIONS	600MG	A 208820	001	Nov 27, 2017	Apr	CAHN
>D>	AB	PAR PHARM INC	600MG	A 208820	001	Nov 27, 2017	Apr	CAHN

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

@	HIKMA	15MG/5ML	A 040401	001	Feb 27, 2003	Mar	DISC
@	PHARM ASSOC	15MG/5ML	A 040399	001	Mar 05, 2003	Feb	DISC

TABLET;ORAL

PREDNISOLONE

>A>	AB	ZHEJIANG XIANJU	5MG	A 218083	001	May 02, 2024	Apr	NEWA
-----	----	-----------------	-----	----------	-----	--------------	-----	------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

@	HIKMA	EQ 5MG BASE/5ML	A 075183	001	Mar 26, 2003	Mar	DISC
@	PHARM ASSOC	EQ 30MG BASE/5ML	A 204962	001	Mar 11, 2020	Mar	DISC

PREDNISONE

SOLUTION;ORAL

PREDNISONE INTENSOL

+!	HIKMA	5MG/ML	A 088810	001	Feb 20, 1985	Jan	CRLD
----	-------	--------	----------	-----	--------------	-----	------

TABLET;ORAL

PREDNISONE

>A>	AB	ENDO OPERATIONS	1MG	A 040584	001	Dec 21, 2004	Apr	CAHN
>A>	AB		2.5MG	A 040581	001	Dec 21, 2004	Apr	CAHN
>A>	AB		5MG	A 040256	001	Jul 12, 2002	Apr	CAHN
>A>	AB		10MG	A 040256	002	Jul 12, 2002	Apr	CAHN
>A>	AB		20MG	A 040392	001	Feb 12, 2003	Apr	CAHN
		@ GENEYORK PHARMS	1MG	A 211496	001	Dec 28, 2018	Feb	DISC
		@	2.5MG	A 210525	004	Dec 07, 2018	Feb	DISC
		@	5MG	A 210525	005	Dec 07, 2018	Feb	DISC
		@	10MG	A 210525	001	Dec 04, 2018	Feb	DISC
		@	20MG	A 210525	002	Dec 04, 2018	Feb	DISC
		@	50MG	A 210525	003	Dec 04, 2018	Feb	DISC
>D>	AB	VINTAGE PHARMS	1MG	A 040584	001	Dec 21, 2004	Apr	CAHN
>D>	AB		2.5MG	A 040581	001	Dec 21, 2004	Apr	CAHN
>D>	AB		5MG	A 040256	001	Jul 12, 2002	Apr	CAHN
>D>	AB		10MG	A 040256	002	Jul 12, 2002	Apr	CAHN
>D>	AB		20MG	A 040392	001	Feb 12, 2003	Apr	CAHN

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB		ACI	25MG	A 215755	001	Apr 26, 2023	Feb	CMFD
AB			50MG	A 215755	002	Apr 26, 2023	Feb	CMFD
AB			75MG	A 215755	003	Apr 26, 2023	Feb	CMFD
AB			100MG	A 215755	004	Apr 26, 2023	Feb	CMFD
AB			150MG	A 215755	005	Apr 26, 2023	Feb	CMFD
AB			200MG	A 215755	006	Apr 26, 2023	Feb	CMFD
AB			225MG	A 215755	007	Apr 26, 2023	Feb	CMFD
AB			300MG	A 215755	008	Apr 26, 2023	Feb	CMFD
		@ CADILA PHARMS LTD	25MG	A 206452	001	Jul 12, 2023	Jan	DISC
		@	50MG	A 206452	002	Jul 12, 2023	Jan	DISC
		@	75MG	A 206452	003	Jul 12, 2023	Jan	DISC
		@	100MG	A 206452	004	Jul 12, 2023	Jan	DISC
		@	150MG	A 206452	005	Jul 12, 2023	Jan	DISC
		@	200MG	A 206452	006	Jul 12, 2023	Jan	DISC

CAPSULE;ORAL
PREGABALIN

	@	225MG	A206452	007	Jul 12, 2023	Jan	DISC
	@	300MG	A206452	008	Jul 12, 2023	Jan	DISC
AB	STRIDES PHARMA	25MG	A209883	001	Jan 24, 2024	Jan	NEWA
AB		50MG	A209883	002	Jan 24, 2024	Jan	NEWA
AB		75MG	A209883	003	Jan 24, 2024	Jan	NEWA
AB		100MG	A209883	004	Jan 24, 2024	Jan	NEWA
AB		150MG	A209883	005	Jan 24, 2024	Jan	NEWA
AB		200MG	A209883	006	Jan 24, 2024	Jan	NEWA
AB		225MG	A209883	007	Jan 24, 2024	Jan	NEWA
AB		300MG	A209883	008	Jan 24, 2024	Jan	NEWA
	@ SUN PHARM	25MG	A091157	001	Nov 29, 2019	Jan	DISC
	@	50MG	A091157	002	Nov 29, 2019	Jan	DISC
	@	75MG	A091157	003	Nov 29, 2019	Jan	DISC
	@	100MG	A091157	004	Nov 29, 2019	Jan	DISC
	@	150MG	A091157	005	Nov 29, 2019	Jan	DISC
	@	200MG	A091157	006	Nov 29, 2019	Jan	DISC
	@	225MG	A091157	007	Nov 29, 2019	Jan	DISC
	@	300MG	A091157	008	Nov 29, 2019	Jan	DISC

PRIMIDONE

SUSPENSION;ORAL
MYSOLINE

	+ @ FHTA	250MG/5ML	N010401	001		Jan	CAHN
--	----------	-----------	---------	-----	--	-----	------

TABLET;ORAL
PRIMIDONE

AB	CARNEGIE	50MG	A218366	001	Jan 23, 2024	Jan	NEWA
AB		250MG	A218366	002	Jan 23, 2024	Jan	NEWA

PROCHLORPERAZINE MALEATE

TABLET;ORAL

PROCHLORPERAZINE MALEATE

>A>	AB	AJANTA PHARMA LTD	EQ 5MG BASE	A218515	001	May 09, 2024	Apr	NEWA
>A>	AB		EQ 10MG BASE	A218515	002	May 09, 2024	Apr	NEWA

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

AB	TWI PHARMS	225MG	A212928	001	Jun 18, 2020	Mar	CAHN
AB		325MG	A212928	002	Jun 18, 2020	Mar	CAHN
AB		425MG	A212928	003	Jun 18, 2020	Mar	CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
PROPRANOLOL HYDROCHLORIDE

>D>	AB	LUPIN LTD	60MG	A204349	001	Jan 12, 2024	Apr	DISC
>A>		@	60MG	A204349	001	Jan 12, 2024	Apr	DISC
	AB		60MG	A204349	001	Jan 12, 2024	Jan	NEWA
>D>	AB		80MG	A204349	002	Jan 12, 2024	Apr	DISC
>A>		@	80MG	A204349	002	Jan 12, 2024	Apr	DISC
	AB		80MG	A204349	002	Jan 12, 2024	Jan	NEWA
>D>	AB		120MG	A204349	003	Jan 12, 2024	Apr	DISC
>A>		@	120MG	A204349	003	Jan 12, 2024	Apr	DISC
	AB		120MG	A204349	003	Jan 12, 2024	Jan	NEWA
>D>	AB		160MG	A204349	004	Jan 12, 2024	Apr	DISC
>A>		@	160MG	A204349	004	Jan 12, 2024	Apr	DISC
	AB		160MG	A204349	004	Jan 12, 2024	Jan	NEWA

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

>A>	AB	ENDO OPERATIONS	10MG	A070221	002	Aug 01, 1986	Apr	CAHN
>A>	AB		20MG	A070221	003	Aug 01, 1986	Apr	CAHN
>A>	AB		40MG	A070221	004	Aug 01, 1986	Apr	CAHN
>A>	AB		60MG	A070221	005	Sep 24, 1986	Apr	CAHN
>A>	AB		80MG	A070221	001	Apr 14, 1986	Apr	CAHN
>D>	AB	VINTAGE PHARMS	10MG	A070221	002	Aug 01, 1986	Apr	CAHN
>D>	AB		20MG	A070221	003	Aug 01, 1986	Apr	CAHN
>D>	AB		40MG	A070221	004	Aug 01, 1986	Apr	CAHN
>D>	AB		60MG	A070221	005	Sep 24, 1986	Apr	CAHN
>D>	AB		80MG	A070221	001	Apr 14, 1986	Apr	CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

>D>	AB	+	!	DAVA PHARMS INC	50MG	N006188	001		Apr	CAHN
>A>	AB	+	!	ENDO OPERATIONS	50MG	N006188	001		Apr	CAHN

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

AB				ANI PHARMS	60MG	A040512	001	Oct 08, 2003	Jan	CMFD
AB				MLV	30MG	A211181	002	May 14, 2019	Mar	CAHN
AB					60MG	A211181	001	Jul 20, 2018	Mar	CAHN

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

		@		PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Feb	DISC
		@			EQ 150MG BASE	A090482	002	May 09, 2017	Feb	DISC
		@			EQ 200MG BASE	A090482	003	May 09, 2017	Feb	DISC
		@			EQ 300MG BASE	A090482	004	May 09, 2017	Feb	DISC
		@			EQ 400MG BASE	A090482	005	May 09, 2017	Feb	DISC
AB				PRINSTON INC	EQ 400MG BASE	A208781	005	Mar 11, 2024	Mar	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

		@		INVAGEN PHARMS	EQ 5MG BASE	A078457	001	Aug 24, 2007	Mar	DISC
		@			EQ 10MG BASE	A078457	002	Aug 24, 2007	Mar	DISC
		@			EQ 20MG BASE	A078457	003	Aug 24, 2007	Mar	DISC
		@			EQ 40MG BASE	A078457	004	Aug 24, 2007	Mar	DISC

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

>A>		+	@	WAYLIS THERAP	10MG	N020973	001	May 29, 2002	Apr	CAHN
>A>	AB	+	!		20MG	N020973	002	Aug 19, 1999	Apr	CAHN
>D>		+	@	WOODWARD	10MG	N020973	001	May 29, 2002	Apr	CAHN
>D>	AB	+	!		20MG	N020973	002	Aug 19, 1999	Apr	CAHN

RANITIDINE HYDROCHLORIDE

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

		@		LANNETT CO INC	EQ 15MG BASE/ML	A091288	001	Dec 09, 2010	Mar	DISC
		@		PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	Mar	DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

		@		PAR PHARM	EQ 150MG BASE	A075180	001	Jan 28, 1999	Feb	DISC
		@			EQ 300MG BASE	A075180	002	Jan 28, 1999	Feb	DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

		@		PIRAMAL HLTHCARE UK	500MG	A213085	001	Jul 25, 2023	Jan	DISC
		@			1GM	A213085	002	Jul 25, 2023	Jan	DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB				SKG PHARMA	EQ 0.5MG BASE	A218163	001	Apr 09, 2024	Mar	NEWA
AB					EQ 1MG BASE	A218163	002	Apr 09, 2024	Mar	NEWA

RESMETIROM

TABLET;ORAL

REZDIFFRA

+				MADRIGAL	60MG	N217785	001	Mar 14, 2024	Mar	NEWA
+					80MG	N217785	002	Mar 14, 2024	Mar	NEWA
+					100MG	N217785	003	Mar 14, 2024	Mar	NEWA

RIFAMPIN

CAPSULE;ORAL

RIFAMPIN

@	HIKMA	150MG	A065028	001	Mar 14, 2001	Mar	DISC
@		300MG	A065028	002	Mar 14, 2001	Mar	DISC

RILPIVIRINE HYDROCHLORIDE

TABLET, FOR SUSPENSION;ORAL

EDURANT PED

+	JANSSEN PRODS	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Mar	NEWA
---	---------------	---------------	---------	-----	--------------	-----	------

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RISVAN

+	LABS FARMS ROVI SA	75MG	N214835	001	Mar 29, 2024	Mar	NEWA
+		100MG	N214835	002	Mar 29, 2024	Mar	NEWA

INJECTABLE;INTRAMUSCULAR

RISPERDAL CONSTA

AB	+	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan	CMS1
AB	+		25MG/VIAL	N021346	001	Oct 29, 2003	Jan	CMS1
AB	+		37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan	CMS1
AB	+		50MG/VIAL	N021346	003	Oct 29, 2003	Jan	CMS1

RISPERIDONE

AB		TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan	CMS1
AB			25MG/VIAL	A214068	002	Dec 05, 2023	Jan	CMS1
AB			37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan	CMS1
AB			50MG/VIAL	A214068	004	Dec 05, 2023	Jan	CMS1

SOLUTION;ORAL

RISPERIDONE

@	HIKMA	1MG/ML	A076904	001	Jul 29, 2009	Mar	DISC
@	PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009	Feb	DISC

TABLET;ORAL

RISPERIDONE

AB		RENATA	0.25MG	A078707	001	Dec 29, 2008	Feb	CAHN
AB			0.5MG	A078707	002	Dec 29, 2008	Feb	CAHN
AB			1MG	A078707	003	Dec 29, 2008	Feb	CAHN
AB			2MG	A078707	004	Dec 29, 2008	Feb	CAHN
AB			3MG	A078707	005	Dec 29, 2008	Feb	CAHN
AB			4MG	A078707	006	Dec 29, 2008	Feb	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

>A>		ENDO OPERATIONS	0.25MG	A077494	001	Apr 30, 2009	Apr	CAHN
>A>	AB		0.5MG	A077494	002	Apr 30, 2009	Apr	CAHN
>A>	AB		1MG	A077494	003	Oct 26, 2009	Apr	CAHN
>A>	AB		2MG	A077494	004	Apr 30, 2009	Apr	CAHN
>A>	AB		3MG	A077494	005	Apr 30, 2009	Apr	CAHN
>A>	AB		4MG	A077494	006	Apr 30, 2009	Apr	CAHN
>D>		PAR PHARM	0.25MG	A077494	001	Apr 30, 2009	Apr	CAHN
>D>	AB		0.5MG	A077494	002	Apr 30, 2009	Apr	CAHN
>D>	AB		1MG	A077494	003	Oct 26, 2009	Apr	CAHN
>D>	AB		2MG	A077494	004	Apr 30, 2009	Apr	CAHN
>D>	AB		3MG	A077494	005	Apr 30, 2009	Apr	CAHN
>D>	AB		4MG	A077494	006	Apr 30, 2009	Apr	CAHN

RITONAVIR

CAPSULE;ORAL

RITONAVIR

	MYLAN	100MG	A205024	001	Feb 16, 2024	Feb	NEWA
--	-------	-------	---------	-----	--------------	-----	------

RIVASTIGMINE TARTRATE

SOLUTION;ORAL

EXELON

>D>		@ NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000	Apr	CRLD
>A>		+ @	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000	Apr	CRLD

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

>D>	AB		INVAGEN PHARMS	EQ 5MG BASE	A204339	001	Jul 01, 2013	Apr	DISC
>A>		@		EQ 5MG BASE	A204339	001	Jul 01, 2013	Apr	DISC
>D>	AB			EQ 10MG BASE	A204339	002	Jul 01, 2013	Apr	DISC

	TABLET;ORAL							
	RIZATRIPTAN BENZOATE							
>A>	@	EQ 10MG BASE	A204339	002	Jul 01, 2013	Apr	DISC	
	<u>ROSUVASTATIN CALCIUM</u>							
	TABLET;ORAL							
	ROSUVASTATIN CALCIUM							
	@ SANDOZ	EQ 5MG BASE	A079171	001	Jul 19, 2016	Jan	DISC	
	@	EQ 10MG BASE	A079171	002	Jul 19, 2016	Jan	DISC	
	@	EQ 20MG BASE	A079171	003	Jul 19, 2016	Jan	DISC	
	@	EQ 40MG BASE	A079171	004	Jul 19, 2016	Jan	DISC	
	<u>SACUBITRIL; VALSARTAN</u>							
>A>	CAPSULE, PELLETS;ORAL							
>A>	ENTRESTO SPRINKLE							
>A>	+ NOVARTIS	6MG;6MG	N218591	001	Apr 12, 2024	Apr	NEWA	
>A>	+	15MG;16MG	N218591	002	Apr 12, 2024	Apr	NEWA	
	<u>SAFINAMIDE MESYLATE</u>							
	TABLET;ORAL							
	SAFINAMIDE MESYLATE							
>A>	AB	PRINSTON INC	EQ 50MG BASE	A215739	001	Apr 25, 2024	Apr	NEWA
>A>	AB		EQ 100MG BASE	A215739	002	Apr 25, 2024	Apr	NEWA
	XADAGO							
>D>	+ MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Apr	CTEC	
>A>	AB	+	EQ 50MG BASE	N207145	001	Mar 21, 2017	Apr	CTEC
>D>	+	EQ 100MG BASE	N207145	002	Mar 21, 2017	Apr	CTEC	
>A>	AB	+	EQ 100MG BASE	N207145	002	Mar 21, 2017	Apr	CTEC
	<u>SAXAGLIPTIN HYDROCHLORIDE</u>							
	TABLET;ORAL							
	SAXAGLIPTIN							
	@ AMNEAL	EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Feb	DISC	
	@	EQ 5MG BASE	A205941	002	Jul 31, 2023	Feb	DISC	
	<u>SCOPOLAMINE</u>							
	SYSTEM;TRANSDERMAL							
	SCOPOLAMINE							
>A>	AB	RHODES PHARMS	1MG/72HR	A215329	001	May 06, 2024	Apr	NEWA
	<u>SELPERCATINIB</u>							
>A>	TABLET;ORAL							
>A>	RETEVMO							
>A>	+ LOXO ONCOL ELI LILLY	40MG	N218160	001	Apr 10, 2024	Apr	NEWA	
>A>	+	80MG	N218160	002	Apr 10, 2024	Apr	NEWA	
>A>	+	120MG	N218160	003	Apr 10, 2024	Apr	NEWA	
>A>	+	160MG	N218160	004	Apr 10, 2024	Apr	NEWA	
	<u>SEVELAMER CARBONATE</u>							
	FOR SUSPENSION;ORAL							
	SEVELAMER CARBONATE							
>A>	AB	MACLEODS PHARMS LTD	800MG/PACKET	A207291	001	Apr 25, 2024	Apr	NEWA
>A>	AB		2.4GM/PACKET	A207291	002	Apr 25, 2024	Apr	NEWA
	TABLET;ORAL							
	SEVELAMER CARBONATE							
>D>	AB	ANXIN	800MG	A212970	001	Apr 09, 2020	Apr	DISC
>A>	@		800MG	A212970	001	Apr 09, 2020	Apr	DISC
	<u>SILDENAFIL CITRATE</u>							
	TABLET;ORAL							
	SILDENAFIL CITRATE							
>D>	AB	MYLAN PHARMS INC	EQ 20MG BASE	A201150	001	Nov 09, 2012	Apr	DISC
>A>	@		EQ 20MG BASE	A201150	001	Nov 09, 2012	Apr	DISC
	<u>SILODOSIN</u>							
	CAPSULE;ORAL							
	SILODOSIN							
AB	CHARTWELL RX	4MG	A204726	001	Mar 31, 2017	Mar	CAHN	
AB		8MG	A204726	002	Mar 31, 2017	Mar	CAHN	

SILVER SULFADIAZINECREAM; TOPICAL
SSD

AB	+	DR REDDYS LA	1%	N018578	001	Feb 25, 1982	Jan	CRLD
AB	!		1%	N018578	001	Feb 25, 1982	Jan	CHRS

SIMVASTATINSUSPENSION; ORAL
FLOLIPID

>A>	+	SALERNO PHARMS	20MG/5ML	N206679	001	Apr 21, 2016	Apr	CAHN
>A>	+		40MG/5ML	N206679	002	Apr 21, 2016	Apr	CAHN
>D>	+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016	Apr	CAHN
>D>	+		40MG/5ML	N206679	002	Apr 21, 2016	Apr	CAHN

SODIUM ACETATE>D> INJECTABLE; INJECTION
>D> SODIUM ACETATE

>D>	AP	FRESENIUS KABI USA	4MEQ/ML	A206687	001	Oct 30, 2017	Apr	CPOT	
>A>	AP		400MEQ/100ML (4MEQ/ML)	A206687	001	Oct 30, 2017	Apr	CPOT	
>D>	AP	MILLA PHARMS	4MEQ/ML	A214805	002	Aug 25, 2023	Apr	CPOT	
>A>	AP		400MEQ/100ML (4MEQ/ML)	A214805	002	Aug 25, 2023	Apr	CPOT	
>A>		SOLUTION; INTRAVENOUS							
>A>		SODIUM ACETATE							
>A>	AP	!	FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A206687	001	Oct 30, 2017	Apr	CDFR
	AP		HIKMA	40MEQ/20ML (2MEQ/ML)	A216920	001	Mar 15, 2024	Mar	NEWA
	AP			100MEQ/50ML (2MEQ/ML)	A216920	002	Mar 15, 2024	Mar	NEWA
	AP			200MEQ/100ML (2MEQ/ML)	A216920	003	Mar 15, 2024	Mar	NEWA
	AP	+	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Mar	CDFR
	AP	+		40MEQ/20ML (2MEQ/ML)	N018893	001	May 04, 1983	Mar	CPOT
	AP	+		100MEQ/50ML (2MEQ/ML)	N018893	002	Sep 02, 2014	Mar	CMS1
	AP	+		200MEQ/100ML (2MEQ/ML)	N018893	003	Sep 02, 2014	Mar	CMS1
	AP		MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Mar	CDFR
	AP			40MEQ/20ML (2MEQ/ML)	A214805	004	Jan 22, 2024	Mar	CMS1
	AP			100MEQ/50ML (2MEQ/ML)	A214805	001	May 04, 2021	Mar	CPOT
	AP			200MEQ/100ML (2MEQ/ML)	A214805	003	May 04, 2021	Mar	CMS1
>A>	AP			400MEQ/100ML (4MEQ/ML)	A214805	002	Aug 25, 2023	Apr	CDFR

SODIUM BICARBONATEINJECTABLE; INJECTION
SODIUM BICARBONATE

	AP		NIVAGEN PHARMS INC	1MEQ/ML	A216042	001	Feb 27, 2024	Feb	NEWA
>D>		@	STERISCIENCE	1MEQ/ML	A217594	001	Jun 28, 2023	Apr	CMFD
>A>	AP			1MEQ/ML	A217594	001	Jun 28, 2023	Apr	CMFD
		@		1MEQ/ML	A217594	001	Jun 28, 2023	Jan	DISC

SODIUM CHLORIDESOLUTION; INJECTION
SODIUM CHLORIDE 0.9%
@ HIKMA

				90MG/10ML (9MG/ML)	A201850	001	Jan 20, 2012	Mar	DISC
--	--	--	--	--------------------	---------	-----	--------------	-----	------

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

AP	!	PETNET	10-200mCi/ML	A203890	001	Sep 28, 2015	Jan	CHRS	
		@	SOFIE	10-200mCi/ML	A203544	001	Dec 26, 2012	Jan	DISC

SODIUM PHENYLBUTYRATEPOWDER; ORAL
SODIUM PHENYLBUTYRATE

>A>	AB		ENDO OPERATIONS	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Apr	CAHN
>D>	AB		PAR PHARM	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Apr	CAHN

TABLET; ORAL

SODIUM PHENYLBUTYRATE

>A>	AB		ENDO OPERATIONS	500MG	A204395	001	Apr 15, 2016	Apr	CAHN
>D>	AB		PAR PHARM	500MG	A204395	001	Apr 15, 2016	Apr	CAHN

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

AB	GLENMARK PHARMS	5MG	A209239	001	May 20, 2019	Mar CAHN
AB		10MG	A209239	002	May 20, 2019	Mar CAHN
AB	MACLEODS PHARMS LTD	5MG	A204374	001	Feb 20, 2024	Feb NEWA
AB		10MG	A204374	002	Feb 20, 2024	Feb NEWA

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

	@ RISING	80MG	A075725	001	Dec 19, 2000	Feb CAHN
	@	120MG	A075725	002	Dec 19, 2000	Feb CAHN
	@	160MG	A075725	003	Dec 19, 2000	Feb CAHN
	@	240MG	A075725	004	Dec 19, 2000	Feb CAHN

STERILE WATER FOR INJECTION

LIQUID; N/A

STERILE WATER FOR INJECTION

AP	AM REGENT	100% (5ML)	A217341	003	Feb 09, 2024	Feb NEWA
----	-----------	------------	---------	-----	--------------	----------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCCINYLCHOLINE CHLORIDE

>D>	AP	EUGIA PHARMA	20MG/ML	A217808	001	Oct 16, 2023	Apr DISC
>A>		@	20MG/ML	A217808	001	Oct 16, 2023	Apr DISC
		@ NEXUS	20MG/ML	A213552	001	Oct 27, 2020	Mar DISC
AP		NIVAGEN PHARMS INC	20MG/ML	A211625	001	May 19, 2020	Jan CAHN
		SOLUTION; INTRAMUSCULAR, INTRAVENOUS					
		SUCCINYLCHOLINE CHLORIDE					
AP	DR REDDYS	100MG/5ML (20MG/ML)	A218467	001	Jan 17, 2024	Jan NEWA	
AP	+! HIKMA	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Jan CFTG	

SUCRALFATE

SUSPENSION; ORAL

SUCRALFATE

AB	ABON PHARMS LLC	1GM/10ML	A216726	001	Mar 21, 2024	Mar NEWA	
AB	PD PARTNERS	1GM/10ML	A213549	001	Jan 17, 2024	Jan NEWA	
>D>	AB	VISTAPHARM	1GM/10ML	A211884	001	Mar 15, 2022	Apr CAHN
>A>	AB	VISTAPHARM LLC	1GM/10ML	A211884	001	Mar 15, 2022	Apr CAHN

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

SUGAMMADEX SODIUM

	@ ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214290	001	Oct 04, 2023	Mar DISC
	@	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214290	002	Oct 04, 2023	Mar DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	! AUROBINDO PHARMA	200MG/5ML; 40MG/5ML	A091348	001	Jun 08, 2010	Mar CHRS
	@ HIKMA	200MG/5ML; 40MG/5ML	A074650	001	Dec 29, 1997	Mar DISC

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX

	+ @ GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	001	Dec 28, 1992	Jan DISC
--	---------------------	-------------------------------------	---------	-----	--------------	----------

SUMATRIPTAN SUCCINATE

AP	! EUGIA PHARMA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013	Jan CHRS
----	----------------	-------------------------------------	---------	-----	--------------	----------

SUNITINIB MALATE

CAPSULE; ORAL

SUNITINIB MALATE

AB	EUGIA PHARMA	EQ 12.5MG BASE	A218615	001	Mar 14, 2024	Mar NEWA
AB		EQ 25MG BASE	A218615	002	Mar 14, 2024	Mar NEWA
AB		EQ 37.5MG BASE	A218615	003	Mar 14, 2024	Mar NEWA
AB		EQ 50MG BASE	A218615	004	Mar 14, 2024	Mar NEWA

TACROLIMUSCAPSULE, EXTENDED RELEASE;ORAL
ASTAGRAF XL

AB	+	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013	Jan CFTG
AB	+		EQ 1MG BASE	N204096	002	Jul 19, 2013	Jan CFTG
AB	+		EQ 5MG BASE	N204096	003	Jul 19, 2013	Jan CFTG
TACROLIMUS							
AB		CHENGDU	EQ 0.5MG BASE	A215012	001	Jan 25, 2024	Jan NFTG
AB			EQ 1MG BASE	A215012	002	Jan 25, 2024	Jan NFTG
AB			EQ 5MG BASE	A215012	003	Jan 25, 2024	Jan NFTG

TADALAFILTABLET;ORAL
TADALAFIL

AB1		HANGZHOU BINJIANG	2.5MG	A208824	001	Oct 27, 2020	Mar CAHN
AB1			5MG	A208824	002	Oct 27, 2020	Mar CAHN
AB1			10MG	A208824	003	Oct 27, 2020	Mar CAHN
AB1			20MG	A208824	004	Oct 27, 2020	Mar CAHN
AB1		SHANDONG	20MG	A216279	001	Mar 04, 2024	Feb NEWA

TAFLUPROSTSOLUTION/DROPS;OPHTHALMIC
TAFLUPROST

AT		INGENUS PHARMS LLC	0.0015%	A218002	001	Apr 05, 2024	Mar NEWA
----	--	--------------------	---------	---------	-----	--------------	----------

TALAZOPARIB TOSYLATECAPSULE;ORAL
TALZENNA

+		PFIZER	EQ 0.1MG BASE	N217439	001	Mar 07, 2024	Mar NEWA
+			EQ 0.25MG BASE	N217439	002	Mar 07, 2024	Mar NEWA
+			EQ 0.35MG BASE	N217439	003	Mar 07, 2024	Mar NEWA
+			EQ 0.5MG BASE	N217439	004	Mar 07, 2024	Mar NEWA
+			EQ 0.75MG BASE	N217439	005	Mar 07, 2024	Mar NEWA
+			EQ 1MG BASE	N217439	006	Mar 07, 2024	Mar NEWA

TAVABOROLESOLUTION;TOPICAL
KERYDIN

+	@	ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014	Mar DISC
AB	!	ENCUBE	5%	A211297	001	Oct 13, 2020	Mar CHRS

TEDUGLUTIDEPOWDER;SUBCUTANEOUS
GATTEX KIT

+	!	TAKEDA PHARMS USA	5MG/VIAL	N203441	001	Dec 21, 2012	Mar CAIN
---	---	-------------------	----------	---------	-----	--------------	----------

TEMAZEPAMCAPSULE;ORAL
TEMAZEPAM

AB		CHARTWELL RX	15MG	A071427	001	Jan 12, 1988	Jan CAHN
AB			30MG	A071428	001	Jan 12, 1988	Jan CAHN

TENAPANOR HYDROCHLORIDETABLET;ORAL
XPHOZAH

>D>	+	ARDELYX INC	EQ 10MG BASE	N213931	001	Oct 17, 2023	Apr DISC
>A>	+	@	EQ 10MG BASE	N213931	001	Oct 17, 2023	Apr DISC

TENOFOVIR ALAFENAMIDE FUMARATETABLET;ORAL
TENOFOVIR ALAFENAMIDE FUMARATE

AB		APOTEX	EQ 25MG BASE	A213867	001	Mar 21, 2024	Mar NEWA
----	--	--------	--------------	---------	-----	--------------	----------

TENOFOVIR DISOPROXIL FUMARATETABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE

AB		MYLAN LABS LTD	300MG	A079071	001	Feb 29, 2024	Feb NEWA
----	--	----------------	-------	---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDE

	CAPSULE;ORAL						
	TERAZOSIN HYDROCHLORIDE						
AB	BIONPHARMA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Jan	CMFD
AB		EQ 2MG BASE	A075667	002	Jul 28, 2000	Jan	CMFD
AB		EQ 5MG BASE	A075667	003	Jul 28, 2000	Jan	CMFD
AB		EQ 10MG BASE	A075667	004	Jul 28, 2000	Jan	CMFD

TERBINAFINE

	GEL;TOPICAL						
	LAMISIL						
	@ KARO HLTHCARE	1%	N020846	001	Apr 29, 1998	Feb	CAHN

TERBINAFINE HYDROCHLORIDE

	SOLUTION;TOPICAL						
	LAMISIL						
	@ KARO HLTHCARE	1%	N020749	001	Oct 17, 1997	Feb	CAHN
	TABLET;ORAL						
	TERBINAFINE HYDROCHLORIDE						
	@ CIPLA	EQ 250MG BASE	A077137	001	Jul 02, 2007	Mar	DISC

TERBUTALINE SULFATE

	INJECTABLE;INJECTION							
	TERBUTALINE SULFATE							
>A>	AP	AREVA PHARMS	1MG/ML	A200122	001	Nov 08, 2013	Apr	CAHN
>D>	AP	UNITED BIOMEDCL	1MG/ML	A200122	001	Nov 08, 2013	Apr	CAHN

TERIFLUNOMIDE

	TABLET;ORAL							
	TERIFLUNOMIDE							
AB	GLENMARK PHARMS	7MG	A209663	001	Nov 15, 2018	Mar	CAHN	
AB		14MG	A209663	002	Nov 15, 2018	Mar	CAHN	
>D>	AB	MYLAN	7MG	A209702	001	Feb 28, 2020	Apr	DISC
>A>	@	7MG	A209702	001	Feb 28, 2020	Apr	DISC	
>D>	AB	14MG	A209702	002	Feb 28, 2020	Apr	DISC	
>A>	@	14MG	A209702	002	Feb 28, 2020	Apr	DISC	
AB	TORRENT	7MG	A209697	001	Apr 04, 2024	Mar	NEWA	
AB		14MG	A209697	002	Apr 04, 2024	Mar	NEWA	

TESTOSTERONE

	GEL;TRANSDERMAL							
	TESTIM							
>D>	AB2	+! AUXILIUM PHARMS LLC	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Apr	CAHN
>A>	AB2	+! ENDO OPERATIONS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Apr	CAHN
	GEL, METERED;TRANSDERMAL							
	FORTESTA							
>A>	+ @	ENDO OPERATIONS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Apr	CAHN
>D>	+ @	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Apr	CAHN
	+ @		10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jan	DISC
	TESTOSTERONE							
	!	ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jan	CTEC
AB	!		10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jan	CHRS
>D>	BX	!	12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Apr	CTEC
>A>	AB1	!	12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Apr	CTEC
>A>	AB1	ENCUBE	12.5MG/1.25GM ACTUATION	A212984	002	Feb 09, 2024	Apr	NEWA
	PELLET;IMPLANTATION							
	TESTOPEL							
>D>	!	AUXILIUM PHARMS INC	75MG	A080911	001		Apr	CAHN
>A>	!	ENDO OPERATIONS	75MG	A080911	001		Apr	CAHN
	SOLUTION, METERED;TRANSDERMAL							
	TESTOSTERONE							
>A>	AT	ENCUBE	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Apr	CAHN
>D>	AT	FEMPHARM	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Apr	CAHN
AT			30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Mar	CAHN

TESTOSTERONE ENANTHATEINJECTABLE; INJECTION
TESTOSTERONE ENANTHATE

AO	EUGIA PHARMA	200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA
AO		200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA

TESTOSTERONE UNDECANOATECAPSULE; ORAL
TLANDO

+! VERITY 112.5MG

N208088 001 Mar 28, 2022 Jan CAHN

INJECTABLE; INTRAMUSCULAR
AVEED

>A> +! ENDO OPERATIONS 750MG/3ML (250MG/ML)

N022219 001 Mar 05, 2014 Apr CAHN

>D> +! ENDO PHARMS INC 750MG/3ML (250MG/ML)

N022219 001 Mar 05, 2014 Apr CAHN

TETRABENAZINETABLET; ORAL
TETRABENAZINE

AB SLATE RUN PHARMA 12.5MG

A213316 001 Jan 22, 2020 Feb CAHN

AB 25MG

A213316 002 Jan 22, 2020 Feb CAHN

TETRACYCLINE HYDROCHLORIDETABLET; ORAL
SUMYCIN

STRIDES PHARMA 250MG

A061147 001

Jan CMFD

! 500MG

A061147 004

Jan CMFD

THEOPHYLLINECAPSULE, EXTENDED RELEASE; ORAL
THEO-24

>D> AUXILIUM PHARMS LLC 100MG

A087943 002 Aug 22, 1983 Apr CAHN

>D> + 200MG

A087943 001 Aug 22, 1983 Apr CAHN

>D> 300MG

A087943 003 Aug 22, 1983 Apr CAHN

>D> ! 400MG

A087943 004 Feb 28, 1992 Apr CAHN

>A> ENDO OPERATIONS 100MG

A087943 002 Aug 22, 1983 Apr CAHN

>A> + 200MG

A087943 001 Aug 22, 1983 Apr CAHN

>A> 300MG

A087943 003 Aug 22, 1983 Apr CAHN

>A> ! 400MG

A087943 004 Feb 28, 1992 Apr CAHN

TIOPRONINTABLET, DELAYED RELEASE; ORAL
THIOLA EC

AB + MISSION PHARMACAL 100MG

N211843 001 Jun 28, 2019 Jan CFTG

TIOPRONIN

AB TORRENT 100MG

A216990 001 Jan 30, 2024 Jan NFTG

AB 300MG

A216990 002 Jan 30, 2024 Jan NEWA

TIRZEPATIDESOLUTION; SUBCUTANEOUS
MOUNJARO

+! ELI LILLY AND CO 2.5MG/0.5ML (2.5MG/0.5ML)

N215866 007 Jul 28, 2023 Jan NEWA

+! 5MG/0.5ML (5MG/0.5ML)

N215866 008 Jul 28, 2023 Jan NEWA

+! 7.5MG/0.5ML (7.5MG/0.5ML)

N215866 009 Jul 28, 2023 Jan NEWA

+! 10MG/0.5ML (10MG/0.5ML)

N215866 010 Jul 28, 2023 Jan NEWA

+! 12.5MG/0.5ML (12.5MG/0.5ML)

N215866 011 Jul 28, 2023 Jan NEWA

+! 15MG/0.5ML (15MG/0.5ML)

N215866 012 Jul 28, 2023 Jan NEWA

MOUNJARO (AUTOINJECTOR)

+! ELI LILLY AND CO 2.5MG/0.5ML (2.5MG/0.5ML)

N215866 001 May 13, 2022 Jan CTNA

+! 5MG/0.5ML (5MG/0.5ML)

N215866 002 May 13, 2022 Jan CTNA

+! 7.5MG/0.5ML (7.5MG/0.5ML)

N215866 003 May 13, 2022 Jan CTNA

+! 10MG/0.5ML (10MG/0.5ML)

N215866 004 May 13, 2022 Jan CTNA

+! 12.5MG/0.5ML (12.5MG/0.5ML)

N215866 005 May 13, 2022 Jan CTNA

+! 15MG/0.5ML (15MG/0.5ML)

N215866 006 May 13, 2022 Jan CTNA

ZEPBOUND

+! ELI LILLY AND CO 2.5MG/0.5ML (2.5MG/0.5ML)

N217806 007 Mar 28, 2024 Mar NEWA

+! 5MG/0.5ML (5MG/0.5ML)

N217806 008 Mar 28, 2024 Mar NEWA

+! 7.5MG/0.5ML (7.5MG/0.5ML)

N217806 009 Mar 28, 2024 Mar NEWA

+! 10MG/0.5ML (10MG/0.5ML)

N217806 010 Mar 28, 2024 Mar NEWA

+! 12.5MG/0.5ML (12.5MG/0.5ML)

N217806 011 Mar 28, 2024 Mar NEWA

+! 15MG/0.5ML (15MG/0.5ML)

N217806 012 Mar 28, 2024 Mar NEWA

SOLUTION;SUBCUTANEOUS
ZEPBOUND (AUTOINJECTOR)

+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	001	Nov 08, 2023	Mar	CTNA
+!		5MG/0.5ML (5MG/0.5ML)	N217806	002	Nov 08, 2023	Mar	CTNA
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	003	Nov 08, 2023	Mar	CTNA
+!		10MG/0.5ML (10MG/0.5ML)	N217806	004	Nov 08, 2023	Mar	CTNA
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	005	Nov 08, 2023	Mar	CTNA
+!		15MG/0.5ML (15MG/0.5ML)	N217806	006	Nov 08, 2023	Mar	CTNA

TIZANIDINE HYDROCHLORIDE

TABLET;ORAL
TIZANIDINE HYDROCHLORIDE

>D>	AB	CASI PHARMS INC	EQ 2MG BASE	A076280	001	Nov 26, 2002	Apr	DISC
>A>		@	EQ 2MG BASE	A076280	001	Nov 26, 2002	Apr	DISC
>D>	AB		EQ 4MG BASE	A076280	002	Jun 27, 2002	Apr	DISC
>A>		@	EQ 4MG BASE	A076280	002	Jun 27, 2002	Apr	DISC

TOBRAMYCIN

SOLUTION/DROPS;OPHTHALMIC
TOBRAMYCIN

>D>	AT	SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Apr	CHRS
>A>	AT	!	0.3%	A207444	001	Jun 28, 2017	Apr	CHRS
		TOBREX						
>D>	AT	+! NOVARTIS	0.3%	N050541	001		Apr	DISC
>A>		+ @	0.3%	N050541	001		Apr	DISC

TOFACITINIB CITRATE

SOLUTION;ORAL
TOFACITINIB CITRATE

>A>	AA	HIKMA	EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	Apr	CAHN
>D>	AA	SLAYBACK PHARMA LLC	EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	Apr	CAHN

TOLCAPONE

TABLET;ORAL
TOLCAPONE

		@ PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar	DISC
--	--	-----------------	-------	---------	-----	--------------	-----	------

TOPIRAMATE

CAPSULE;ORAL
TOPIRAMATE

>D>		@ STRIDES PHARMA	15MG	A078418	001	Oct 14, 2009	Apr	CMFD
>A>	AB		15MG	A078418	001	Oct 14, 2009	Apr	CMFD
>D>		@	25MG	A078418	002	Oct 14, 2009	Apr	CMFD
>A>	AB		25MG	A078418	002	Oct 14, 2009	Apr	CMFD

CAPSULE, EXTENDED RELEASE;ORAL
TOPIRAMATE

		@ AJANTA PHARMA LTD	25MG	A215663	001	Aug 15, 2023	Feb	DISC
		@	50MG	A215663	002	Aug 15, 2023	Feb	DISC
		@	100MG	A215663	003	Aug 15, 2023	Feb	DISC
		@	200MG	A215663	004	Aug 15, 2023	Feb	DISC

TABLET;ORAL
TOPIRAMATE

		@ AIPING PHARM INC	25MG	A078499	001	Jan 07, 2010	Feb	CAHN
		@	50MG	A078499	002	Jan 07, 2010	Feb	CAHN
		@	100MG	A078499	003	Jan 07, 2010	Feb	CAHN
		@	200MG	A078499	004	Jan 07, 2010	Feb	CAHN
		@ SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Jan	DISC
		@	100MG	A076327	002	Mar 27, 2009	Jan	DISC
		@	200MG	A076327	003	Mar 27, 2009	Jan	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION
TOPOTECAN HYDROCHLORIDE

		@ RISING	EQ 4MG BASE/VIAL	A091542	001	Aug 28, 2012	Mar	CAHN
--	--	----------	------------------	---------	-----	--------------	-----	------

TORSEMIDE

SOLUTION;INTRAVENOUS
DEMADEX

+ @	ROCHE	50MG/5ML (10MG/ML)	N020137	002	Aug 23, 1993	Mar	CDFR
+ @		20MG/2ML (10MG/ML)	N020137	001	Aug 23, 1993	Mar	CDFR

SOLUTION; INTRAVENOUS								
TORSEMIDE								
@	AM REGENT	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Mar	CDFR	
@		50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Mar	CDFR	
@	WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Mar	CDFR	
@		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Mar	CDFR	
>A>	<u>TOVORAFENIB</u>							
>A>	FOR SUSPENSION; ORAL							
>A>	OJEMDA							
>A>	+! DAY ONE BIOPHARMS	25MG/ML	N218033	001	Apr 23, 2024	Apr	NEWA	
>A>	TABLET; ORAL							
>A>	OJEMDA							
>A>	+! DAY ONE BIOPHARMS	100MG	N217700	001	Apr 23, 2024	Apr	NEWA	
<u>TRAMADOL HYDROCHLORIDE</u>								
TABLET; ORAL								
TRAMADOL HYDROCHLORIDE								
	RUBICON	75MG	A208708	004	Apr 04, 2024	Mar	NFTG	
TABLET, EXTENDED RELEASE; ORAL								
TRAMADOL HYDROCHLORIDE								
>D>	@ ANCHEN PHARMS	100MG	A200491	001	Jun 27, 2012	Apr	CAHN	
>D>	@	200MG	A200491	002	Jun 27, 2012	Apr	CAHN	
>D>	@	300MG	A200491	003	Jun 27, 2012	Apr	CAHN	
>A>	@ ENDO OPERATIONS	100MG	A200491	001	Jun 27, 2012	Apr	CAHN	
>A>	@	200MG	A200491	002	Jun 27, 2012	Apr	CAHN	
>A>	@	300MG	A200491	003	Jun 27, 2012	Apr	CAHN	
<u>TRANEXAMIC ACID</u>								
SOLUTION; INTRAVENOUS								
TRANEXAMIC ACID								
>A>	AP GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A218599	001	Apr 16, 2024	Apr	NEWA	
>A>	AP NEXUS	1GM/100ML (10MG/ML)	A216877	001	Apr 16, 2024	Apr	NEWA	
<u>TRAVOPROST</u>								
SOLUTION/DROPS; OPHTHALMIC								
TRAVOPROST								
>A>	AT LUPIN LTD	0.004%	A207040	001	May 03, 2024	Apr	NEWA	
<u>TRETINOIN</u>								
CAPSULE; ORAL								
TRETINOIN								
>D>	AB ANCHEN PHARMS	10MG	A201687	001	Oct 24, 2012	Apr	CAHN	
>A>	AB ENDO OPERATIONS	10MG	A201687	001	Oct 24, 2012	Apr	CAHN	
CREAM; TOPICAL								
TRETINOIN								
>A>	AB ALEMBIC	0.1%	A217804	001	Apr 29, 2024	Apr	NEWA	
>A>	AB ZYDUS LIFESCIENCES	0.1%	A218561	001	Apr 25, 2024	Apr	NEWA	
<u>TRIAMCINOLONE ACETONIDE</u>								
OINTMENT; TOPICAL								
TRIAMCINOLONE ACETONIDE								
@	AUROBINDO PHARMA LTD	0.1%	A211315	001	Mar 18, 2020	Jan	CAHN	
@		0.5%	A211315	002	Mar 18, 2020	Jan	CAHN	
>D>	AT COSETTE	0.5%	A208925	001	Oct 06, 2017	Apr	DISC	
>A>	@	0.5%	A208925	001	Oct 06, 2017	Apr	DISC	
SPRAY; TOPICAL								
TRIAMCINOLONE ACETONIDE								
AT	SAPTALIS PHARMS	0.147MG/GM	A207094	001	Dec 07, 2016	Feb	CAHN	
<u>TRIAZOLAM</u>								
TABLET; ORAL								
TRIAZOLAM								
@	HIKMA	0.125MG	A074224	001	Jun 01, 1994	Feb	DISC	
@		0.25MG	A074224	002	Jun 01, 1994	Feb	DISC	

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

>A>	AB	ENDO OPERATIONS	250MG	A210096	001	Sep 25, 2019	Apr	CAHN
>D>	AB	PAR PHARM INC	250MG	A210096	001	Sep 25, 2019	Apr	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

TIGAN

>A>	+	!	ENDO OPERATIONS	100MG/ML	N017530	001		Apr	CAHN
>D>	+	!	PAR STERILE PRODUCTS	100MG/ML	N017530	001		Apr	CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

TRIMIPRAMINE MALEATE

AB		BRECKENRIDGE	EQ 25MG BASE	A208127	001	Apr 15, 2016	Mar	CAHN
AB	!		EQ 50MG BASE	A208127	002	Apr 15, 2016	Mar	CAHN
AB			EQ 100MG BASE	A208127	003	Apr 15, 2016	Mar	CAHN

TROSPIUM CHLORIDE

TABLET;ORAL

TROSPIUM CHLORIDE

AB		ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Feb	CAHN
----	--	---------------	------	---------	-----	--------------	-----	------

UMECLIDINIUM BROMIDE

POWDER;INHALATION

INCRUSE ELLIPTA

+	!	GLAXO GRP ENGLAND	EQ 0.0625MG BASE/INH	N205382	001	Apr 30, 2014	Jan	CPOT
---	---	-------------------	----------------------	---------	-----	--------------	-----	------

UPADACITINIB

>A> SOLUTION;ORAL

>A> RINVOQ LQ

>A>	+	!	ABBVIE	1MG/ML	N218347	001	Apr 26, 2024	Apr	NEWA
-----	---	---	--------	--------	---------	-----	--------------	-----	------

URSODIOL

TABLET;ORAL

URSODIOL

>A>	AB	ENDO OPERATIONS	250MG	A202540	001	Feb 14, 2013	Apr	CAHN
>A>	AB		500MG	A202540	002	Feb 14, 2013	Apr	CAHN
>D>	AB	PAR PHARM	250MG	A202540	001	Feb 14, 2013	Apr	CAHN
>D>	AB		500MG	A202540	002	Feb 14, 2013	Apr	CAHN

VADADUSTAT

TABLET;ORAL

VAFSEO

+		AKEBIA	150MG	N215192	001	Mar 27, 2024	Mar	NEWA
+			300MG	N215192	002	Mar 27, 2024	Mar	NEWA
+	!		450MG	N215192	003	Mar 27, 2024	Mar	NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

>D>	AB	CIPLA	EQ 500MG BASE	A077135	001	May 24, 2010	Apr	DISC
>A>		@	EQ 500MG BASE	A077135	001	May 24, 2010	Apr	DISC
>D>	AB		EQ 1GM BASE	A077135	002	May 24, 2010	Apr	DISC
>A>		@	EQ 1GM BASE	A077135	002	May 24, 2010	Apr	DISC

VALBENZAZINE TOSYLATE

CAPSULE;ORAL

INGREZZA

AB	+	NEUROCRINE	EQ 40MG BASE	N209241	001	Apr 11, 2017	Mar	CFTG
AB	+	!	EQ 80MG BASE	N209241	002	Oct 04, 2017	Mar	CFTG
>A>		INGREZZA SPRINKLE						
>A>	+	NEUROCRINE	EQ 40MG BASE	N218390	001	Apr 30, 2024	Apr	NEWA
>A>	+		EQ 60MG BASE	N218390	002	Apr 30, 2024	Apr	NEWA
>A>	+	!	EQ 80MG BASE	N218390	003	Apr 30, 2024	Apr	NEWA
		VALBENZAZINE TOSYLATE						
AB		LUPIN LTD	EQ 40MG BASE	A216064	001	Apr 05, 2024	Mar	NFTG
AB			EQ 80MG BASE	A216064	002	Apr 05, 2024	Mar	NFTG

VALPROIC ACID

		CAPSULE;ORAL							
		VALPROIC ACID							
		@ EYWA	250MG		A207611	001	Aug 05, 2019	Mar	DISC
		SYRUP;ORAL							
		VALPROIC ACID							
		@ HIKMA	250MG/5ML		A074060	001	Jan 13, 1995	Mar	DISC
AA		QUAGEN	250MG/5ML		A090517	001	May 28, 2010	Jan	CAHN

VALRUBICIN

		SOLUTION;INTRAVESICAL							
		VALSTAR PRESERVATIVE FREE							
>A>	AO	+! ENDO OPERATIONS	40MG/ML		N020892	001	Sep 25, 1998	Apr	CAHN
>D>	AO	+! ENDO PHARM	40MG/ML		N020892	001	Sep 25, 1998	Apr	CAHN

VANCOMYCIN HYDROCHLORIDE

		CAPSULE;ORAL							
		VANCOMYCIN HYDROCHLORIDE							
		@ PAI HOLDINGS PHARM	EQ 125MG BASE		A065478	001	Apr 09, 2012	Feb	DISC
		@	EQ 250MG BASE		A065478	002	Apr 09, 2012	Feb	DISC
		INJECTABLE;INJECTION							
		VANCOMYCIN HYDROCHLORIDE							
		@ PHARM ASSOC	EQ 500MG BASE/VIAL		A065401	001	Jun 30, 2008	Feb	DISC
		@	EQ 1GM BASE/VIAL		A065401	002	Jun 30, 2008	Feb	DISC
>D>	AP	SANDOZ INC	EQ 5GM BASE/VIAL		A201048	001	Aug 10, 2012	Apr	DISC
>A>		@	EQ 5GM BASE/VIAL		A201048	001	Aug 10, 2012	Apr	DISC
>D>	AP		EQ 10GM BASE/VIAL		A201048	002	Aug 10, 2012	Apr	DISC
>A>		@	EQ 10GM BASE/VIAL		A201048	002	Aug 10, 2012	Apr	DISC
		VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER							
		+! BAXTER HLTHCARE	EQ 500MG BASE/100ML		N050671	001	Apr 29, 1993	Feb	CTNA
		+!	EQ 750MG BASE/150ML		N050671	002	Dec 20, 2010	Feb	CTNA
		+!	EQ 1GM BASE/200ML		N050671	003	Mar 01, 1999	Feb	CTNA
		SOLUTION;INTRAVENOUS							
		VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER							
		+! BAXTER HLTHCARE	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)		N050671	001	Apr 29, 1993	Feb	CPOT
		+!	EQ 500MG BASE/100ML		N050671	001	Apr 29, 1993	Feb	CDFR
		+!	EQ 750MG BASE/150ML (EQ 5MG BASE/ML)		N050671	002	Dec 20, 2010	Feb	CPOT
		+!	EQ 750MG BASE/150ML		N050671	002	Dec 20, 2010	Feb	CDFR
		+!	EQ 1GM BASE/200ML (EQ 5MG BASE/ML)		N050671	003	Mar 01, 1999	Feb	CPOT
		+!	EQ 1GM BASE/200ML		N050671	003	Mar 01, 1999	Feb	CDFR
		+!	EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)		N050671	004	Jan 25, 2024	Feb	NEWA
		+!	EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)		N050671	005	Jan 25, 2024	Feb	NEWA

VARENICLINE TARTRATE

		TABLET;ORAL							
		VARENICLINE TARTRATE							
AB		AJANTA PHARMA LTD	EQ 0.5MG BASE		A213019	001	Mar 19, 2024	Mar	NEWA
AB			EQ 1MG BASE		A213019	002	Mar 19, 2024	Mar	NEWA
AB		AVALANCHE PHARM	EQ 0.5MG BASE		A217283	001	Mar 06, 2024	Feb	NEWA
AB			EQ 1MG BASE		A217283	002	Mar 06, 2024	Feb	NEWA
AB		MYLAN	EQ 0.5MG BASE		A202019	001	Feb 28, 2024	Feb	NEWA
AB			EQ 1MG BASE		A202019	002	Feb 28, 2024	Feb	NEWA

VASOPRESSIN

		SOLUTION;INTRAVENOUS							
		VASOPRESSIN							
>A>	AP	DR REDDYS	20UNITS/ML (20UNITS/ML)		A213988	001	May 08, 2024	Apr	NEWA
	AP	GLAND PHARMA LTD	20UNITS/ML (20UNITS/ML)		A216963	001	Feb 09, 2024	Feb	NEWA

VERAPAMIL HYDROCHLORIDE

		INJECTABLE;INJECTION							
		VERAPAMIL HYDROCHLORIDE							
>A>	AP	FRESENIUS KABI USA	2.5MG/ML		A216471	001	Apr 23, 2024	Apr	NEWA
		SOLUTION;INTRAVENOUS							
		VERAPAMIL HYDROCHLORIDE							
>D>	AP	AREVA PHARMS	5MG/2ML (2.5MG/ML)		A213352	002	Sep 16, 2020	Apr	CAHN
>D>	AP		10MG/4ML (2.5MG/ML)		A213352	001	Mar 17, 2020	Apr	CAHN
>A>	AP	NEPHRON	5MG/2ML (2.5MG/ML)		A213352	002	Sep 16, 2020	Apr	CAHN

	SOLUTION;INTRAVENOUS							
	VERAPAMIL HYDROCHLORIDE							
>A>	AP	10MG/4ML (2.5MG/ML)		A213352	001	Mar 17, 2020	Apr	CAHN
	<u>VINORELBINE TARTRATE</u>							
	INJECTABLE;INJECTION							
	VINORELBINE TARTRATE							
	@	RISING	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Mar	CAHN
	<u>VORAPAXAR SULFATE</u>							
	TABLET;ORAL							
	ZONTIVITY							
>A>	+	KEY THERAP	EQ 2.08MG BASE	N204886	001	May 08, 2014	Apr	CAHN
>D>	+	XSPIRE PHARMA	EQ 2.08MG BASE	N204886	001	May 08, 2014	Apr	CAHN
	<u>VORICONAZOLE</u>							
	INJECTABLE;INTRAVENOUS							
	VORICONAZOLE							
AP		ASPIRO	200MG/VIAL	A218533	001	Apr 03, 2024	Mar	NEWA
	<u>ZIDOVUDINE</u>							
	TABLET;ORAL							
	ZIDOVUDINE							
>D>	AB	MYLAN PHARMS INC	300MG	A078922	001	Feb 14, 2008	Apr	DISC
>A>	@		300MG	A078922	001	Feb 14, 2008	Apr	DISC
	<u>ZOLMITRIPTAN</u>							
	SPRAY;NASAL							
	ZOLMITRIPTAN							
AB	!	PADAGIS ISRAEL	5MG/SPRAY	A212469	002	Sep 30, 2021	Feb	CHRS
	TABLET;ORAL							
	ZOLMITRIPTAN							
	@	INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar	DISC
	@		5MG	A204284	002	Apr 09, 2014	Mar	DISC
	<u>ZOLPIDEM TARTRATE</u>							
	TABLET;ORAL							
	ZOLPIDEM TARTRATE							
	@	INVAGEN PHARMS	5MG	A078184	001	Sep 07, 2007	Mar	DISC
	@		10MG	A078184	002	Sep 07, 2007	Mar	DISC
	TABLET;SUBLINGUAL							
	ZOLPIDEM TARTRATE							
>A>	AB	ENDO OPERATIONS	1.75MG	A204229	001	Sep 11, 2017	Apr	CAHN
>A>	AB		3.5MG	A204229	002	Sep 11, 2017	Apr	CAHN
>D>	AB	PAR PHARM INC	1.75MG	A204229	001	Sep 11, 2017	Apr	CAHN
>D>	AB		3.5MG	A204229	002	Sep 11, 2017	Apr	CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ COSETTE	120MG	N018060	001		Mar	DISC
@	325MG	A072344	001	Mar 27, 1992	Mar	DISC
@	650MG	A072237	001	Mar 27, 1992	Mar	DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

>A>	ACETAMINOPHEN AND IBUPROFEN					
>A>	AUROBINDO PHARMA LTD	250MG;125MG	A218359	001	Mar 26, 2024	Apr CTNA
>A>	GLENMARK PHARMS LTD	250MG;125MG	A218311	001	Apr 26, 2024	Apr NEWA
>D>	ACETAMINOPHEN; IBUPROFEN					
>D>	AUROBINDO PHARMA LTD	250MG;125MG	A218359	001	Mar 26, 2024	Apr CTNA
		250MG;125MG	A218359	001	Mar 26, 2024	Mar NEWA

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

ALCAFTADINE

GLAND PHARMA LTD	0.25%	A209706	001	Mar 01, 2024	Feb	NEWA
------------------	-------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

>A>	PADAGIS ISRAEL	0.2055MG/SPRAY	A216801	001	May 08, 2024	Apr NEWA
-----	----------------	----------------	---------	-----	--------------	----------

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

>A>	DR REDDYS LABS SA	0.025%	A216361	001	Feb 16, 2024	Feb NFTG
>A>	LUMIFY PRESERVATIVE FREE					
>A>	+! BAUSCH AND LOMB INC	0.025%	N218424	001	Apr 19, 2024	Apr NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009	Feb	CDFR
@ APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009	Feb	CDFR
AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010	Feb	CDFR
BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011	Feb	CDFR
CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011	Feb	CDFR
@ CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008	Feb	CDFR
@ CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Feb	CDFR
HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	CDFR
PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Feb	CDFR
	5MG/5ML	A090254	002	Apr 09, 2008	Feb	CDFR
@ PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008	Feb	CDFR
QUAGEN	5MG/5ML	A212266	001	May 16, 2019	Feb	CDFR
@ RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Feb	CDFR
TARO	5MG/5ML	A090182	002	Apr 22, 2008	Feb	CDFR
	5MG/5ML	A201546	001	May 20, 2011	Feb	CDFR
@ TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012	Feb	CDFR

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009	Feb	CDFR
@ APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009	Feb	CDFR
AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010	Feb	CDFR
BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011	Feb	CDFR
CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011	Feb	CDFR
@ CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008	Feb	CDFR
@ CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Feb	CDFR
PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008	Feb	CDFR
@ PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008	Feb	CDFR
@ RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Feb	CDFR
TARO	5MG/5ML	A090182	001	Apr 22, 2008	Feb	CDFR
	5MG/5ML	A201546	002	May 20, 2011	Feb	CDFR
@ TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012	Feb	CDFR

CHILDREN'S ZYRTEC ALLERGY

+! J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007	Feb	CDFR
CHILDREN'S ZYRTEC HIVES RELIEF						
+! J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007	Feb	CDFR

	TABLET, CHEWABLE;ORAL								
	CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY								
	@ SUN PHARM	5MG			A090142	001	Aug 30, 2011	Mar	DISC
	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF								
	@ SUN PHARM	5MG			A090142	003	Aug 30, 2011	Mar	DISC
	<u>CLOTTRIMAZOLE</u>								
	CREAM;VAGINAL								
	TRIVAGIZOLE 3								
	TARO	2%			N021143	001	Apr 12, 2000	Mar	CAHN
	<u>DICLOFENAC SODIUM</u>								
	GEL;TOPICAL								
	DICLOFENAC SODIUM								
	@ HIKMA	1%			A209484	001	Nov 21, 2018	Mar	DISC
	<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN</u>								
	TABLET;ORAL								
	IBUPROFEN AND DIPHENHYDRAMINE CITRATE								
>A>	PLD ACQUISITIONS LLC	38MG;200MG			A211404	001	Apr 11, 2024	Apr	NEWA
	<u>DOCOSANOL</u>								
	CREAM;TOPICAL								
	DOCOSANOL								
	AUROBINDO PHARMA LTD	10%			A217090	001	Mar 01, 2024	Feb	NEWA
	P AND L DEVELOPMENT	10%			A212385	001	Oct 07, 2022	Mar	CAHN
	<u>ESOMEPRAZOLE MAGNESIUM</u>								
	CAPSULE, DELAYED RELEASE;ORAL								
	ESOMEPRAZOLE MAGNESIUM								
>A>	DR REDDYS	EQ 20MG BASE			A207198	001	Apr 30, 2024	Apr	NEWA
	GUARDIAN DRUG	EQ 20MG BASE			A216149	001	Mar 15, 2023	Feb	CAHN
	TABLET, DELAYED RELEASE;ORAL								
	ESOMEPRAZOLE MAGNESIUM								
>D>	@ AUROBINDO PHARMA LTD	EQ 20MG BASE			A214473	001	Jul 12, 2023	Apr	CMFD
>A>	@	EQ 20MG BASE			A214473	001	Jul 12, 2023	Apr	CMFD
	@	EQ 20MG BASE			A214473	001	Jul 12, 2023	Jan	DISC
	<u>FAMOTIDINE</u>								
	TABLET;ORAL								
	FAMOTIDINE								
	GRAVITI PHARMS	10MG			A218461	001	Mar 14, 2024	Mar	NEWA
		20MG			A218461	002	Mar 14, 2024	Mar	NEWA
>D>	SUN PHARM INDS LTD	10MG			A090283	001	Nov 17, 2009	Apr	DISC
>A>	@	10MG			A090283	001	Nov 17, 2009	Apr	DISC
>D>	@	20MG			A090283	002	Nov 17, 2009	Apr	DISC
>A>	@	20MG			A090283	002	Nov 17, 2009	Apr	DISC
	<u>FLUTICASONE PROPIONATE</u>								
	SPRAY, METERED;NASAL								
	FLUTICASONE PROPIONATE								
	@ HIKMA	0.05MG/SPRAY			A208024	001	Apr 17, 2019	Mar	DISC
	<u>IBUPROFEN</u>								
	CAPSULE;ORAL								
	IBUPROFEN								
	@ AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT			A215777	001	Sep 14, 2023	Mar	DISC
	PATHEON SOFTGELS	EQ 200MG FREE ACID AND POTASSIUM SALT			A217236	001	Feb 13, 2024	Mar	CAHN
		EQ 200MG FREE ACID AND POTASSIUM SALT			A217236	001	Feb 13, 2024	Feb	NEWA
	SUSPENSION/DROPS;ORAL								
	IBUPROFEN								
	AUROBINDO PHARMA LTD	40MG/ML			A213506	001	Apr 08, 2024	Mar	NEWA
	<u>LEVONORGESTREL</u>								
	TABLET;ORAL								
	LEVONORGESTREL								
>D>	@ NAARI PTE LTD	1.5MG			A207660	001	May 02, 2019	Apr	CMFD
>A>	@	1.5MG			A207660	001	May 02, 2019	Apr	CMFD

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

LOPERAMIDE HYDROCHLORIDE

@ SAPTALIS PHARMS 1MG/5ML

A 074352 001 Nov 17, 1995 Jan CAHN

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

>D> COSETTE 2%

A 074366 001 Feb 22, 1996 Apr DISC

>A> @ 2%

A 074366 001 Feb 22, 1996 Apr DISC

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

>D> COSETTE 100MG

A 074414 001 Apr 30, 1997 Apr DISC

>A> @ 100MG

A 074414 001 Apr 30, 1997 Apr DISC

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL (FOR MEN)

>A> AUROBINDO PHARMA 5%

A 218616 001 Apr 22, 2024 Apr NEWA

MINOXIDIL (FOR WOMEN)

>A> AUROBINDO PHARMA 5%

A 218616 002 Apr 22, 2024 Apr NEWA

MOMETASONE FUROATE

SPRAY, METERED;NASAL

MOMETASONE FUROATE

>A> APOTEX 0.05MG/SPRAY

A 217438 001 Apr 23, 2024 Apr NEWA

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

NALOXONE HYDROCHLORIDE

>A> AMNEAL 4MG/SPRAY

A 217992 001 Apr 23, 2024 Apr NEWA

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

@ SUN PHARM INDS LTD 220MG

A 091183 001 May 20, 2011 Jan DISC

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICORETTE

+ HALEON US HOLDINGS EQ 2MG BASE

N 022360 001 May 18, 2009 Jan CAHN

+! EQ 4MG BASE

N 022360 002 May 18, 2009 Jan CAHN

NORGESTREL

TABLET;ORAL

OPILL

+! LABORATOIRE HRA 0.075MG

N 017031 001 Feb CMFD

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

@ SAPTALIS PHARMS EQ 0.2% BASE

A 204723 001 Dec 05, 2017 Jan CAHN

>A> SOMERSET THERAPS LLC EQ 0.1% BASE

A 206306 001 Dec 07, 2015 Apr CMKT

POVIDONE-IODINE

SPONGE;TOPICAL

E-Z SCRUB 201

+ @ BECTON DICKINSON 20%

N 019240 001 Nov 29, 1985 Feb DISC

E-Z SCRUB 241

+ @ BECTON DICKINSON 10%

N 019476 001 Jan 07, 1987 Feb DISC

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1%

N 021958 001 Jul 24, 2006 Feb CAHN

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

+! KARO HLTHCARE 1% N020980 001 Mar 09, 1999 Feb CAHN

SOLUTION; TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1% N021124 001 Mar 17, 2000 Feb CAHN

SPRAY; TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1% N021124 002 Mar 17, 2000 Feb CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 4 APRIL 2024

NO APRIL 2024 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2024 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001	11918693	Jul 09, 2041	DP			
<u>ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV</u>						
N 215320 001	11896567	Oct 26, 2031	U-3744			
	11896567	Oct 26, 2031	U-3745			
<u>ACYCLOVIR - ACYCLOVIR</u>						
A 212361 001					CGT	Jun 12, 2024
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001 >A>	11903908	Jun 17, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002 >A>	11903908	Jun 17, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	11890261	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	11890261	Feb 15, 2038	U-2497			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	11918685	Oct 06, 2037	U-3447			
	11918685	Oct 06, 2037	U-3448			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	11878011	May 27, 2042	U-3816			
	11931463	Feb 12, 2034	DP U-3866			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001 >A>	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002 >A>	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003 >A>	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004 >A>	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005 >A>	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006 >A>	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	11896562	Mar 10, 2037	U-3299			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	11896562	Mar 10, 2037	U-3299			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	>A> 11963952	Jan 30, 2040	U-3888			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	>A> 11963952	Jan 30, 2040	U-3888			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	>A> 10092541	May 29, 2034	U-2403			
	>A> 10092541	May 29, 2034	U-2659			
	>A> 10092541*PED	Nov 29, 2034				
	>A> 7427638	Feb 16, 2028	DS DP			
	>A> 7427638*PED	Aug 16, 2028				
	>A> 9872854	May 29, 2034	U-2232			
	>A> 9872854	May 29, 2034	U-2233			
	>A> 9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 002	>A> 10092541	May 29, 2034	U-2403			
	>A> 10092541	May 29, 2034	U-2659			
	>A> 10092541*PED	Nov 29, 2034				
	>A> 7427638	Feb 16, 2028	DS DP			
	>A> 7427638*PED	Aug 16, 2028				
	>A> 9872854	May 29, 2034	U-2232			
	>A> 9872854	May 29, 2034	U-2233			
	>A> 9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 003	>A> 10092541	May 29, 2034	U-2403			
	>A> 10092541	May 29, 2034	U-2659			
	>A> 10092541*PED	Nov 29, 2034				
	>A> 7427638	Feb 16, 2028	DS DP			
	>A> 7427638*PED	Aug 16, 2028				
	>A> 9872854	May 29, 2034	U-2232			
	>A> 9872854	May 29, 2034	U-2233			
	>A> 9872854*PED	Nov 29, 2034				
<u>APREPITANT - APONVIE</u>						
N 216457 001	11878074	Sep 18, 2035	U-3787			
<u>APROCITENTAN - TRYVIO</u>						
N 217686 001	>A> 10919881	Feb 26, 2038	DS DP	>A> NCE		Mar 22, 2029
	>A> 11174247	Nov 06, 2037	U-3879			
	>A> 11680058	Jul 26, 2038	U-3878			
	>A> 11787782	Mar 02, 2038	U-3877			
	>A> 8324232	Sep 21, 2029	DS DP U-3878			
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	11925704	Jun 07, 2037	DP U-3853			
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	>A> 11951214	Nov 27, 2039	DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	>A> 11964980	Apr 10, 2040	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002 >A>	11964980	Apr 10, 2040	DS DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003 >A>	11964980	Apr 10, 2040	DS DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004 >A>	11964980	Apr 10, 2040	DS DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005 >A>	11964980	Apr 10, 2040	DS DP			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	7638536	Jul 28, 2027	DS DP			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244		NPP	Jan 26, 2027
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
	7112592	Jan 07, 2026	DS DP U-3818			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	11925648	Apr 21, 2041	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	8158616	May 31, 2032	DS DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001					I-931	Dec 14, 2026
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001 >A>	11744816	Mar 14, 2036	U-3883			
	11926584	Jun 19, 2040	U-3873			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	>A> 10912751	Mar 14, 2036	U-3224			
	>A> 10912751	Mar 14, 2036	U-3884			
	>A> 11744816	Mar 14, 2036	U-3692			
	>A> 11744816	Mar 14, 2036	U-3883			
	11926584	Jun 19, 2040	U-3873			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11872214	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11872214	Jan 28, 2031	DP			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11865100	Feb 19, 2040	U-3357			
	11877997	Feb 19, 2040	U-3356			
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	10258564	Nov 22, 2034	U-3797		NCE	Jan 05, 2029
	10258564	Nov 22, 2034	U-3798			
	10258564	Nov 22, 2034	U-3799			
	10265334	Jul 03, 2032	DP			
	10322081	Jul 10, 2035	U-3793			
	10322081	Jul 10, 2035	U-3794			
	10322081	Jul 10, 2035	U-3795			
	10322081	Jul 10, 2035	U-3796			
	10376538	Aug 20, 2030	DP			
	10736839	Jul 10, 2035	U-3790			
	10736839	Jul 10, 2035	U-3791			
	10736839	Jul 10, 2035	U-3792			
	11040006	Jul 10, 2035	DP U-3789			
	11285098	Feb 28, 2034	DP			
	11723858	Jul 10, 2035	DP U-3788			
	8282967	May 30, 2026	DS			
	8956658	May 30, 2026	DS			
	9289442	Jul 03, 2032	DP U-3803			
	9526738	Sep 03, 2031	DP			
	9737561	Aug 20, 2030	U-3802			
	9855211	Feb 27, 2034	DP U-3800			
	9855211	Feb 27, 2034	DP U-3801			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001				>A> I-942		Feb 23, 2027
				>A> M-305		Apr 24, 2027
				ODE-468		Feb 23, 2031
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Apr 17, 2025	DS DP	>A> I-942		Feb 23, 2027
	7390791*PED	Oct 17, 2025		ODE-468		Feb 23, 2031
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2025	DS DP			
<u>BIRCH TRITERPENES - FILSUVUZ</u>						
N 215064 001	11083733	Jan 04, 2039	DP		NCE	Dec 18, 2028
	11266660	Jan 04, 2039	U-3811		ODE-460	Dec 18, 2030
	8828444	Jun 21, 2025	DP			
	9352041	Nov 24, 2030	U-3811			
	9827214	Nov 24, 2030	U-3811			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BIVALIRUDIN - ANGIOMAX RTU</u>						
N 211215 001	11903993	May 20, 2039	U-3817			
	11918622	May 20, 2039	U-3817			
<u>BROMFENAC SODIUM - BROMFENAC SODIUM</u>						
A 206027 001					PC	Jul 06, 2024
<u>BUDESONIDE - FOHILIA</u>						
N 213976 001	10293052	Nov 22, 2028	DP		NP	Feb 09, 2027
	11197822	Nov 09, 2026	DP		ODE-466	Feb 09, 2031
	11260064	Jan 10, 2039	DP			
	11357859	Nov 12, 2028	U-3820			
	11413296	Nov 09, 2026	DP			
	11564934	Jan 10, 2039	U-3820			
	8324192	Aug 03, 2029	U-3820			
	8497258	Nov 09, 2026	U-3820			
	8679545	Nov 09, 2026	DP			
	8975243	Nov 09, 2026	U-3820			
	9050368	Aug 01, 2029	DP			
	9119863	Nov 09, 2026	U-3820			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	11896719	Jan 23, 2043	U-3810		ODE-464	Dec 20, 2030
	8491932	May 07, 2029	DP U-3269			
	8491932	May 07, 2029	DP U-3781			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004					I-933	Jan 23, 2027
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11883373	Jan 23, 2043	U-3419			
	11896563	Dec 01, 2041	U-3419			
	11925636	Jan 20, 2043	U-3419			
	>A> 11969421	Nov 05, 2034	U-3419			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	11154509	Apr 25, 2028	U-3815			
	9498486	Apr 25, 2028	U-3814			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11865102	Apr 26, 2039	DS DP U-2781			
	11865102	Apr 26, 2039	DS DP U-3236			
	11865102	Apr 26, 2039	DS DP U-3277			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11865102	Apr 26, 2039	DS DP U-2781			
	11865102	Apr 26, 2039	DS DP U-3236			
	11865102	Apr 26, 2039	DS DP U-3277			
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001					NCE	Jul 21, 2028
<u>CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM - EXBLIFEP</u>						
N 216165 001	11124526	Nov 07, 2034	U-3852		NCE	Feb 22, 2029
	7687488	Dec 03, 2027	DS DP U-3851		GAIN	Feb 22, 2034
<u>CEFTOBIPROLE MEDOCARIL SODIUM - ZEVTERA</u>						
N 218275 001					>A> NCE >A> GAIN	Apr 03, 2029 Apr 03, 2034
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
N 218158 001	10588913	May 09, 2036	DP		NP	Mar 04, 2027
	11376262	May 09, 2036	DP U-19			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	>A> 10130585	May 09, 2034	U-3642			
	>A> 10206891	Nov 01, 2033	U-3641			
	>A> 10265281	Nov 01, 2033	U-3639			
	>A> 10842762	Nov 01, 2033	U-3640			
	>A> 11026899	Nov 01, 2033	U-3639			
	>A> 11026900	Nov 01, 2033	U-3639			
	>A> 11026901	Nov 01, 2033	U-3638			
	11944594	Nov 01, 2033	U-3864			
	11944595	Nov 01, 2033	U-3867			
	11944595	Nov 01, 2033	U-3868			
	>A> 9744144	Nov 01, 2033	U-3643			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001	>A> 11975022	Jul 01, 2041	U-3899			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002	>A> 11975022	Jul 01, 2041	U-3899			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRY5</u>						
N 209376 003	>A> 11975022	Jul 01, 2041	U-3900			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8629111	Aug 27, 2024	DP	Y		
	8633162	Aug 27, 2024	U-1479	Y		
	8642556	Aug 27, 2024	DP	Y		
	8648048	Aug 27, 2024	U-1483	Y		
	8685930	Aug 27, 2024	DP	Y		
	9248191	Aug 27, 2024	U-1479	Y		
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	>A> 11951153	Feb 28, 2037	U-1483			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	11504333*PED	Dec 29, 2038			ODE-428	Mar 16, 2030
	7994185	Jan 20, 2030	DS DP		PED	Sep 16, 2026
	7994185*PED	Jul 20, 2030			PED	Sep 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-3565			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-3565			
	8835443*PED	Dec 10, 2025				
<u>DANICOPAN - VOYDEYA</u>						
N 218037 001					>A> NCE >A> ODE-476	Mar 29, 2029 Mar 29, 2031
<u>DANICOPAN - VOYDEYA</u>						
N 218037 002					>A> NCE >A> ODE-476	Mar 29, 2029 Mar 29, 2031
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	7456254	Jun 30, 2025	U-2139			
	8431685	Apr 13, 2025	U-2139			
	8461105	Apr 13, 2025	U-2139			
	9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	11903955	Mar 09, 2040	U-3825			
	7456254	Jun 30, 2025	U-2139			
	8431685	Apr 13, 2025	U-2139			
	8461105	Apr 13, 2025	U-2139			
	9238076	Apr 15, 2024	U-2139			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11890272	Jul 17, 2040	U-3756			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11890272	Jul 17, 2040	U-3756			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP		Y	
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641		Y	
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP		Y	
	8598233*PED	May 22, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8168209	Nov 22, 2025	DP	Y		
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641	Y		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641	Y		
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP	Y		
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641	Y		
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP	Y		
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8168209	Nov 22, 2025	DP	Y		
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641	Y		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641	Y		
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP	Y		
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641	Y		
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP	Y		
	8598233*PED	May 22, 2026				
<u>DROSPIRENONE - SLYND</u>						
N 211367 001 >A>	11951213	Jun 28, 2031	U-2553			
<u>DROSPIRENONE - DROSPIRENONE</u>						
N 216285 001 >A>	11951213	Jun 28, 2031	U-2553			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001 >A>	11957694	Jun 17, 2036	DP			
	>A> 11964055	Jun 17, 2036	DP			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001 >A>	11957660	Nov 01, 2039	DP		ODE-144	May 12, 2029
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-14	Oct 18, 2026
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11872218	Jan 03, 2028	U-1969			
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500 001					NP ODE-462	Dec 13, 2026 Dec 13, 2030
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	7419983	Jul 06, 2029	DS DP U-2360			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	7419983	Jul 06, 2029	DS DP			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002					ODE-457	Jan 07, 2029
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	10683499	Aug 25, 2034	DS DP U-2378		NCE	Dec 21, 2028
	8101743	Apr 01, 2025	DS DP		ODE-461	Dec 21, 2030
	9127276	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	>A> 10898482	Feb 09, 2036	DP U-2518		I-930	Jan 19, 2027
	>A> 10898482	Feb 09, 2036	DP U-3065			
	>A> 10898482	Feb 09, 2036	DP U-3066			
	>A> 10898482	Feb 09, 2036	DP U-3067			
	>A> 10898482	Feb 09, 2036	DP U-3805			
	>A> 10898482	Feb 09, 2036	DP U-3806			
	>A> 10898482	Feb 09, 2036	DP U-3807			
	>A> 11077106	Feb 02, 2038	U-3196			
	>A> 11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	>A> 10898482	Feb 09, 2036	DP U-2518		I-930	Jan 19, 2027
	>A> 10898482	Feb 09, 2036	DP U-3065			
	>A> 10898482	Feb 09, 2036	DP U-3066			
	>A> 10898482	Feb 09, 2036	DP U-3067			
	>A> 10898482	Feb 09, 2036	DP U-3805			
	>A> 10898482	Feb 09, 2036	DP U-3806			
	>A> 10898482	Feb 09, 2036	DP U-3807			
	>A> 11077106	Feb 02, 2038	U-3196			
	>A> 11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	>A> 10898482	Feb 09, 2036	DP U-2518		I-930	Jan 19, 2027
	>A> 10898482	Feb 09, 2036	DP U-3065			
	>A> 10898482	Feb 09, 2036	DP U-3066			
	>A> 10898482	Feb 09, 2036	DP U-3067			
	>A> 10898482	Feb 09, 2036	DP U-3805			
	>A> 10898482	Feb 09, 2036	DP U-3806			
	>A> 10898482	Feb 09, 2036	DP U-3807			
	>A> 11077106	Feb 02, 2038	U-3196			
	>A> 11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	>A> 11957684	Sep 29, 2037	U-3129			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11865179	Nov 21, 2032	DS DP			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	11865179	Nov 21, 2032	DS DP			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	11850251	Jun 21, 2039		U-3785		
<u>ETRASIMOD ARGININE - VELSIPITY</u>						
N 216956 001	11884626	Jun 21, 2036		U-3731		
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2025	DS DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	8586551*PED	Jan 15, 2024				
<u>FINERENONE - KERENDIA</u>						
N 215341 001	RE49826	Jul 29, 2035	DS			
<u>FINERENONE - KERENDIA</u>						
N 215341 002	RE49826	Jul 29, 2035	DS			
<u>FLUOROMETHOLONE - FLUOROMETHOLONE</u>						
A 216348 001					CGT	Jul 07, 2024
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001					>A> I-940	Mar 15, 2027
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950 001	8168615	Jul 13, 2029	DP			
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 001					NCE	Nov 30, 2028
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 002					NCE	Nov 30, 2028
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001	>A> 11938130	Jul 01, 2036	DP			
	>A> 11938131	Jul 01, 2036	DP			
	>A> 11938132	Jul 01, 2036	DP			
	>A> 11938133	Jul 01, 2036	DP			
	>A> 11944620	Jul 01, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001	8969336	Nov 28, 2032	DS DP			
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	>A> 10688047	Oct 28, 2036	DP U-3885		>A> NCE	Mar 21, 2029
	>A> 7329689	Jan 15, 2025	DS DP		>A> ODE-473	Mar 21, 2031
	>A> 9421184	Feb 03, 2032	U-3885			
	>A> 9867799	Feb 03, 2032	U-3885			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	11891372	Apr 13, 2036	U-3254			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	11891372	Apr 13, 2036	U-3254			
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001	8404215	Mar 09, 2032	U-1383	Y		
	>A> 9254278	Sep 22, 2030	U-1816			
	>A> 9326966	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	11938217	Oct 25, 2038	DP			
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
A 215266 001					PC	Jun 24, 2024
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HYDROXYUREA - XROMI</u>						
N 216593 001					ODE-470	Apr 04, 2031
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8754090	Jun 03, 2031	U-1456	Y		
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8754090	Jun 03, 2031	U-1456	Y		
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	>A> 8754090	Jun 03, 2031	U-1456	Y		
	>A> 8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	>A> 8754090	Jun 03, 2031	U-1456	Y		
	>A> 8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	>A> 8754090	Jun 03, 2031	U-1456	Y		
	>A> 8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10004746	Jun 03, 2031	U-3846			
	10004746	Jun 03, 2031	U-3847			
	10004746	Jun 03, 2031	U-3848			
	10004746	Jun 03, 2031	U-3849			
	10016435	Jun 03, 2031	U-3845			
	10463668	Oct 24, 2034	U-2970			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10478439	Jun 03, 2031	U-2666			
	10478439	Jun 03, 2031	U-2970			
	10478439	Jun 03, 2031	U-3422			
	10478439	Jun 03, 2031	U-3842			
	10478439	Jun 03, 2031	U-3843			
	10478439	Jun 03, 2031	U-3844			
	10478439	Jun 03, 2031	U-3845			
	10478439*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2970			
	10751342	Jun 03, 2031	U-2666			
	10751342	Jun 03, 2031	U-3842			
	10751342	Jun 03, 2031	U-3843			
	10751342	Jun 03, 2031	U-3844			
	11672803	Jun 03, 2031	U-2666			
	11672803	Jun 03, 2031	U-3842			
	11672803	Jun 03, 2031	U-3843			
	11672803	Jun 03, 2031	U-3844			
	8476284	Dec 28, 2026	U-3843			
	8476284	Dec 28, 2026	U-3844			
	8476284	Dec 28, 2026	U-3845			
	8497277	Dec 28, 2026	U-2666			
	8497277	Dec 28, 2026	U-2970			
	8497277	Dec 28, 2026	U-3422			
	8497277	Dec 28, 2026	U-3842			
	8497277	Dec 28, 2026	U-3843			
	8497277	Dec 28, 2026	U-3844			
	8497277	Dec 28, 2026	U-3845			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-2666			
	8563563	Apr 26, 2027	U-3842			
	8563563	Apr 26, 2027	U-3843			
	8563563	Apr 26, 2027	U-3844			
	8563563	Apr 26, 2027	U-3845			
	8703780	Dec 28, 2026	U-2666			
	8703780	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-2666			
	8952015	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-3843			
	8952015	Dec 28, 2026	U-3844			
	8952015	Dec 28, 2026	U-3845			
	8999999	Jun 03, 2031	U-2666			
	8999999	Jun 03, 2031	U-3842			
	8999999	Jun 03, 2031	U-3843			
	8999999	Jun 03, 2031	U-3844			
	9125889	Jun 03, 2031	U-3845			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-3846			
	9801881	Jun 03, 2031	U-3847			
	9801883	Jun 03, 2031	U-2666			
	9801883	Jun 03, 2031	U-3842			
	9801883	Jun 03, 2031	U-3843			
	9801883	Jun 03, 2031	U-3844			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003					NPP	May 11, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					>A> I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					>A> I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					>A> I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					>A> I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					>A> I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					>A> I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					>A> I-939	Apr 02, 2027
<u>ILOPROST - AURLUMYN</u>						
N 217933 001					NP ODE-465	Feb 13, 2027 Feb 13, 2031
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	11850245	Apr 30, 2030	U-1455			
	11850245	Apr 30, 2030	U-172			
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 217883 001					CGT	Jul 10, 2024
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276 001	>A> 11951101	Jul 15, 2041	U-3895		NCE ODE-456	Dec 05, 2028 Dec 05, 2030
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	11344552	Aug 19, 2036	U-3824		I-932 ODE-463	Feb 13, 2027 Feb 13, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001					NPP ODE-454 ODE-458 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 002					NPP ODE-454 ODE-458 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001					NPP ODE-453 ODE-459 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001 >A>	11951212	Apr 14, 2035	DP U-3894			
<u>LATANOPROST - IYUZEH</u>						
N 216472 001	8637054	Jul 08, 2031	DP U-446			
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795 001	8058467	Feb 21, 2029	DS U-2144			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001 >A>	11944611	Jun 04, 2041	U-3507			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974 001 >A>	11944611	Jun 04, 2041	DS DP U-3507			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-269	Jul 21, 2024
	10407393	Aug 26, 2035	DS		M-272	Dec 19, 2024
	10407393*PED	Feb 26, 2036			ODE-196	Aug 15, 2025
	11090386	Feb 23, 2036	U-3519		PED	Feb 15, 2026
	11090386*PED	Aug 23, 2036				
	11186547	Aug 26, 2035	DS			
	11186547*PED	Feb 26, 2036				
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027	U-1695			
	9006256*PED	Jan 27, 2028				
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-269	Jul 21, 2024
	10407393	Aug 26, 2035	DS		M-272	Dec 19, 2024
	10407393*PED	Feb 26, 2036			ODE-196	Aug 15, 2025
	11090386	Feb 23, 2036	U-3519		PED	Feb 15, 2026
	11090386*PED	Aug 23, 2036				
	11186547	Aug 26, 2035	DS			
	11186547*PED	Feb 26, 2036				
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027	U-1695			
	9006256*PED	Jan 27, 2028				
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	RE46791	Jan 18, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	RE46791	Jan 18, 2029	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021343 001 >A>	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379 001 >A>	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488 001 >A>	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731 001 >A>	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001 >A>	11931559	Dec 22, 2041	DS			
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	11903940	Mar 02, 2040	U-3821			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001				>A> M-304		Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002				>A> M-304		Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003				>A> M-304		Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004				>A> M-304		Mar 24, 2026
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	11850182	Sep 14, 2029	DP U-3819			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	11911388	Apr 10, 2030	U-3854			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11872318	May 03, 2033	DP			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11872318	May 03, 2033	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	8598119	Dec 28, 2029	U-543	Y		
<u>LUTETIUM LU 177 DOTATATE - LUTATHERA</u>						
N 208700 001	>A> 10596276	Jul 25, 2038	DP		>A> ODE-166	Jan 26, 2025
	>A> 10596276*PED	Jan 25, 2039			>A> PED	Jul 26, 2025
	>A> 10596278	Jul 25, 2038	DP			
	>A> 10596278*PED	Jan 25, 2039				
	>A> 11904027	Jul 25, 2038	DP			
	>A> 11904027*PED	Jan 25, 2039				
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 001	>A> 10946015	Sep 11, 2026	DP U-3881		>A> NP	Mar 22, 2027
	>A> 7094781	Dec 05, 2025	DS DP		>A> ODE-475	Mar 22, 2031
	>A> 8268847	Apr 18, 2029	DP U-3882			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 002	>A> 10946015	Sep 11, 2026	DP U-3881		>A> NP	Mar 22, 2027
	>A> 7094781	Dec 05, 2025	DS DP		>A> ODE-475	Mar 22, 2031
	>A> 8268847	Apr 18, 2029	DP U-3882			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	10512657	Oct 26, 2032	U-3850		I-938	Mar 13, 2027
	11229661	Oct 26, 2032	U-3850		>A> ODE-471	Mar 13, 2031
	11918578	Feb 12, 2040	U-3290			
<u>METAXALONE - METAXALONE</u>						
N 022503 001	11918559	Jul 29, 2039	DP			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					M-303	Jan 08, 2027
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					M-303	Jan 08, 2027
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11911518	Mar 23, 2032	U-2357			
<u>MIFEPRISTONE - MIFEPRISTONE</u>						
A 211436 001					PC	Jul 17, 2024
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11903938	Aug 17, 2038	DS U-2371			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	11944634	Oct 16, 2032	DP			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	11878049	Jul 31, 2041	U-3782			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	11903918	Feb 27, 2035	U-1384			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001				>A> NP		Apr 29, 2024
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	11806428	May 11, 2032	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	11872211	May 19, 2043	U-3754		NCE	Nov 27, 2028
	11884634	Aug 09, 2039	DP		ODE-452	Nov 27, 2030
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	>A> 11951096	May 19, 2043	U-3754			
	>A> 11957662	May 19, 2043	U-3754			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	>A> 10590087	Aug 09, 2039	DS		>A> NCE	Nov 27, 2028
	>A> 10710966	Aug 09, 2039	DS U-3754		>A> ODE*	Nov 27, 2030
	>A> 10941118	Aug 09, 2039	DS U-3754			
	>A> 11504354	Jul 08, 2042	DP			
	>A> 11612588	Jul 08, 2042	DP U-3754			
	>A> 11807611	Sep 08, 2042	DP U-3754			
	>A> 11820748	Aug 09, 2039	DP			
	>A> 11844780	Sep 08, 2042	DP U-3754			
	>A> 11845732	Aug 09, 2039	DS U-3754			
	>A> 11872211	May 19, 2043	U-3754			
	>A> 11884634	Aug 09, 2039	DP			
	>A> 11884635	Aug 09, 2039	DP			
	>A> 11905255	Aug 09, 2039	DP			
	>A> 11925619	May 19, 2043	U-3754			
	>A> 11925620	May 19, 2043	U-3754			
	>A> 11938116	May 19, 2043	U-3754			
	>A> 11951096	May 19, 2043	U-3754			
	>A> 11957662	May 19, 2043	U-3754			
	>A> 7342118	Aug 18, 2025	DS			
	>A> 7795447	Aug 18, 2025	DS			
	>A> 7951958	Mar 11, 2025	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	>A> 10590087	Aug 09, 2039	DS		>A> NCE	Nov 27, 2028
	>A> 10710966	Aug 09, 2039	DS U-3754		>A> ODE*	Nov 27, 2030
	>A> 10941118	Aug 09, 2039	DS U-3754			
	>A> 11504354	Jul 08, 2042	DP			
	>A> 11612588	Jul 08, 2042	DP U-3754			
	>A> 11807611	Sep 08, 2042	DP U-3754			
	>A> 11820748	Aug 09, 2039	DP			
	>A> 11844780	Sep 08, 2042	DP U-3754			
	>A> 11845732	Aug 09, 2039	DS U-3754			
	>A> 11872211	May 19, 2043	U-3754			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	>A> 11884634	Aug 09, 2039	DP			
	>A> 11884635	Aug 09, 2039	DP			
	>A> 11905255	Aug 09, 2039	DP			
	>A> 11925619	May 19, 2043			U-3754	
	>A> 11925620	May 19, 2043			U-3754	
	>A> 11938116	May 19, 2043			U-3754	
	>A> 11951096	May 19, 2043			U-3754	
	>A> 11957662	May 19, 2043			U-3754	
	>A> 7342118	Aug 18, 2025	DS			
	>A> 7795447	Aug 18, 2025	DS			
	>A> 7951958	Mar 11, 2025	DS			
<u>NITROGLYCERIN - NITROGLYCERIN</u>						
A 216103 001					CGT	Aug 21, 2024
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	8361977	Dec 23, 2030	DS DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11857595	Feb 03, 2036			>A> ODE-474	Jun 26, 2027
	11890316	Dec 28, 2040			U-3232	
	>A> 11969471	Sep 17, 2029	DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	>A> 11951111	Nov 12, 2041			U-3886	
	>A> 11951111	Nov 12, 2041			U-3887	
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	>A> 11951111	Nov 12, 2041			U-3886	
	>A> 11951111	Nov 12, 2041			U-3887	
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	>A> 11951111	Nov 12, 2041			U-3886	
	>A> 11951111	Nov 12, 2041			U-3887	
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	>A> 11951111	Nov 12, 2041			U-3886	
	>A> 11951111	Nov 12, 2041			U-3887	
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	7449464	Sep 08, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	7449464	Sep 08, 2027	DS DP			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001	11931350	Mar 23, 2032	DS		U-2986	
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002	11931350	Mar 23, 2032	DS		U-2986	
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003	11931350	Mar 23, 2032	DS		U-2986	
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11919838	Apr 20, 2029			U-3862	
	11919838	Apr 20, 2029			U-3863	
<u>OMEFRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	11911473	Jul 16, 2039			U-623	
	11911473	Jul 16, 2039			U-624	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10583130	Mar 31, 2030	U-3869			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10583130	Mar 31, 2030	U-3869			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		>A> I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289			
	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		>A> I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289			
	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	11896599	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	>A> 11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	>A> 11964056	Aug 24, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	>A> 11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	>A> 11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	>A> 11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	>A> 11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	>A> 11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200534 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 002					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 201194 001					M-14	Jul 21, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	10239846	Nov 15, 2030	U-3740			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	10239846	Nov 15, 2030	U-3740			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	10239846	Nov 15, 2030	U-3740			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11844841	Dec 09, 2038	DP U-3172			
	11844841	Dec 09, 2038	DP U-3173			
	11844841	Dec 09, 2038	DP U-3174			
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	11903994	Feb 22, 2037	U-3826			
	11903994	Feb 22, 2037	U-3827			
	11903994	Feb 22, 2037	U-3828			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	>A> 10285759	Dec 08, 2031	U-3890			
	>A> 9032965	Dec 08, 2031	U-3890			
	>A> 9155471	Oct 12, 2031	U-3890			
	>A> 9532835	Dec 08, 2031	U-3890			
	>A> 9763577	Sep 14, 2034	DS DP U-3890			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11857646	Mar 16, 2037	U-665			
	11925695	Mar 16, 2037	U-665			
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11857646	Mar 16, 2037	U-665			
	11925695	Mar 16, 2037	U-665			
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	10278918	Jan 31, 2034	DP			
	10772829	Jan 31, 2034	DP			
	11090261	Jan 31, 2034	DP			
	11400077	Oct 25, 2039	U-3804			
	11844858	Jan 31, 2034	DP			
	9795560	Jan 31, 2034	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001	11839487	Jul 15, 2031	U-3685			
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	11851407	Jun 09, 2037	DS DP U-3130			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001				ODE-451		Dec 01, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059	002				ODE-451	Dec 01, 2030
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	001				I-934 >A> ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	002				I-934 >A> ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	003				I-934 >A> ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	004				I-934 >A> ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONESIMOD - PONVORY</u>						
N 213498	001	>A> 11951097	Oct 10, 2042	U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498	002	>A> 11951097	Oct 10, 2042	U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498	003	>A> 11951097	Oct 10, 2042	U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498	004	>A> 11951097	Oct 10, 2042	U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498	005	>A> 11951097	Oct 10, 2042	U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498	006	>A> 11951097	Oct 10, 2042	U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498	007	>A> 11951097	Oct 10, 2042	U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498	008	>A> 11951097	Oct 10, 2042	U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498	009	>A> 11951097	Oct 10, 2042	U-3891		
<u>PONESIMOD - PONVORY</u>						
N 213498	010	>A> 11951097	Oct 10, 2042	U-3891		
<u>PRALSETINIB - GAVRETO</u>						
N 213721	001	11872192	Apr 03, 2039	U-2952		
<u>REMDESIVIR - VEKLURY</u>						
N 214787	001	10065958	Sep 16, 2031	DS	D-183	Jan 21, 2025
		10065958*PED	Mar 16, 2032		M-301	Jul 13, 2026
		10675296	Jul 10, 2038	DP	NCE	Oct 22, 2025
		10675296*PED	Jan 10, 2039		NPP	Apr 25, 2025
		10695361	Sep 16, 2036	U-3831	PED	Jul 21, 2025
		10695361	Sep 16, 2036	U-3832	PED	Oct 25, 2025
		10695361*PED	Mar 16, 2037		PED	Apr 22, 2026
		11007208	Sep 16, 2036	U-3831	PED	Jan 13, 2027
		11007208	Sep 16, 2036	U-3832		
		11007208*PED	Mar 16, 2037			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	11266681	Jul 10, 2038	U-3831			
	11266681	Jul 10, 2038	U-3832			
	11266681*PED	Jan 10, 2039				
	11382926	Sep 16, 2036	U-3831			
	11382926	Sep 16, 2036	U-3832			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3835			
	11491169	May 28, 2041	U-3836			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3835			
	11903953	May 28, 2041	U-3836			
	11903953*PED	Nov 28, 2041				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10695361	Sep 16, 2036	U-3829		NCE	Oct 22, 2025
	10695361	Sep 16, 2036	U-3830		NPP	Apr 25, 2025
	10695361*PED	Mar 16, 2037			PED	Jul 21, 2025
	11007208	Sep 16, 2036	U-3829		PED	Oct 25, 2025
	11007208	Sep 16, 2036	U-3830		PED	Apr 22, 2026
	11007208*PED	Mar 16, 2037			PED	Jan 13, 2027
	11382926	Sep 16, 2036	U-3829			
	11382926	Sep 16, 2036	U-3830			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3833			
	11491169	May 28, 2041	U-3834			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3837			
	11903953	May 28, 2041	U-3838			
	11903953*PED	Nov 28, 2041				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001					NCE ODE-455	Nov 15, 2028 Nov 15, 2030
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 001	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 002	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 003	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	>A> 7125879	Apr 21, 2025	DS DP U-1153			
	>A> 7125879	Apr 21, 2025	DS DP U-1307			
	>A> 7125879	Apr 21, 2025	DS DP U-1740			
	>A> 7125879	Apr 21, 2025	DS DP U-3353			
	>A> 7125879	Apr 21, 2025	DS DP U-3874			
	>A> 7125879*PED	Oct 21, 2025				
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT PED</u>						
N 219016 001	>A> 11065198	Oct 23, 2037	DP			
	>A> 7125879	Apr 21, 2025	DS DP U-3874			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11896585	Dec 30, 2040	DP			
	11903933	Dec 30, 2040	DP			
	11911370	Dec 30, 2040	DP			
	11918564	Dec 30, 2040	DP			
	>A> 11969414	Feb 08, 2041	U-3897			
	>A> 11969415	Dec 30, 2040	U-3219			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	>A> 11938136	Nov 08, 2036	DP			
<u>RISPERIDONE - RISVAN</u>						
N 214835 001					>A> NP	Mar 29, 2027
<u>RISPERIDONE - RISVAN</u>						
N 214835 002					>A> NP	Mar 29, 2027
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP			
	7157456*PED	Feb 28, 2025				
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001					NP	Dec 15, 2026
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 001	>A> 10722471	Feb 02, 2037	DP U-3896			
	>A> 8101659	Jan 15, 2025	DP			
	>A> 8877938	May 27, 2027	DS DP			
	>A> 9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 002	>A> 10722471	Feb 02, 2037	DP U-3896			
	>A> 8101659	Jan 15, 2025	DP			
	>A> 8877938	May 27, 2027	DS DP			
	>A> 9388134	Nov 08, 2026	U-1723			
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 001	>A> 10112942	Oct 10, 2037	DS DP			
	>A> 10137124	Oct 10, 2037	U-3450			
	>A> 10137124	Oct 10, 2037	U-3451			
	>A> 10137124	Oct 10, 2037	U-3452			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 001	>A> 10137124	Oct 10, 2037				U-3453
	>A> 10172851	Oct 10, 2037				U-3450
	>A> 10172851	Oct 10, 2037				U-3451
	>A> 10172851	Oct 10, 2037				U-3452
	>A> 10172851	Oct 10, 2037				U-3453
	>A> 10584124	Oct 10, 2038	DS			U-3450
	>A> 10584124	Oct 10, 2038	DS			U-3451
	>A> 10584124	Oct 10, 2038	DS			U-3452
	>A> 10584124	Oct 10, 2038	DS			U-3453
	>A> 10786489	Oct 10, 2038		DP		U-3450
	>A> 10786489	Oct 10, 2038		DP		U-3451
	>A> 10786489	Oct 10, 2038		DP		U-3452
	>A> 10786489	Oct 10, 2038		DP		U-3453
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 002	>A> 10112942	Oct 10, 2037	DS DP			
	>A> 10137124	Oct 10, 2037				U-3450
	>A> 10137124	Oct 10, 2037				U-3451
	>A> 10137124	Oct 10, 2037				U-3452
	>A> 10137124	Oct 10, 2037				U-3453
	>A> 10172851	Oct 10, 2037				U-3450
	>A> 10172851	Oct 10, 2037				U-3451
	>A> 10172851	Oct 10, 2037				U-3452
	>A> 10172851	Oct 10, 2037				U-3453
	>A> 10584124	Oct 10, 2038	DS			U-3450
	>A> 10584124	Oct 10, 2038	DS			U-3451
	>A> 10584124	Oct 10, 2038	DS			U-3452
	>A> 10584124	Oct 10, 2038	DS			U-3453
	>A> 10786489	Oct 10, 2038		DP		U-3450
	>A> 10786489	Oct 10, 2038		DP		U-3451
	>A> 10786489	Oct 10, 2038		DP		U-3452
	>A> 10786489	Oct 10, 2038		DP		U-3453
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 003	>A> 10112942	Oct 10, 2037	DS DP			
	>A> 10137124	Oct 10, 2037				U-3450
	>A> 10137124	Oct 10, 2037				U-3451
	>A> 10137124	Oct 10, 2037				U-3452
	>A> 10137124	Oct 10, 2037				U-3453
	>A> 10172851	Oct 10, 2037				U-3450
	>A> 10172851	Oct 10, 2037				U-3451
	>A> 10172851	Oct 10, 2037				U-3452
	>A> 10172851	Oct 10, 2037				U-3453
	>A> 10584124	Oct 10, 2038	DS			U-3450
	>A> 10584124	Oct 10, 2038	DS			U-3451
	>A> 10584124	Oct 10, 2038	DS			U-3452
	>A> 10584124	Oct 10, 2038	DS			U-3453
	>A> 10786489	Oct 10, 2038		DP		U-3450
	>A> 10786489	Oct 10, 2038		DP		U-3451
	>A> 10786489	Oct 10, 2038		DP		U-3452
	>A> 10786489	Oct 10, 2038		DP		U-3453
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 004	>A> 10112942	Oct 10, 2037	DS DP			
	>A> 10137124	Oct 10, 2037				U-3450
	>A> 10137124	Oct 10, 2037				U-3451
	>A> 10137124	Oct 10, 2037				U-3452
	>A> 10137124	Oct 10, 2037				U-3453
	>A> 10172851	Oct 10, 2037				U-3450
	>A> 10172851	Oct 10, 2037				U-3451
	>A> 10172851	Oct 10, 2037				U-3452
	>A> 10172851	Oct 10, 2037				U-3453
	>A> 10584124	Oct 10, 2038	DS			U-3450
	>A> 10584124	Oct 10, 2038	DS			U-3451
	>A> 10584124	Oct 10, 2038	DS			U-3452
	>A> 10584124	Oct 10, 2038	DS			U-3453
	>A> 10786489	Oct 10, 2038		DP		U-3450

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 004	>A> 10786489	Oct 10, 2038	DP U-3451			
	>A> 10786489	Oct 10, 2038	DP U-3452			
	>A> 10786489	Oct 10, 2038	DP U-3453			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005					I-935	Mar 08, 2027
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					ODE-469	Jan 31, 2030
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	>A> 11944602	Jul 24, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	>A> 11944602	Jul 24, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	>A> 11944602	Jul 24, 2036	U-3889			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	11896572	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	11896572	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	11896572	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	11896572	Jul 21, 2037	DP			
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	>A> 11964018	Jul 01, 2039	U-3898			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	>A> 11969404	Mar 19, 2040	U-3892			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	>A> 11969404	Mar 19, 2040	U-3892			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 001	10189837	Oct 20, 2031	DS DP		>A> I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 002	10189837	Oct 20, 2031	DS DP		>A> I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 003	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 004	10189837	Oct 20, 2031	DS DP		>A> I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 005	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 006	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11826339	Jan 25, 2033	U-3342			
	11826339	Jan 25, 2033	U-3343			
	11918556	Jan 25, 2033	U-3342			
	11918556	Jan 25, 2033	U-3343			
	11918557	Apr 07, 2033	U-3003			
	11918557	Apr 07, 2033	U-3865			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001	11826339	Jan 25, 2033	U-3342			
	11918556	Jan 25, 2033	U-3342			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TASIMELTRON - HETLIOZ LO</u>						
N 214517 001	11918557	Apr 07, 2033	U-3003			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2852			
	10420775	Sep 12, 2031	U-2853			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-2852			
	11052093	Apr 13, 2032	DS DP U-2853			
	11491163	Apr 11, 2033	U-2736			
	11491163	Apr 11, 2033	U-2852			
	11491163	Apr 11, 2033	U-2853			
	8765732	Sep 12, 2031	U-2852			
	8765732	Sep 12, 2031	U-2853			
	9090562	Sep 12, 2031	DS DP			
	9549931	Sep 12, 2031	U-2736			
	9549931	Sep 12, 2031	U-2852			
	9549931	Sep 12, 2031	U-2853			
	9855275	Sep 12, 2031	U-2736			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	11890270	Aug 08, 2032	U-2346			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMOLIDY</u>						
N 208464 001	>A> 8754065	Aug 15, 2032	DS DP U-1275			
	>A> 8754065	Aug 15, 2032	DS DP U-3880			
	>A> 8754065	Aug 15, 2032	DS DP U-999			
	>A> 8754065*PED	Feb 15, 2033				
	>A> 9296769	Aug 15, 2032	DS DP U-1275			
	>A> 9296769	Aug 15, 2032	DS DP U-3880			
	>A> 9296769	Aug 15, 2032	DS DP U-999			
	>A> 9296769*PED	Feb 15, 2033				
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	11844804	Jun 04, 2033	U-2418			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	>A> 11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	>A> 11918623	Jun 14, 2039	U-3855			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	>A> 11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	>A> 11918623	Jun 14, 2039	U-3855			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	>A> 11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	>A> 11918623	Jun 14, 2039	U-3855			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	>A> 11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	>A> 11918623	Jun 14, 2039	U-3855			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	>A> 11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	>A> 11918623	Jun 14, 2039	U-3855			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	>A> 11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	>A> 11918623	Jun 14, 2039	U-3855			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	>A> 6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	>A> 6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11911362	Aug 21, 2040	DP U-3413			
	11911362	Aug 21, 2040	DP U-3414			
	11911362	Aug 21, 2040	DP U-3415			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11911362	Aug 21, 2040	DP U-3413			
	11911362	Aug 21, 2040	DP U-3414			
	11911362	Aug 21, 2040	DP U-3415			
<u>TOVORAFENIB - OJEMDA</u>						
N 217700 001	>A> 10426782	Jun 23, 2035	DP			
	>A> 8293752	Aug 04, 2031	DS DP			
<u>TOVORAFENIB - OJEMDA</u>						
N 218033 001	>A> 10426782	Jun 23, 2035	DP			
	>A> 8293752	Aug 04, 2031	DS DP			
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001					NP	Dec 13, 2026
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	11826327	Feb 03, 2042	U-3749			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	11857542	Dec 22, 2041	U-3786			
	>A> 11925709	Jan 30, 2035	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	>A> 11925709	Jan 30, 2035	DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001	>A> 10149842	Nov 14, 2034	DS DP		>A> NCE	Mar 27, 2029
	>A> 11065237	Nov 14, 2034	DS DP U-3876			
	>A> 11324734	Mar 31, 2036	DP			
	>A> 11844756	Mar 31, 2036	U-3876			
	>A> 11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			
	>A> 8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	>A> 8598210	Jun 26, 2027	DS DP			
	>A> 8940773	Jun 26, 2027	U-3876			
	>A> 9701636	Nov 14, 2034	DS DP			
	>A> 9987262	Nov 14, 2034	U-3876			
	>A> RE47437	Jun 26, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002	>A> 10149842	Nov 14, 2034	DS DP		>A> NCE	Mar 27, 2029
	>A> 11065237	Nov 14, 2034	DS DP U-3876			
	>A> 11324734	Mar 31, 2036	DP			
	>A> 11844756	Mar 31, 2036	U-3876			
	>A> 11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			
	>A> 8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	>A> 8598210	Jun 26, 2027	DS DP			
	>A> 8940773	Jun 26, 2027	U-3876			
	>A> 9701636	Nov 14, 2034	DS DP			
	>A> 9987262	Nov 14, 2034	U-3876			
	>A> RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003	>A> 10149842	Nov 14, 2034	DS DP		>A> NCE	Mar 27, 2029
	>A> 11065237	Nov 14, 2034	DS DP U-3876			
	>A> 11324734	Mar 31, 2036	DP			
	>A> 11844756	Mar 31, 2036	U-3876			
	>A> 11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			
	>A> 8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	>A> 8598210	Jun 26, 2027	DS DP			
	>A> 8940773	Jun 26, 2027	U-3876			
	>A> 9701636	Nov 14, 2034	DS DP			
	>A> 9987262	Nov 14, 2034	U-3876			
	>A> RE47437	Jun 26, 2027	DS DP			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	11690853	Mar 07, 2033	U-3747			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11903941	Oct 19, 2035	U-1900			
	11903942	Oct 19, 2035	DP			
	11903943	Oct 19, 2035	U-1900			
	11911380	Oct 19, 2035	U-1900			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	>A> 11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002	>A> 11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	>A> 11944612	Dec 02, 2036	U-3893			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	>A> 10570139	Apr 22, 2034	U-1745		I-936	Mar 07, 2027
	>A> 10570139	Apr 22, 2034	U-2145		ODE-467	Mar 07, 2031
	>A> 10570139	Apr 22, 2034	U-2537			
	>A> 10570139	Apr 22, 2034	U-2666			
	>A> 10570139	Apr 22, 2034	U-3063			
	>A> 10570139	Apr 22, 2034	U-3486			
	>A> 10570139	Apr 22, 2034	U-3860			
	>A> 11142528	Apr 22, 2034	DP U-1745			
	>A> 11142528	Apr 22, 2034	DP U-2145			
	>A> 11142528	Apr 22, 2034	DP U-2537			
	>A> 11142528	Apr 22, 2034	DP U-2666			
	>A> 11142528	Apr 22, 2034	DP U-3063			
	>A> 11142528	Apr 22, 2034	DP U-3486			
	>A> 11142528	Apr 22, 2034	DP U-3860			
	11701357	Jun 24, 2039	U-3860			
	>A> 11786531	Jan 19, 2043	U-3715			
	>A> 11786531	Jan 19, 2043	U-3716			
	>A> 11786531	Jan 19, 2043	U-3717			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	>A> 11786531	Jan 19, 2043	U-3718			
	>A> 11786531	Jan 19, 2043	U-3719			
	>A> 11786531	Jan 19, 2043	U-3720			
	>A> 11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	>A> 11896596	Jan 19, 2043	U-3715			
	>A> 11896596	Jan 19, 2043	U-3716			
	>A> 11896596	Jan 19, 2043	U-3717			
	>A> 11896596	Jan 19, 2043	U-3718			
	>A> 11896596	Jan 19, 2043	U-3719			
	>A> 11896596	Jan 19, 2043	U-3720			
	>A> 11896596	Jan 19, 2043	U-3875			
	>A> 11911386	Jan 19, 2043	U-3715			
	>A> 11911386	Jan 19, 2043	U-3716			
	>A> 11911386	Jan 19, 2043	U-3717			
	>A> 11911386	Jan 19, 2043	U-3718			
	>A> 11911386	Jan 19, 2043	U-3719			
	>A> 11911386	Jan 19, 2043	U-3720			
	>A> 11911386	Jan 19, 2043	U-3875			
	>A> 9447106	Apr 22, 2034	DS DP U-1745			
	>A> 9447106	Apr 22, 2034	DS DP U-2145			
	>A> 9447106	Apr 22, 2034	DS DP U-2537			
	>A> 9447106	Apr 22, 2034	DS DP U-2666			
	>A> 9447106	Apr 22, 2034	DS DP U-3063			
	>A> 9447106	Apr 22, 2034	DS DP U-3486			
	>A> 9447106	Apr 22, 2034	DS DP U-3860			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Dec 24, 2037	U-2552			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 44TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm